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Riassunto 
 
 
Una famiglia di malattie neurodegenerative, molto rara ma fatale non solo per gli 
esseri umani ma anche per varie specie animali, è correlata al misfolding della 
proteina prionica (PrP). Negli esseri umani, sono collegate a questa proteina le 
malattie di Creutzfeldt-JaKob, di Gerstmann-Straussler-Scheinker e l’insonnia fatale, 
mentre negli animali, la malattia è stata inizialmente riscontrata nelle pecore (da cui il 
termine scrapie), ma può colpire anche i bovini (Prusiner, 1998) ed altri animali. Le 
malattie prioniche possono sorgere spontaneamente, per induzione mediante 
mutazioni del gene della proteina prionica oppure per acquisizione tramite infezione. 
In quest’ultimo caso le malattie prendono il nome di encefalopatie spongiformi 
trasmissibili (TSE). La patogenesi di queste malattie è associata all’accumulo di 
aggregati amiloidi insolubili nel cervello, seguita dalla morte delle cellule neuronali. 
L’evento centrale di questo tipo di malattie neurodegenerative è la conversione 
dell’isoforma cellulare della proteina prionica, PrPC, in quella patologica, PrPSc. La 
conversione PrPC→PrPSc prevede una variazione conformazionale della PrP, 
prevalentemente α-elicoidale, in una struttura ricca di β-sheet (Caughey et al., 2001). 
Il conformero patologico presenta altre caratteristiche, oltre a quelle strutturali, che lo 
distinguono dall’isoforma cellulare. Infatti, la PrPC è monomerica ed è sensibile alla 
proteinasi K mentre la PrPSc è un multimero caratterizzato da un’elevata resistenza 
alla digestione da parte della proteinasi K (Caughey et al., 1991). 
 
La caratteristica più importante e inusuale delle malattie TSE è la natura dell’agente 
patogeno. Anche se non è stato definitivamente dimostrato, si pensa che l’agente 
patogeno sia la proteina prionica stessa e questa asserzione viene indicata come 
“protein-only hypothesis”. Secondo questa ipotesi, la PrPSc auto-catalizza la 
propagazione della propria conformazione patologica usando l’isoforma PrPC come 
substrato (Prusiner, 1998). Infatti, il conformero patogeno della proteina prionica, 
PrPSc, potrebbe indurre la conversione di altre molecole di PrPC verso la forma 
amiloidogenica PrPSc.  
 
Dal punto di vista strutturale, la proteina prionica cellulare è una glicoproteina, 
costituita da circa 210 amminoacidi (nella forma matura) e composta da una regione 
N-terminale non strutturata e da un dominio C-terminale globulare strutturato 
(Hornemann et al., 2004). La proteina prionica è espressa maggiormente nel 
cervello, ma è stata riscontrata anche in altri tessuti non neuronali come le cellule 
linfoidi, il cuore, il tratto gastrointestinale, i muscoli, i reni e le ghiandole mammarie. 
Nonostante la PrP sia altamente conservata lungo le specie e presente in molti 
tessuti, il suo ruolo biologico non è stato ancora chiaramente delucidato. Da studi 
effettuati, sono stati ipotizzati diversi ruoli per la proteina prionica; in particolare, nel 
metabolismo neurotrasmettitore, nell’attivazione delle cellule immunologiche, 
nell’adesione cellulare, nella trasduzione del segnale, nel metabolismo del rame, 
nell’attività antiossidante e nella morte cellulare (Aguzzi et al., 2008). 
 
L’obiettivo di questo lavoro di tesi è quello di studiare le possibili interazioni della 
proteina prionica con altri partner biologici (proteine e acidi nucleici) e con piccole 
molecole organiche, utilizzando molteplici metodologie. In particolare, questo lavoro 
di tesi è stato condotto percorrendo tre linee diverse: a) lo studio dei possibili effetti di 
una piccola molecola organica, il blu di metilene (MB), sui meccanismi di formazione 
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degli oligomeri e degli aggregati amiloidi in modo tale da avere una possibile 
applicazione in ambito farmaceutico, b) lo studio dell’interazione della PrP con piccoli 
aptameri DNA ed RNA, i quali legano in modo specifico la proteina e possono quindi 
essere utilizzati nell’ambito della diagnostica, e infine c) lo studio dell’interazione 
della PrP con un enzima glicolitico, l’aldolasi C, allo scopo di indagare sui possibili 
ruoli biologici della proteina in relazione alla glicolisi (Gawinecka et al., 2010). 
 
La proteina prionica e il blu di metilene. Un importante campo di ricerca nell’ambito 
del prione è la valutazione, in vitro, di composti che possano interferire con il 
meccanismo di conversione della proteina prionica e quindi possano essere utilizzati 
come farmaci contro le malattie prioniche. Per questo scopo, nel presente lavoro è 
stata ricercata una molecola organica con determinate caratteristiche da poter 
essere usata in futuri test clinici. Il blu di metilene soddisfa tutti i criteri richiesti per un 
possibile futuro farmaco nell’ambito delle malattie prioniche: primo, è una molecola 
già utilizzata in ambito farmaceutico, per cui si conoscono le sue caratteristiche 
tossiche e farmacologiche; secondo, è una molecola capace di attraversare la 
barriera encefalica, e quindi in grado di agire nel cervello sui meccanismi che portano 
all’insorgenza di queste malattie; e terzo, il blu di metilene, ha una tossicità limitata 
per gli essere umani e gli animali.  
 
Il blu di metilene è oggi considerato un membro di una nuova classe di inibitori del 
processo di oligomerizzazione e/o fibrillazione delle proteine coinvolte nelle malattie 
neurodegenerative. L’MB è utilizzata in campo medico da più di 120 anni, per diversi 
scopi (Schirmer et al., 2011). Recentemente, l’MB sta riscuotendo molto successo 
grazie agli incoraggianti risultati ottenuti in una fase clinica II in cui questa molecola è 
stata testata su pazienti affetti di Alzheimer (Gura, 2008). Dopo sei mesi di 
somministrazione, i pazienti hanno mostrato un netto miglioramento delle funzioni 
cognitive. L’MB si è dimostrato efficace anche su altre proteine amiloidogeniche, 
come per esempio, nella formazione dei filamenti tau e nella degradazione delle 
poliglutammine (Van Bebber et al., 2010). Inoltre, MB agisce sulla deposizione della 
proteina TAR DNA (TDP-43), la quale ha una elevata tendenza ad aggregare 
(Yamashita et al., 2009). Questi risultati inducono a pensare che l’MB può avere 
proprietà anti-aggreganti che lo rendono adatto ad agire su tutte le proteine coinvolte 
nelle amiloidosi. Nonostante ciò, fino ad ora, non ci sono lavori in cui l’MB sia stato 
testato sui meccanismi di conversione della proteina prionica.  
 
Nella ricerca delle specie tossiche che portano alla morte neuronale nelle amiloidosi 
cerebrali, ci sono evidenze sperimentali che dimostrano la tossicità degli aggregati 
solubili  prefibrillari oltre che delle fibrille insolubili (Stefani et al., 2003). Per la 
proteina prionica, è stato visto che gli oligomeri sono neurotossici sia in vitro, nelle 
colture primarie neuronali, sia in vivo dopo iniezione subcorticale (Simoneau et al., 
2007). Su queste basi, nel presente lavoro si è valutato per la prima volta l’azione 
inibitoria del blu di metilene sia sui processi di oligomerizzazione che di fibrillazione 
della proteina prionica, in vitro, mediante l’utilizzo di varie metodologie, come la 
fluorescenza, la risonanza plasmonica di superficie (SPR), la calorimetria 
differenziale a scansione, la risonanza magnetica nucleare, light scattering statico, la 
microscopia elettronica a trasmissione. I risultati ottenuti dimostrano che l’MB è in 
grado di rallentare la formazione degli oligomeri della PrP, ed inoltre di ridurre la 
quantità di oligomeri che si formano. Inoltre, MB inibisce completamente la 
formazione delle fibrille amiloidi della PrP. In definitiva, i risultati ottenuti pongono le 
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basi per la valutazione del blu di metilene per test in modelli animali, come 
successivo passo verso un possibile utilizzo in fase clinica. 
 
La proteina prionica e gli aptameri del DNA e RNA. L’interazione tra la proteina 
prionica e gli acidi nucleici (NA) è sempre stata una tematica di dibattito nel campo 
del prione, da quando la “protein only hypothesis” ha portato ad un nuovo paradigma 
nella biologia. La proteina prionica è in grado di formare complessi con gli acidi 
nucleici per cui una nuova ed interessante linea di ricerca riguarda lo studio 
dell’interazione della PrP con piccole sequenze di DNA ed RNA (aptameri). Tali 
aptameri hanno una elevata affinità per la PrP e, alcuni di essi, sono in grado di 
discriminare tra le due forme della proteina, i. e., quella cellulare e quella patologica. 
Ciò trova riscontro nell’ambito della diagnostica delle malattie prioniche. Infatti, 
questo campo, nonostante gli innumerevoli sforzi compiuti, è ancora privo di valide 
strategie che permettano la diagnosi precoce di queste malattie, sia negli esseri 
umani sia negli animali. Lo studio dell’interazione della proteina prionica con queste 
piccole sequenze nucleotidiche ha permesso anche di indagare sul significato di 
queste interazioni a livello fisiologico. 
 
Nel tentativo di cercare delle caratteristiche comuni tra gli aptameri di DNA e RNA 
preposti ad interagire con la proteina prionica e finora studiati, ne sono emerse due 
riguardanti sia la sequenza degli acidi nucleici, sia la struttura che questi aptameri 
adottano in soluzione. In particolare, molte delle sequenze sintetizzate, e che hanno 
dimostrato un’elevata affinità per la proteina prionica, presentano triplette contigue di 
guanine nella sequenza (Mercey et al., 2006). La presenza di guanine favorisce la 
formazione delle quadruple eliche o G-quadruplex. Le quadruple eliche di DNA/RNA 
sono strutture gerarchiche composte da due o più tetradi di guanine (G-tetradi) 
coplanari. Molti lavori indicano che questa strutturazione è indispensabile per 
l’interazione con la PrP (Gatto et al., 2009).  
In un precedente lavoro, mediante la tecnica SELEX, un metodo di selezione e 
sintesi di acidi nucleici in grado di interagire con uno specifico target, sono stati isolati 
una serie di RNA capaci di legare in modo specifico la proteina prionica bovina 
(Murakami et al., 2008). Questi aptameri RNA presentano un core di sequenza 
(GGA)4 e si ripiegano in una struttura a quadrupla elica. Gli autori hanno pertanto 
isolato questo core costituito da quattro ripetizioni GGA, dimostrando che questa 
sequenza minima è sufficiente per mantenere un’elevata affinità verso la PrP.  
 
Sulla base di questi risultati, per questo lavoro sono stati presi in considerazione gli 
aptameri DNA ed RNA della stessa sequenza minima studiati da Murakami, et al., 
(GGAGGAGGAGGA), di cui si riferisce più semplicemente come D12 e R12. Anche 
queste sequenze sono in grado di adottare una struttura G-quadruplex, in presenza 
di ioni K+, ed inoltre formano un dimero grazie alle interazioni di stacking che si 
stabiliscono tra le G-tetradi di ogni monomero (Mashima et al., 2009). Durante 
questo progetto di dottorato è stato condotto uno studio cinetico e termodinamico 
completo relativo all’interazione tra la proteina prionica e gli aptameri, D12 e R12, 
mediante l’uso dell’SPR e della calorimetria isoterma a titolazione. Questo studio ha 
permesso di ottenere ulteriori informazioni riguardo le forze che guidano questa 
interazione e le energie connesse. Inoltre, utilizzando diversi domini della PrP (sia la 
PrP (23-234) intera, sia la proteina troncata (103-234)), è stato possibile indagare sui 
siti di legame della proteina prionica. I risultati ottenuti chiaramente dimostrano che: i) 
le forze coinvolte nell’interazione della PrP con il D12 e l’R12 sono diverse; ii) 
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l’interazione tra la PrP intera e l’R12 avviene mediante la formazione di un 
complesso in cui una molecola di PrP interagisce con un dimero R12; iii) l’interazione 
tra la proteina troncata e gli aptameri avviene mediante la formazione di un 
complesso con stechiometria diversa rispetto a quella ottenuta con la proteina intera; 
iv) l’interazione della PrP con questi aptameri coinvolge entrambi i domini della 
proteina, sia l’N-terminale (in cui sono presenti due siti di legame per gli acidi 
nucleici), sia il dominio strutturato C-terminale (in cui è presente un terzo sito di 
legame). Infine, mediante dicroismo circolare (CD), sono state studiate anche le 
variazioni strutturali che avvengono in seguito alla formazione del complesso PrP-
aptamero. L’interazione provoca variazioni strutturali nella proteina, 
indipendentemente dall’aptamero con cui interagisce, mentre è stata osservata una 
variazione strutturale solo dell’R12, in seguito alla formazione del complesso. 
 
Proteina prionica e Aldolasi C. Sebbene molti studi siano stati condotti allo scopo di 
comprendere il ruolo fisiologico della proteina prionica nelle cellule, la sua funzione 
biologica rimane tuttora un mistero. Questi studi sono stati principalmente rivolti alla 
ricerca di possibili interattori biologici che potrebbero chiarire alcuni dei processi 
cellulari in cui è coinvolta la PrP. Infatti, lo studio dell’interattomica relativa ad una 
specifica proteina può delucidare non solo le funzioni della proteina considerata, ma 
anche dei suoi rispettivi partner. Strom, et al. (Strom et al., 2006), hanno individuato 
per la prima volta, mediante tecniche di proteomica, l’interazione tra la PrP e l’enzima 
aldolasi C (AldoC), una delle tre isoforme della famiglia delle aldolasi, localizzata 
principalmente nel cervello. L’aldolasi, un enzima della via glicolitica, catalizza la 
scissione aldolica reversibile del fruttosio-1,6-bis-fosfato e del fruttosio-1-fosfato a 
diidrossiacetone fosfato e gliceraldeide-3-fosfato o gliceraldeide, rispettivamente. 
Questo enzima, nei vertebrati, può essere presente in tre isoforme diverse: aldolasi 
A, B e C le quali hanno una distribuzione differente nei tessuti. L’AldoC è localizzata 
principalmente nelle cellule Purkinje e in altre cellule neuronali, non presenta varianti 
naturali e ha proprietà catalitiche intermedie tra le isoforme A e B (Paolella et al., 
1990).  
In particolare, l’interazione della proteina prionica con l’aldolasi C è stata collegata 
alla perdita delle cellule Purkinje nel cervello di topi PrP0/0. Infatti, l’aldolasi C è 
espressa in queste cellule, e l’interazione con la proteina prionica potrebbe essere 
necessaria per la loro sopravvivenza (Strom et al., 2006). Questa interazione è di 
particolare interesse poiché rafforza l’esistenza di una correlazione fisiologica tra la 
PrP e le aldolasi. Infatti, recenti lavori riportano un aumento dell’espressione di molte 
proteine glicolitiche, tra cui l’aldolasi A e C, in pazienti affetti della malattia di 
Creutzfeldt-Jakob ed inoltre, un aumento dei livelli del trascritto dell’aldolasi C mRNA 
(Dandoy-Dron et al., 2000; Gawinecka et al., 2010).  
 
Mentre per l’aldolasi A e B si conosce in dettaglio il ruolo biologico nella glicolisi e 
nella gluconeogenesi, il ruolo fisiologico dell’aldolasi C nel cervello è molto dibattuto. 
Inoltre, non sono stati ancora riportati dati riguardanti la forza di interazione tra la PrP 
e l’AldoC, per cui l’obiettivo di questo lavoro di tesi è stato quello di caratterizzare 
l’AldoC, dal punto di vista biofisico utilizzando varie tecniche come il CD, la 
cromatografia ad esclusione molecolare e light scattering dinamico, e 
successivamente, di effettuare una dettagliata analisi termodinamica e cinetica della 
formazione del complesso PrP-AldoC mediante SPR. Lo studio di interazione è stato 
esteso anche alle altre isoforme, A e B, le quali hanno una struttura tridimensionale 
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molto simile all’aldolasi C ed hanno contribuito a delineare il tipo di interazione 
esistente tra la proteina prionica e questo enzima.   
I risultati ottenuti da questo studio mostrano per la prima volta una caratteristica 
strutturale della proteina prionica che può contribuire a delucidare un possibile 
coinvolgimento della PrP nella regolazione delle proteine glicolitiche, e quindi nella 
glicolisi. Dai risultati ottenuti si evince che la proteina prionica interagisce con tutte le 
isoforme dell’aldolasi, con comparabile affinità, ed in particolare, l’interazione avviene 
sul dominio C-terminale della PrP. Su queste basi è possibile presumere che 
l’interazione sia basata su un riconoscimento strutturale tra la PrP e le tre aldolasi 
che adottano la stessa struttura tridimensionale. 
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Summary 
 
 
A family of rare but all fatal neurodegenerative diseases which affect not only 
humans but also various animal species is related to the prion protein (PrP). The 
unique feature of these diseases is that, in addition to sporadic and inherited forms, 
they may be acquired by transmission of an infectious agent, which is represented by 
a misfolded form of prion protein, called PrPSc. Despite great efforts in the prion field, 
many questions remain unresolved related to the pathogenic mechanisms underlying 
prion diseases. The understanding of the mechanisms that lead to oligomerization 
and aggregation of PrP is necessary to find effective therapeutic strategies to 
antagonize prionopathies. In addition to the role of PrP on prionopathies, the 
physiological function of this protein in the cell is still a mystery. Many biological roles 
have been assigned to PrP, leading to presume that this protein can act in 
multicellular process, interacting with many biological macromolecules. 
  
Taking in consideration the above main issues on prion field, this thesis work was 
focused on the study of the interaction between PrP and three different molecules: a 
heterocyclic aromatic molecule, methylene blue (MB); small DNA and RNA aptamers 
with a sequence (GGA)4; and a glycolytic enzyme, Aldolase C. These molecules 
were chosen for different aims, in order to obtain further information about:  i) the 
possibility to use a compound, such as MB, for therapy against prionopathies; ii) the 
affinity of the interaction between PrP and DNA and RNA aptamers with specific 
features, that could be used for diagnosis of prion diseases and could give 
information about the biological meaning of these interactions; and finally iii) a 
possible physiological function of PrP regulated by the interaction with aldolases. 
 
In searching for a compound that could interfere with the PrPC->PrPSc conversion, 
and be potentially used as drug against prion diseases, we chose methylene blue for 
its many properties: first, MB fulfills the safety features required for drugs delivery to 
humans and animals, and secondly, it is able to cross the blood brain barrier and, 
thus, suitable to target the toxic species formed in the brain, leading to prion 
diseases. In this thesis work, MB was tested to evaluate its potential inhibition action 
on both oligomerization and fibrillization processes that are thought to be on the 
pathway to the PrP disease occurrence. To this aim, several methodologies were 
used, such as fluorescence, surface plasmon resonance (SPR), nuclear magnetic 
resonance, differential scanning calorimetry, static light scattering and transmission 
electron microscopy. This work is the first that shows the effective action of MB on 
the PrP conversion in vitro. We demonstrate that MB can slow down the formation of 
PrP oligomers and limit the amount of oligomers. Its mechanism of action seems to 
be dependent on the oligomerization pathway of PrP. Finally we demonstrate that 
MB is able to completely suppress the formation of PrP fibrils. As a consequence, we 
believe that our findings deserve the evaluation of MB for in vivo studies and 
preclinical testing for prion disease. 
 
The nucleic acids (NA) correlation with prion protein has ever been an issue of 
debate since the “protein only” hypothesis brought a new biological paradigm. The 
nucleic acids DNA and RNA form an interesting group of PrP molecular partners, and 
although the biological meaning of these interactions is not fully clear, several 
evidences suggest that NAs could have a relevant role for prion physiology and 
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pathology. Small DNA and RNA aptamers have shown to interact with PrP with high 
affinity. In an attempt to find a common shared sequence among the aptamers 
studied, it was found that some of them contain contiguous GG, and moreover, they 
can adopt a quadruplex structure. On this basis, we have studied the interaction of 
PrP with two reported DNA and RNA aptamers of sequence (GGAGGAGGAGGA), 
called D12 and R12. These aptamers, that fold in a G-quadruplex structure and are 
dimers, have shown a specific interaction with the native form of PrP. In this thesis 
work, a complete thermodynamic and kinetic investigation was performed using SPR, 
isothermal titration calorimetry and circular dichroism, in order to gain further 
information about the forces that drive this interaction. Using various PrP domains, it 
was possible to investigate also the nucleic acids-binding regions of PrP. The results 
here obtained demonstrate that the interaction between the full-length PrP and both 
D12 and R12 is driven by different types of forces. Moreover, the binding between 
full-length PrP and R12 occurs through the formation of a complex in which one 
molecule of PrP interacts with one R12 dimer. Differently, both aptamers bind to a 
deleted PrP form with a diverse stoichiometry. Finally, three putative binding sites on 
PrP are presumably involved in the interaction with these aptamers. This study has 
also allowed to evaluate the conformational changes induced by the PrP-nucleic 
acids complex formation, highlighting that PrP undergoes structural changes upon 
D12 and R12 interaction, whereas structural variations were also observed for R12, 
but not for D12. The binding study of DNA and RNA aptamers is an useful tool for the 
development of diagnostic strategies, since aptamers can be used to concentrate 
PrP from biological fluids to remove normal prions from a sample, and consequently 
enrich PrPSc.  
 
The lack of a deep understanding of PrP role in the complex machinery of living cells 
has led to an intensive study of the biological prion partners. In fact, PrP has a 
considerable number of interactors. One of these is the glycolytic enzyme Aldolase 
C, belonging to the fructose-bisphosphate aldolase family and mainly expressed in 
the brain. In our work, taking into account that, so far, no data regarding the binding 
strength of PrP-AldoC interaction have been reported, a detailed thermodynamic and 
kinetic analysis of the binding of PrP to AldoC by SPR was conducted. Our 
interaction study was extended to the other two aldolase isoenzymes, aldolase A and 
B, that share a high sequence identity, to investigate whether the binding was 
sequence specific or not. Our results showed that all three aldolases interact with 
PrP with a binding constant within the micromolar range. Moreover, using various 
PrP domains, we identify the C-terminal domain of prion protein as the binding region 
for aldolases. We surmise that the binding process between PrP and aldolase 
enzymes occurs through a 3D-structural recognition. Further research is required to 
determine the relationship between PrPC and its biological ligands, how the absence 
of the interaction is compensated, and whether the loss-of-function of PrP and its 
interactors is related to prion diseases. 
 
Ultimately, the interaction study conducted during the doctorate has brought a little 
contribution to different branches of the prion field, broadening, through several 
approaches, the knowledge of the energetics and the kinetics of the interaction of the 
prion protein with some biological interactors, such as aldolase C and nucleic acids. 
Moreover, we trust that the work on methylene blue will be taken in consideration for 
future studies and further development in prion diseases therapy.   
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Abbreviations 
 
 
∆PrP Truncated protein (103-234) 
Aa Amino acid 
Aβ Amyloid β-peptide 
AldoA Aldolase A 
AldoB Aldolase B 
AldoC Aldolase C 
bPrP Bovine prion protein 
bPrP-β β isoform of bovine prion protein, oligomer 
BBB Blood brain barrier 
BSE Bovine spongiform encephalopathies 
CD Circular dichroism 
CJD Creutzfeldt-Jakob disease 
CNS Central nervous system 
CM Carboxymethylated dextran  
DSC Differential scanning calorimetry  
Fru-1,6-P2 Fructose-1,6- (bis)phosphate 
Fru-1-P Fructose 1-phosphate 
GSS Gerstmann-Sträussler-Scheinker syndrome 
HuPrP Human prion protein 
ITC Isothermal titration calorimetry 
MALS  Multi-angle light scattering 
MB Methylene blue 
MoPrP Mouse prion protein 
NA Nucleic acid 
NMR Nuclear magnetic resonance 
OvPrP Ovine prion protein 
PAH Phenylalanine hydroxylase 
PKU Phenylketonuria 
PMCA  Protein misfolding cyclic amplification 
PrPC Cellular prion protein 
PrPSc Scrapie prion protein 
rPrP Recombinant prion protein 
SAXS Small-angle X-ray scattering 
SELEX Systematic evolution of ligands by exponential enrichment 
SLS Static light scattering 
SPR Surface plasmon resonance 
SEC Size exclusion chromatography 
TEM Transmission electron microscopy 
ThT Thioflavin T 
TSE Transmissible spongiform encephalopathies 
Wt Wild-type 
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Chapter I Introduction 
 
 
1.1 The main issue of the Prion Protein 
 
  
Prion protein is currently associated with neurodegenerative disorders that affect 
animals and humans. PrP belongs to the class of misfolded proteins that cause 
diseases by conformational changes coupled to aggregation. Besides this general 
concept, PrP diseases are unique among the misfolding-caused pathologies because 
of its causative agent. Prion diseases, in addition to sporadic and inherited forms, 
may be acquired by transmission of an infectious agent. It is near-universal accepted 
that the infectious principle consists merely of protein and is capable of replicating 
and transmitting infections without the need for informational nucleic acids (Griffith, 
1967; Prusiner, 1982; Prusiner, 1998). In fact, the origin of the word “prion” stems 
from the anagram of “proteinaceous infectious particle” resistant to inactivation by 
most procedures that modify nucleic acids, coined by Prusiner to describe such a 
unique pathogen (Prusiner, 1982).  
Since prion diseases are characterized by their transmissibility, they are also termed 
transmissible spongiform encephalopathies. The number of human and animal 
diseases recognized as TSEs has increased steadily and now includes Creutzfeldt-
Jakob disease, Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia, 
and Kuru in humans, BSE in cattle, chronic wasting disease in deer and elk, and 
transmissible mink encephalopathy. BSE has been inadvertently transmitted to a 
variety of captive animals, causing feline spongiform encephalopathy and a plethora 
of diseases in zoo animals including kudus, nyalas, and greater cats. 
The fact that prions could function as infectious agents despite the absence of a 
nucleic acid genome led to the formulation of the “protein only” or prion hypothesis. 
According to this theory, the infectious agent is a self-perpetuating conformer of PrP 
(Prusiner, 1982; Prusiner, 1998). In particular, there are two conformers of this 
protein: cellular PrPC, which is the normal conformer, and scrapie PrPSc, which is the 
infectious conformer. PrPSc was predicted to replicate during infection by contacting 
specific regions on PrPC to recruit this protein and convert it into PrPSc. Therefore, the 
conformational conversion of PrPC into PrPSc is thought to be the fundamental 
molecular event underlying all prion diseases.  
Although PrPC and PrPSc appear to share the same primary structure, they differ 
profoundly in biochemical and biophysical properties (Stahl et al., 1993). Cellular 
PrPC is monomeric, soluble in non-ionic detergents and proteinase-sensitive, 
whereas PrPSc forms large aggregates (and often appears as amyloid fibrils) which 
are insoluble in non-denaturating detergents and shows partial resistance to 
proteinase K (PK) digestion (Caughey et al., 2001; Collinge, 2001; Weissmann, 
2004). Consistent with NMR structural data for recombinant prion protein, PrPC 
isolated from normal brain is primarily α-helical, whereas low-resolution optical 
spectroscopic measurements reveal that PrPSc isolated from diseased brain contains 
mostly β-sheet structure (Pan et al., 1993; Riek et al., 1997). This suggests that the 
differences in biophysical properties between these two isoforms result from distinct 
protein conformations. 
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According to the current hypothesis, the replication of prions occurs by self-
propagation of infectious PrPSc via impression of its own abnormal conformation on 
PrPC, thereby generating additional molecules of PrPSc in an autocatalytic reaction. 
Two prevalent hypotheses exist to explain the molecular mechanism of prion 
propagation. The conversion reaction is thought to occur either by a template-
assisted refolding mechanism, in which binding of PrPSc to PrPC decreases the 
activation energy that separates the two states (Cohen, 1999), or via a nucleated 
polymerization process, in which PrPSc serves as a seed that recruits and stabilizes 
abnormal conformations of PrP, that are in dynamic equilibrium with PrPC (Caughey, 
2001). On the other side, familial prion diseases are presumed to arise because 
germline mutations in the PrnP gene favor conformational conversion of mutant PrPC 
molecules into PrPSc, without the necessity for contact with exogenous prions. 
Finally, sporadic cases are thought to be due to spontaneous conversion of wild-type 
PrPC molecules to the PrPSc state at a low frequency, or alternatively, to rare somatic 
mutations in the PrnP gene. 
A great deal of evidence now supports the validity of the prion hypothesis. A strong 
proof of this hypothesis is that expression of PrP by the host is necessary for the 
propagation of the infectious agent and for the development of the disease. It has 
been convincingly shown that Prn-p0/0 mice, in which the prion protein gene has been 
inactivated, are resistant to prion infection and do not sustain replication of the 
infectious agent (Büeler et al., 1993). There is also compelling evidence that the 
sequence of PrP encoded by the host is a major determinant of the species-
specificity, incubation time, and neuropathological characteristics of prion 
transmission (Westaway et al., 1987; Scott et al., 1989; Prusiner et al., 1990). 
Indeed, the existence of prion strains, that are associated to different incubation 
times and neuropathological profiles in a single host, was considered at the 
beginning as a significant argument against the prion hypothesis. Anyhow, recent 
evidences show that each strain may represent a distinct self-propagating 
conformation of PrPSc (Telling et al., 1996; Safar et al., 1998).  
 
Another important result supporting the prion hypothesis came from the PMCA 
method,  in which PrPSc can be amplified by incubating and sonicating PrPSc-
containing brain homogenate, diluted in normal brain homogenate. Soto and 
coworkers amplified PrPSc derived from scrapie-infected hamsters indefinitely by 
using PMCA in serial dilutions. Amplification of PrPSc was accompanied by 
amplification of infectivity (Castilla et al., 2005). In a fascinating study, there were 
identified the minimal components (PrPC, copurified lipids, and single-stranded 
polyanionic molecules) required for amplification of PrPSc, and they convincingly 
showed that prion infectivity can be generated de novo in brain homogenates derived 
from healthy hamsters using PMCA (Deleault et al., 2007). Inoculation of further 
healthy hamsters with the de novo–formed prions caused a transmissible prion 
disease. This study might be regarded as the final proof of the prion hypothesis. 
 
Despite great efforts in the prion field, many questions remain unresolved related to 
the pathogenic mechanisms underlying prion diseases. In fact, prion hypothesis does 
not explain the neuronal death observed in prion-affected brains, thus, it is still 
unclear if the neuronal damage is caused by a loss of the normal function of PrPC or 
by acquisition of a toxic property of PrPSc. Moreover, the evidence that 
neuropathology can develop in the apparent absence of PrPSc, and that PrPSc can 
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accumulate without causing clinical symptoms, argues that PrPSc itself might not be 
highly neurotoxic and that molecules other than PrPSc could be responsible for prion-
induced neurodegeneration (Lasmezas et al., 1997; Manson et al., 1999; Flechsig et 
al., 2000).  
 
Prions have assumed much wider relevance in understanding other 
neurodegenerative disorders since prionopathies are often associated with the 
deposition of amyloid-like fibrils similar to those observed in other amyloidogenic 
diseases as Alzheimer’s, Huntington’s and Parkinson’s diseases (Caughey et al., 
2003; Chiti et al., 2006). Moreover, other studies are moving toward the hypothesis 
that prion-like transmission could be a common property of all amyloid disorders 
(Walker et al., 2002). 
 
Finally, the most newly fascinating speculation comes from the similarities between 
prion propagation in mammals and fungi, suggesting that prions should no longer be 
considered as a disease-causing biological anomaly but should be thought as a 
novel regulator of cell phenotype (Tuite et al., 2010).   
 
 
1.2 Prion protein: a structural and functional overview 
 
 
Structural features of prion protein. Cellular prion protein is mostly a plasma 
membrane-anchored extracellular glycoprotein. This protein is encoded by a single 
exon as a polypeptide chain of 250 to 260 amino acids, depending on the species, 
containing at the both termini signal sequences of ca. 22 aa each (Oesch et al., 
1985). In the mature form, through post-translational modifications, the N-terminal 
signal peptide (ER SP) is removed during entry into the lumen of the endoplasmic 
reticulum (ER), whereas the C-terminal signal (GPI SP) is cleaved off, upon 
attachment of a glycosyl phosphatidylinositol (GPI) moiety to Ser230 (Basler et al., 
1986; Stahl et al., 1987; Turk et al., 1988). Additionally, inside the ER, PrPC may be 
variably glycosylated at two asparagine residues (N181 and N197) giving rise to di-, 
mono- and un-glycosylated species (Haraguchi et al., 1989).  
 
PrP contains a long NH2-proximal flexible sequence, which is followed by a globular 
COOH-proximal domain. The structurally less-defined N-terminus consists of 
residues 23–124 and contains a stretch of several octapeptide repeats (OR), flanked 
by two positively charged clusters, CC1 (aa 23–27) and CC2 (aa 95–110) (Fig. I.1A). 
Both N-terminus and C-terminus of PrP are linked by a hydrophobic stretch of amino 
acids known as the HC region (aa 111–134). Although NMR experiments showed a 
flexible disorder of the N-terminal region at pH 4.5 without any detectable secondary 
structure (Donne et al., 1997), at pH 6.2, the HGGGW and GWGQ segments of the 
octarepeats were shown to adopt a loop and a β-turn-like conformation respectively 
(Zahn, 2003).  Moreover, each octarepeat has displayed a particular affinity for Cu2+ 
(Millhauser, 2004) and weaker binding with other divalent cations such as Zn2+, Fe2+, 
Ni2+ and Mn2+ (Choi et al., 2006). 
 
In contrast, the C-terminus of PrP is structured and presents a globular fold of three 
α-helices (H1, H2 and H3) and a short, double-stranded, antiparallel β-sheet (S1, S2) 
(Wüthrich et al., 2001). A disulfide bridge between Cys179 and Cys214 (human 
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sequence numbering) links H2 and H3 (Fig. I.1B). In particular, the high degree of 
sequence identity (generally above 90%) among the known mammalian prion protein 
sequences implies an identical three-dimensional fold of the C-terminal domain. In 
Figure I.2 the sequence alignment of three PrP species (MoPrP, HuPrP and OvPrP) 
is shown. 
 
 
Figure I.1 Overview of the sequence and overall fold of PrP. A) Outline of the primary structure of the 
PrPC. CC1 and CC2 define the charged clusters. OR indicates the four octapeptide repeats. HC 
defines the hydrophobic core. MA denotes the membrane anchor region. S-S indicates the single 
disulfide bridge, and the glycosylation sites are designated as CHO. The numbers describe the 
position of the respective amino acids. B) Ribbon representation of the C‑terminal domain of mouse 
PrP. The secondary structure elements and the N‑ and C‑termini are labelled. The sulphur bridge is 
indicated in yellow. 
 
Since the first NMR structure of the C-terminal domain of mouse PrP, solved in 1996 
(Riek et al., 1996), the number of PrP entries in the PDB database has increased 
continuously. Most of them were solved by NMR, having in solution either the full-
length or truncated forms of PrP, while the X-ray structures are few and restricted to 
the C-terminal domains of the human, ovine and rabbit proteins. This could suggest 
an intrinsic tendency of these proteins to elude crystallization, presumably due to 
intrinsic heterogeneity or, more likely, to local flexibility (Pastore et al., 2007). 
 
It is worth noting that all available PrP structures were expressed in simplified host 
organisms such as E. coli, leading to overexpressed recombinant exogenous 
proteins which is neither glycosylated nor GPI anchored. Since PrP is a glycoprotein 
anchored to the lipid membrane, some concern was put into demonstrating that 
recombinant PrP is a relevant model of the native PrPC. A study on PrPC extracted 
from healthy calf brain demonstrated that native bovine PrP exhibits the same 
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circular dichroism and 1H-NMR spectra as the recombinant protein (Hornemann et 
al., 2004). Another report showed that the anchoring of recombinant PrPC to a lipid 
membrane does not affect its fold (Eberl et al., 2004). All together, this evidence 
suggests that PrPC adopts substantially the same three-dimensional structure of its 
recombinant form and legitimated the available structures as reliable models of the 
cellular protein. 
Figure I.2 Sequence alignment of MoPrP, HuPrP and OvPrP sequences. The alignment was obtained 
and color coded by Clustalx. Stars, semicolons and dots refer to conserved and partially conserved 
residues, according to Clustalx convention. 
 
Physiological behavior of prion protein. The biological cellular function of PrPC has 
remained shrouded in mystery, although its expression in most tissues and sequence 
conservation among species. PrPC is expressed most abundantly in the brain, but 
has also been detected in other non-neuronal tissues as diverse as lymphoid cells, 
lung, heart, kidney, gastrointestinal tract, muscle, retina and mammary glands 
(Horiuchi et al., 1995). At the cellular membrane, PrPC, together with other GPI-
anchored proteins, is localized in specialized domains known as lipid rafts, which are 
rich in cholesterol and sphingomyelin (Sunyach et al., 2003). However, besides the 
major GPI-anchored membrane-bound form, a fraction of the PrP molecules may be 
found in distinct topologies, notably transmembrane (De Fea et al., 1994) and 
cytosolic forms (Mironov et al., 2003). A hydrophobic segment of PrP encompassing 
residues A113–S135 (mouse PrP sequence) is a potential membrane-spanning 
domain that accounts for the synthesis of distinct topological isoforms of PrP at the 
ER: in one form, the C-terminal half is luminal and the N-terminal end is cytosolic, 
while the reverse is true for the other form (Hegde et al., 1998). Certainly, knowledge 
on cellular localization is essential to propose possible realistic functions to the PrPC. 
 
Early attempts to identify a function for PrP were hampered by the absence of overt 
phenotypic defects in PrP-null mice and of conserved structural or sequence motifs 
(Aguzzi et al., 2008). Despite these initial setbacks, subsequent studies have shown 
that PrP-null mice differ from their wild-type counterparts in many activities, including 
circadian cycles, neuroprotection, synaptic function, lymphocyte activation, cell 
adhesion, stem cell renewal and proliferation, and olfaction (Steele et al., 2007; 
Aguzzi et al., 2008). Furthermore two recent studies have uncovered new roles for 
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PrP. During zebrafish development, knockdown of either of the duplicated PrnP 
genes induces loss of cell adhesion and altered localization of epithelial-cadherin and 
FYN Tyr kinase, phenotypes that are suppressed by the expression of mouse PrP 
(Màlaga-Trillo et al., 2009). In addition, in adult mice regulated proteolysis and 
expression of PrP on the neuronal cell surface are required for the maintenance of 
myelination through a non-cell autonomous route (Bremer et al., 2010). Together, 
these studies indicate that PrP might have a pleiotropic role in vivo, perhaps 
mediating its broad effects by affecting cell signalling pathways. Figure I.3 depicts 
some theoretical models of how PrPC might influence cell signaling, endocytosis, and 
cell adhesion.  
 
 
Figure I.3 Models of the possible ways by which PrPC could exert its physiological function. 
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Endocytosis of PrPC via clathrin-coated pits or caveolae may represent a mechanism 
for the downregulation of PrPC on the cell surface. Alternatively, or additionally, 
endocytosis of PrPC leads to cointernalization of another cell component, e.g., a 
proteinaceous interacting partner, thereby regulating the presence of the latter on the 
cell surface. This regulation could positively or negatively modulate the activity of 
signal transduction pathways, e.g., via inducing degradation of the cointernalized 
partner. Moreover, an interaction with a transmembrane protein may lead to 
modulation of signal transduction pathways in the cell carrying PrPC on its cell 
surface and modulation of adhesion to adjacent cells (Aguzzi et al., 2008). 
 
Perhaps PrPC and PrPSc do not possess any intrinsic biological activity of their own, 
but modify the function of other proteins. GPI-anchored proteins must interact with 
transmembrane adaptors on the same cell or an adjacent cell to influence 
intracellular signal transduction pathway. This supposition has led to the search for 
PrP-interacting partners. In Table I.1 are summarized some of the PrPC interaction 
partners identified thus far, such as membrane proteins (receptors, enzymes, 
Caveolin-1, Na-K-ATPase, and a potassium channel), cytoplasmic proteins 
(components of the cytoskeleton, heat-shock proteins, and adaptor proteins involved 
in signaling), and even the nuclear protein CBP70.  
 
Table I.1 Molecules identified as interaction partners to PrPC or PrPSc 
Interaction parter Subcellular localization Binding Site 
Function of interaction 
partner and references 
Hsp60 and GoEL Mitochondria 180-210 Chaperone (Edenhofer et al., 1996) 
Laminin Extracellular, basement 
membrane Unknown 
Signal transduction, cell 
adhesion, neuritogenesis 
(Graner et al., 2000) 
Synapsin Ib 
 
Synaptic vesicles 
23–100 and 
90–231 
 
Synaptic vesicle formation, 
modulation of neurotransmitter 
release and in synaptogenesis 
(Spielhaupter et al., 2001) 
 
Grb2 Cytoplasm 
23–100 and 
90–231 
 
Adaptor protein mediating 
signal transduction 
(Spielhaupter et al., 2001) 
 
N-CAM 
Plasma membrane 
(transmembrane/ 
GPI-anchored) 
 
141–176 Cell adhesion, signaling, etc. (Maness et al., 2007) 
Caveolin-1 
Caveolae, plasma 
membrane 
(transmembrane) 
 
Unknown 
Caveolae formation and 
endocytosis; cross-linking of 
PrP induces Fyn activation 
(Mouillet-Richard et al., 2000) 
Fyn kinase 
Cytoplasm, associated 
with cytosolic side of 
plasma membrane 
 
Unknown Signal transducer molecule (Mouillet-Richard et al., 2000) 
β-dystroglycan 
Plasma membrane 
(transmembrane, part of 
the dystroglycan 
complex) 
 
Unknown 
Transmembrane protein, binds 
extracellularly to α-dystroglycan 
and, intracellularly, to 
dystrophin (Keshet et al., 2000) 
Dp71 (dystrophin) Cytoplasmic face of plasma Unknown 
Cytoskeletal protein (Keshet et 
al., 2000) 
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membrane (part of the 
dystroglycan complex) 
 
α-syntrophin 
 
Cytoplasmic face of 
Membrane Unknown 
Adaptor protein, in sarcolemma 
and the neuromuscular junction 
(Keshet et al., 2000) 
α-tubulin Microtubules, cytoplasm Unknown Microtubule subunit (Keshet et 
al., 2000) 
Β-actin Intracellular 
cytoskeleton protein Unknown 
Subunit of microfilaments of the 
cytoskeleton (Keshet et al., 
2000) 
BACE-1 Plasma membrane (transmembrane) Unknown 
APP processing (Parkin et al., 
2007) 
TREK-1 
 
Plasma membrane 
(transmembrane) 
 
128–230 
Two-pore potassium channel 
protein (Azzalin et al., 2006) 
 
Bcl-2 
 
Cytoplasmic face of 
mitochondrial 
outer membrane, 
nuclear envelop, and ER 
 
72–254 Inhibition of apoptosis (Kurschner et al., 1995) 
Mouse amyloid 
precursor-like 
protein 1 (APLP1) 
Plasma membrane 
(transmembrane) 
 
Unknown Neuronal survival and neurite 
outgrowth (Sakai et al., 2006) 
αB-crystalline Cytoplasm Unknown Small heat-shock protein, 
chaperone (Sun et al., 2005) 
Clathrin heavy 
chain 1 
Cytosolic face of coated 
vesicles and coated pits 
 
Unknown 
Involved in intracellular 
trafficking of receptors and 
endocytosis (Petrakis et al., 
2006) 
 
Na+/K+ ATPase 
α3 Plasma membrane Unknown 
Catalytic subunit of P-type 
ATPase, active transport of 
cations across cell membranes 
(Petrakis et al., 2006) 
Vitronectin 
Extracellular matrix 
glycoprotein 
 
105–119 
Axonal growth in the peripheral 
nervous system (Hajj et al., 
2007) 
CBP70 Nuclear and 
cytoplasmatic  Lectin (Rybner et al., 2002) 
Glycosaminoglycans 
(GAG) 
Connective tissues, 
covalently linked to 
proteins to form 
proteoglycans 
 
23–35, 23–52, 
53–93,  
110–128 
Various functions (Pan et al., 
2002) 
Aldolase C Cytoplasm Unknown 
Enzymatic activity in the 
glycolytic pathway (Strom et al., 
2006) 
ApoE Secreted 
23–90 
109–141 
 
Main apolipoprotein of 
chylomicrons, involved in 
neurodegenerative diseases 
such as Alzheimer disease 
(Gao et al., 2006) 
Plasminogen Secreted Unknown 
Inactive zymogen form of 
plasmin, which participates in 
thrombolysis or extracellular 
matrix degradation (Ellis et al., 
2002) 
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Unfortunately, the physiological relevance of most of the proposed interaction 
partners remains unconfirmed. Proteins that are not even localized to the outer leaflet 
of the cell membrane, where PrPC is located and believed to exert its function, would 
at least require an additional interacting cell component, meaning that their 
interaction with PrPC must be indirect (Aguzzi et al., 2008). 
 
Another intensive field of research is the interaction of PrP with nucleic acids. The 
exact biochemical nature of the scrapie agent is still a matter of debate, and some 
studies revealed the presence of residual amounts of nonspecific nucleic acids in 
purified preparations of PrP infectious material. These findings have motivated the 
studies of prion protein’s binding with nucleic acids (Kellings et al., 1994; Safar et al., 
2005).   
 
Many studies, in fact, have shown the more or less specifically interaction of PrP with 
various nucleic acids or nucleic acid-like molecules (Adler et al., 2003; Kocisko et al., 
2006; Lima et al., 2006). In particular, the recently developed SELEX method has 
allowed to select both DNA (Takemura et al., 2006) and RNA aptamers (Weiss et al., 
1997; Mercey et al., 2006) to specifically bind to PrP and/or PrPSc. Regarding the 
nucleic acid-binding site on PrP, some reports indicate the N-terminal half of the 
protein as a binding site of low specificity and high affinity primarily based on charge 
interaction, coinciding with the two lysine cluster (Rhie et al., 2003; Mercey et al., 
2006). On the other hand, data from small angle X-ray scattering and NMR 
spectroscopy showed that both the globular and unstructured domains of PrP are 
involved in its interaction with nucleic acids (Lima et al., 2006). 
 
The biological significance of PrP binding to nucleic acids is perhaps suggested by 
the modifications induced in both partners as a result of their interaction. Specific 
DNA sequences could reduce PrPSc accumulation (Proske et al., 2002; Rhie et al., 
2003) or, in contrast, induce conversion of recombinant PrP to a soluble β-sheet 
isoform (Cordeiro et al., 2001). Reciprocally, PrP also modified the conformation of 
nucleic acid (Gabus et al., 2001). 
 
The physiological meaning of the complexes PrP-NAs, certainly, depends upon the 
subcellular topology of PrP. If one takes into account only the location of PrP at the 
outer face of the cell membrane, the probability of encountering nucleic acids is low. 
On the other hand, both cytosolic and transmembrane forms of PrP are likely to 
interact with cellular nucleic acids.  
 
 
1.3 The dark side of prion protein: PrP as a disease-causing agent 
 
 
In the case of TSEs, a clear and irrefutable role for PrP in the appearance of 
phenotypic manifestation and spread of disease has been established. PrP is the 
major constituent of biochemically enriched preparations of the TSE agent (Prusiner, 
1998), and mice devoid of PrnP gene cannot replicate the infectious agent and are 
resistant to TSEs (Aguzzi et al., 2008). In addition, depletion of PrP, after infection, 
extends incubation times and reverses both neuropathology and behavioral defects 
induced by the infection (Mallucci et al., 2007). These observations are consistent 
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with a main role of PrP in TSE aetiology. However, an important question remains: 
what is the molecular basis of prion replication?  
 
1.3.1 Mechanisms of PrP conversion 
 
Transgenic mouse studies have provided genetic (Prusiner et al., 1990) and 
biochemical (Meier et al., 2003) evidence that the conversion of PrPC to PrPSc occurs 
through the formation of a PrPC/PrPSc complex. However, such a complex has never 
been isolated to purity.  
 
There are two models to explain the conformational conversion of PrPC into PrPSc. 
The “template-directed refolding” hypothesis predicates an instructionist role for 
PrPSc on PrPC. This model postulates an interaction between exogenously introduced 
PrPSc and endogenous PrPC, which is induced to transform itself into further PrPSc 
(Fig. I.4A). An important concept involved in this mechanism is that PrPC is 
thermodynamically less stable than PrPSc, but spontaneous conversion is kinetically 
limited. Alternatively, the seeded nucleation hypothesis suggests that PrPSc exists in 
equilibrium with PrPC. In a non-disease state, such an equilibrium would be heavily 
shifted toward the PrPC conformation, such that only minute amounts of PrPSc would 
coexist with PrPC. According to this “seeded nucleation” hypothesis, the infectious 
agent would consist of a highly ordered aggregate of PrPSc molecules and only if 
several monomeric PrPSc molecules are mounted into this ordered seed, further 
monomeric PrPSc can be recruited and eventually aggregate to amyloid. Therefore, 
monomeric PrPSc would be harmless, but it might be prone to incorporation into 
nascent PrPSc aggregates (Fig. I.4B) (Aguzzi et al., 2004). 
 
 
Figure I.4 Models for the conformational conversion of PrPC into PrPSc. A) The refolding or template 
assistance model. A high-energy barrier may prevent spontaneous conversion of PrPC into PrPSc. B) 
The seeding or nucleation-polymerization model proposes that both PrP isoforms are in a reversible 
thermodynamic equilibrium. Fragmentation of PrPSc aggregates increases the number of nuclei, which 
can recruit further PrPSc and thus results in apparent replication of the agent. 
 
In the seeding or nucleation-polymerization model, it is necessary to evoke a 
mechanism for generating new templates, since the seeded polymerization process 
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cannot account for the exponential increase in infectious titre, that is observed over 
the course of disease in mammals. Thus, in addition to the seeded-polymerization 
step, there must be ongoing polymer fragmentation to generate new templates, 
known as propagons (Masel et al., 1999) (Fig. I.3B). These “propagons” or shorter 
fibrils, which may result from breakage of frangible structures, should be more 
infectious than longer fibrils (Silveira et al., 2005), an observation consistent with the 
fact that a larger number of free ends in a short fibril population leads to more rapid 
conversion of soluble cellular prion protein into misfolded fibrillar form (Aguzzi et al., 
2009). Furthermore, in in vitro growth assays of many amyloid fibril systems, it has 
been noted that agitation significantly enhances the overall conversion rate of 
proteins into fibrillar forms (Kim et al., 2007), indicating that fibril breakage is an 
essential factor determining the rate of amyloid formation. 
 
The polymer fragmentation mechanism that would follow the first step of PrPSc 
oligomer-growth is now well supported by experimental studies with yeast prions, in 
which the fragmentation of prion polymers is catalyzed by the molecular chaperone 
heat shock protein 104 (Hsp104), in conjunction with other co-chaperones 
(Haslberger et al., 2010). Analogously, there are indications that similar processes 
govern the growth of mammalian prions (Legname et al., 2004; Castilla et al., 2005) 
as well as non-prion-related amyloid fibrils (Dobson, 2003).  
 
1.3.2 Intermediates in prion protein conversion: PrP polymerization 
 
In the evolution of prion pathology, the conformational change of PrP is accompanied 
by an increase in β-sheet content and in the same way an increase of the 
amyloidogenic propensity of the PrP (Mckinley et al., 1983). The amyloid property of 
PrPSc implicates an important specificity that is the polymeric state of the pathological 
protein. Thus, the acquisition of amyloidic properties during PrP conversion 
underlines the importance of the polymerization process (i.e. acquisition of a 
quaternary structure) in the evolution of the pathology. 
  
Many efforts have been made to characterize the quaternary structure of PrPSc to 
better understand the mechanism underlying PrP conversion, and to establish what 
is the toxic PrP form that ultimately leads to neuronal death. Indeed, while the PrP 
fibrillization conditions were widely studied previously (Swietnicki et al., 2000; 
Baskakov et al., 2002; Rezaei et al., 2005), only recently, amyloidogenic oligomeric 
structures have been associated with the manifested biological effects, highlighting 
the neurotoxic activity of recombinant PrP oligomers, in vitro and in vivo 
(Kazlauskaite et al., 2005; Simoneau et al., 2007), in agreement with other studies on 
neurodegenerative diseases (Lashuel et al., 2002). A few years ago, Silveira et al. 
(Silveira et al., 2005) determined the smallest size of infectious PrP assemblage. 
This investigation revealed that 15 to 28 mer of PrP harbour the necessary 
information for the replication of the infectious agent whereas smaller (less than 
5mer) and larger PrP oligomers show less or no infectivity. Thus, in vitro and in vivo 
independent studies converge on the key role of PrP oligomers. 
 
It has been shown that the folding pathway of PrP differs depending on the species 
considered and the physico-chemical conditions used (Chakroun et al., 2010). There 
are several types of conditions that lead to the formation of either β-enriched PrP 
oligomers or PrP amyloid fibrils. The first condition used was a partial unfolding 
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induced by chaotropic agent as urea or Guanidine HCl at acidic pH (Bjorndahl et al., 
2011). Further, formation of β-enriched oligomers was induced by heating and acidic 
pH or neutral pH without using other agents (Lu et al., 2002; Rezaei et al., 2002; 
Rezaei et al., 2005). The latter condition has the advantage of affecting exclusively 
the folding energetics of the protein, whereas either chaotropic agents or detergents 
may also impact the surrounding water molecules and/or participate to the newly 
formed structure as either cofactors or chemical chaperon (Rezaei, 2008). 
 
With the assumption that oligomeric intermediates, having a peculiar structure, are 
the neurotoxic initiators in prion diseases, a consequent question arises: why these 
PrP forms are toxic to cells?. The conversion of a protein from its native state into an 
oligomeric form invariably generates a wide distribution of misfolded species, which 
expose an array of groups that are normally masked in globular proteins. The 
improper interactions between oligomers and cellular components, such as 
membranes, small metabolites, proteins, or other macromolecules, may conceivably 
lead to the malfunctioning of the cellular machinery. Depending on the cell type 
involved, the result could be impairment of axonal transport, oxidative stress, 
sequestration of essential proteins, or a combination of disparate factors, ultimately 
leading to apoptosis or other forms of cell death. For this reason, an optimal strategy 
used in the research of possible anti-prion agents, is to prevent aggregation or even 
production of the amyloidogenic protein before it can generate any potentially 
damaging intermediates. 
 
1.3.3 The uncertain landscape of therapeutic strategies in prion diseases 
 
The current therapeutic strategies for prion diseases are not fully satisfactory. Thus 
far, no vaccine, nor disease reversing therapeutic compounds nor strategies (cure) 
exist. The current therapeutic strategies are primarily aimed at preventing the PrPC-> 
PrPSc conversion. Indeed, different strategies can be applied in order to prevent the 
interaction of cellular PrP with the pathological isoform and so averting subsequent 
conversion. 
 
Targeting PrPC expression is one of the strategies that have been experimented to 
avoid the prion conversion, and is based on the following observations: i) PrPC is 
required for susceptibility to prion disease (Brandner et al., 1996), and ii) a reversal of 
neuropathological and behavioral abnormalities has been observed in scrapie-
inoculated mice when neuronal expression of PrPC was eliminated, despite the 
continued presence of PrPSc deposits and accumulation of infectivity (Mallucci et al., 
2003; Mallucci et al., 2007). Effective methods for reducing PrPC expression in cell 
culture include the use of small interfering RNA (siRNA) to the Prnp gene (Tilly et al., 
2003), and recently, a lentivirus vector, designed to express a short hairpin RNA 
(shRNA) had significant effect in vitro and in a chimeric mouse infected with scrapie 
(Pfeifer et al., 2006).  
 
Another strategy takes into account that compatibility of PrPC and PrPSc is necessary 
for efficient conversion of PrPC by a particular PrPSc strain. Indeed, incompatibility 
can be a result of differences in prion protein between species (Horiuchi et al., 2000) 
or specific amino acid substitutions (Palmer et al., 1991). These studies indicate that 
incompatible PrPC not only resists to conversion but is also capable of blocking the 
conversion of compatible sensitive PrPC molecules. Alternatively, PrPSc may be 
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prevented from migrating to the central nervous system (CNS) or measures may be 
taken to increase clearance of PrPSc using branched polyamines or β-breaker 
peptides.  
 
Finally, an impressive wealth of molecules has been considered as potential antiprion 
compounds capable to bind PrPC and, thus, rendering the cellular form inaccessible 
or incompatible for conversion to PrPSc. Even if many of these compounds were 
shown to be able to slow down the progression of prion disease in vitro or in rodent 
models, few have made their way into human trials or case reports, including early or 
prophylactic treatments and later stage therapies. The unsatisfactory conclusion is 
that none of these therapeutic lead compounds has yet proven their usefulness in 
clinical settings, and some have conspicuously failed. 
 
A non-exhaustive list includes compounds as diverse as Congo red (Caughey et al., 
1992), amphotericin B, anthracyclins (Tagliavini et al., 1997), sulfated polyanions 
(Caughey et al., 1993), porphyrins and phthalocyanines (Caughey et al., 1998), 
lysosomotropic factors as quinacrine (Barret et al., 2003), acridines and 
phenothiazines (Korth et al., 2001), the spice curcumin (Caughey et al., 2003), and 
the single-stranded phosphorothioated analogs of natural nucleic acids (Kocisko et 
al., 2006). 
 
Additional hurdles may lie in the identification of compounds that have specific 
features to act in the CNS. They must be effective in vivo, with a low toxicity for 
humans and animals, must have a well-known pharmacological behavior and a 
safety profile to allow for applicability in the clinical phase of disease. Finally, but not 
less important, they must be able to cross the blood-brain barrier. This is a feature 
that has been underestimated in the past, in finding suitable anti-prion agents. In fact, 
some of the compounds that showed good results on the inhibition of prion 
conversion in vitro, inevitably failed in vivo, for the simple reason that they are not 
able to pass the blood-brain barrier.  
 
However, many compounds show some prophylactic or early treatment effect in 
TSE-infected animals. Therefore, there are hopes that future advances on drug-
research could bring better clinical results.  
 
 
1.4 Thesis aims 
 
 
The main protagonist of this work is the prion protein, a complex entity, involved in 
fatal neurodegenerative disorders. Although prion field has undergone excellent 
progress in recent years, many questions still need to find an answer, starting from 
the physiological role of this protein in the cell, to the actual propagation mechanism 
of the infectious disease and the possible diagnosis and cures for prionopathies. 
 
This thesis work was focused on the study of the interaction between PrP and three 
different molecules: a heterocyclic aromatic molecule, methylene blue; small DNA 
and RNA aptamers with a sequence (GGA)4; and a glycolytic enzyme, Aldolase C. 
These molecules were chosen for different aims, in order to obtain further information 
about: i) the possibility to use a compound, such as MB, for therapy against 
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prionopathies; ii) the affinity of the interaction between PrP and DNA and RNA 
aptamers with specific features, that could be used for diagnosis of prion diseases 
and could clarify the biological meaning of these interactions; and finally iii) a 
possible physiological function of PrP regulated by the interaction with aldolases. 
 
In Chapter II, the study of the effects of methylene blue on both oligomerization and 
fibrillization process of prion protein is addressed. A widely explored field in prion is 
the evaluation, primarily in vitro, of compounds that can interfere with the PrPC -> 
PrPSc conversion, and be potentially used as drugs to avoid, suppress or ameliorate 
the clinical phase of prion diseases. To this purpose, we have not added a new 
molecule to the large ensemble of existing compounds and alleged anti-prion agent. 
Conversely, we sought a known molecule that, firstly, fulfilled safety features to act in 
humans and animals, and secondly, can actually be considered for future in vivo 
tests. Methylene blue has satisfactorily answered all the requests that we demanded 
for an anti-prion agent. Therefore, in this work, methylene blue was tested to 
evaluate its potential inhibition action on both oligomerization and fibrillization 
processes that are thought to be on the pathway forward the disease occurrence. 
The results obtained could be taken in consideration for future test of MB on animal 
models. 
 
In Chapter III, the specific interaction of two DNA and RNA sequence aptamers, 
(GGAGGAGGAGGA), with prion protein is described. Small DNA and RNA aptamers 
form an interesting group, that is gaining increasing attention as tools to investigate 
the biological meaning of the interactions of PrP with nucleic acids and to develop 
new diagnostic assays for prion diseases. In this thesis work, a complete 
thermodynamic and kinetic investigation was performed to gain further information 
about the forces that drive this interaction. Moreover, using various PrP domains, it 
was possible to investigate also the putative nucleic acids-binding sites of PrP. This 
study has allowed also to evaluate the effects of the PrP-nucleic acids complexes 
formation on both complex partners.  
 
Finally, one of the most intriguing puzzles of prion biology is the physiological role of 
prion protein in the cell. The lack of a deep understanding of PrP role in the complex 
machinery of living cells has led to an intensive study of the biological prion partners 
that might help to fill the gap still present in this field. In fact, the prion protein has a 
considerable number of interactors that can give rise to simple complexes or 
supramolecular systems, in which PrP interacts with more proteins. One of these 
interactors is the glycolytic enzyme Aldolase C, belonging to the fructose-
bisphosphate aldolase family. Therefore, we carried out a detailed thermodynamic 
and kinetic analysis of the binding of PrP to AldoC, that is presented in Chapter IV. 
Our interaction study was extended to the other two aldolase isoenzymes, aldolase A 
and B, to investigate whether the binding was sequence specific or not. This study 
has afforded to add a gusset over the mysterious backdrop of the biological 
interactions of prion protein.  
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Chapter II Prion Protein and Methylene Blue 
 
 
2.1 Methylene Blue and its role in the therapeutic world 
 
 
In the field of prion disease therapies, many classes of compounds have been 
evaluated in vitro and in animal models to prevent and treat these diseases in 
animals and humans. Of the many compounds studied, a few have made their way 
into human trials or case reports, and the effectiveness of treatment administered at 
the onset of clinical symptoms, or at late stage, is low. The development of 
successful treatments has been hindered by the incomplete understanding of prion 
disease pathogenesis. Indeed, it is not known how PrPSc formation and/or 
accumulation leads to pathology. Large aggregates of PrPSc are neither necessary 
nor sufficient to cause clinical disease in all cases, and it may be that soluble 
oligomeric forms of prion protein (PrP) are more relevant to mechanisms of infection, 
conversion and toxicity (Silveira et al., 2005). 
 
The research of prion disease treatment moves on two different tracks. One is 
referred to the early treatment regimes, that include various prophylactic compounds 
and immunotherapies, and it has sought efficacy through neutralization of infectious 
sources, blockade of infection via the most common peripheral routes, and/or 
blockade of neuroinvasion. This research line has encountered many difficulties due 
to the lack of early diagnosis methods for prionopathies. Therapies targeting later 
disease, that are initiated after the appearance of clinical signs, are included in the 
second track of research. These therapies would involve some combination of 
inhibiting pathogenic PrP formation, destabilizing or enhancing clearance of existing 
pathogenic PrPSc, blocking neurotoxic effects of the infection, and/or promoting the 
recovery of lost functions in the CNS.  
 
Most of the studies searching for anti-aggregation compounds, not only for prion 
diseases, but also for all the pathologies that involve formation and deposition of 
amyloid aggregates in the brain, have been conducted in vitro. Although in vivo tests 
provide the most rigorous evaluations of anti-TSE treatments, the low occurrence of 
this type of test is due to their slowness, high cost, and impracticability for screening 
purposes. On the contrary, a great variety of relatively high throughput, low cost, cell 
culture models and noncellular in vitro assays have enabled the identification of a 
number of different classes of anti-prion compounds, that then have shown efficacy 
in animal models. Moreover, in vitro assays have allowed investigation of the 
mechanisms of prion inhibition (Sim et al., 2009).  
 
Some screened and tested in vitro class of compounds, aimed to inhibit the PrPC -> 
PrPSc conversion, are polyanions, sulphonated dyes as congo red and curcumin, 
cyclic tetrapyrroles, lysosomotropic factors as quinacrine, acridines and 
phenotiazines, peptide aptamers and β-sheet breakers. Many inhibitors prevent 
conversion by directly binding to PrPC (Caspi et al., 1998; Kuwata et al., 2007) or to 
PrPSc (Nicolla et al., 2010) and, thus, blocking interactions between them. Others 
affect conversion by interfering with intermediates formed during the PrP conversion, 
or by altering PrPC expression and distribution (Caughey et al., 2006). 
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Recent investigations are increasingly devoted to seek anti-aggregation compounds 
that may help to treat a whole set of independent proteinopathies. This new approach 
is grounded on the common structure of amyloids. In this scenario, a phenothiazine 
derivative, methylene blue, has shown to possess anti-aggregation activity for many 
misfolded-proteins associated to amyloidogenic diseases. Indeed, it was reported 
that MB is able to inhibit the beta amyloid Aβ42 oligomerization (Necula et al., 2007), 
as well as tau filament formation, in vitro (Taniguchi et al., 2005; Van Bebber et al., 
2010). Moreover, MB prevents deposition of the TAR DNA-binding protein of 43 kDa 
(TDP-43) in a cell culture model based on ectopic overexpression of TDP-43 
variants, lacking their nuclear localization signals and thus facilitating cytoplasmic 
accumulation and aggregation (Yamashita et al., 2009). Finally, MB has recently 
attracted an increasing attention, since the outcome of a phase II clinical trial of MB 
treatment for AD patients has shown encouraging results as significant improvement 
of cognitive functions (Oz et al., 2009).  
 
Although other molecules, belonging to the phenothiazine class, have been 
evaluated, in vitro, in order to test their inhibition action on prion protein (Korth et al., 
2001; Barret et al., 2003), MB was almost neglected for investigations on prion 
diseases. Nevertheless, MB gathers several properties required for drug candidates 
expected to act in the central nervous system: it has a low toxicity in rats and humans 
(Riha et al., 2005), is able to cross the blood-brain barrier (Peter et al., 2000) and is 
approved for use in humans (Di Santo et al., 1972).  
 
MB is a tricyclic phenothiazine drug (Wainwright et al., 2005). Under physiological 
conditions it is a blue cation which undergoes a catalytic redox cycle: MB is reduced 
by nicotinamide adenine dinucleotide phosphate (NADPH) or thioredoxin to give 
leucoMB, an uncharged colorless compound. LeucoMB is then spontaneously 
reoxidized by O2 to MB (Fig. II.1). The typical redoxcycling of MB in vivo can be 
illustrated in vitro using the famous blue bottle experiment: MB is visibly reduced by 
glucose to give leucoMB and then, by opening the lid of the bottle it is reoxidized by 
atmospheric O2: the blue color comes back. After closing the lid, there is a lag phase 
and then MB is reduced again (Schirmer et al., 2011). 
 
 
Figure II.1 The catalytic redox cycle of methylene blue in vivo. 
 
The chemico-physical properties corresponding to both MB reduced and oxidized 
forms are summarized in Table II.1. It is worth mentioning that, at concentrations 
higher than 10 µM, MB forms dimers.  
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Table II.1 Chemico-physical properties of both MB forms 
 
  * KD corresponds to the dissociation process of the MB dimer: (MB)2  2MB 
MB, the first synthetic drug used, has 120-year history in several areas of medicine, 
and one of its first uses was in the treatment of malaria (Guttmann et al., 1891). It 
has shown to exhibit effects on several cellular targets including NO synthase, 
cythocrome c oxidase, and the 70-kDa heat shock protein (Callaway et al., 2002; 
Atamna et al., 2008; Jinwal et al., 2009). Furthermore, its biochemical properties 
make it a very effective redox cycling compound, with antioxidant and 
neuroprotective properties (Hajieva et al., 2009).  
Current indications for MB, approved by the US Food and Drug Administration, are 
enzymopenic hereditary met-hemoglobinemia and acute acquired met-
hemoglobinemia (Cawein et al., 1964), prevention of urinary tract infections in elderly 
patients, and intra-operative visualization of nerves, nerve tissues, and endocrine 
glands as well as of pathologic fistulae (O’leary et al., 1968). Of great practical 
importance is also the administration of MB for the prevention and treatment of 
ifosfamid-induced neurotoxicity in cancer patients (Kupfer et al., 1994). 
 
In clinical practice, MB is available as a solution (1%, w/v; 10 g/l or 26.74 mM) and 
the recommended safe dose appears to be within 1-4 mg/kg (Clifton II et al., 2003). 
Typically, MB is administered i.v. or orally (50–300 mg), but interosseous MB infusion 
has also been described (Herman et al., 1999). After oral administration of 100 mg 
MB, whole blood MB concentrations in healthy individuals were reported to be one 
order of magnitude lower than after i.v. administration of the same dosage (Peter et 
al., 2000). However, a recent study comparing the administration of single doses of 
MB (50 mg i.v. versus 500 mg orally) indicated that the absolute bioavailability of MB 
after oral administration was 72.3% (Walter-Sack et al., 2009). 
 
From the toxicological point of view, MB is relatively non-toxic and has an enviable 
safety record. In one notable pediatric case report (Blass et al., 1976), a child was 
given a dose that was 16 times the recommended maximum. The child’s skin was 
intensely blue, but there were no other documented ill effects. Most side effects of 
MB appear to be dose-dependent and do not occur with doses < 2 mg/kg, a dose 
range that is widely used in the clinical applications of MB. In in vitro studies, MB 
demonstrates biological actions at a wide range of concentrations, from 0.1 nM to 10 
mM, and toxic effects have only been reported at concentrations higher than 100 
mM. 
* 
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Aware of the fact that in the prion field there is an urgent need to find an effective 
treatment for prion diseases, and that the extreme cost of drug development is the 
major obstacle when new drug programs have to be processed, we aimed to give a 
little contribution, looking for a known molecule, that fulfills all the safety features 
required to be used in animals and humans, and furthermore, a molecule with 
specific properties to act in the CNS. MB satisfies the criteria for a BONARIA drug. In 
the acronym BONARIA, BON stands for safe and efficacious, A stands for affordable, 
R stands for registered, and IA stands for internationally accessible. 
In particular, we carried out an in vitro study, testing the action of methylene blue on 
the oligomerization and fibrillization of prion protein, the two main processes on the 
pathogenic pathway of the disease. We have found that MB is able to slow down the 
PrP oligomer formation, and completely suppress the fibril formation. In this work we 
finally propose a possible mechanism of action of MB on prion conversion. 
 
 
2.2 Experimental procedures 
 
 
• Protein production 
The full-length PrP from sheep OvPrP (A136 R154 Q171 variant), the truncated form 
∆OvPrP (103-234) and the mouse PrP (MoPrP) were produced in Escherichia coli 
and purified as previously described (Rezaei et al., 2000). All the mutants from 
sheep, OvPrP_H190A, OvPrP_H190KI208M and ∆OvPrP_I206W were obtained by 
introducing the respective mutations into the ARQ gene cloned in a pET22bC vector 
by using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA). The mutants 
were purified through the protocol used for the wild-type prion protein. Different 
buffers were used to desalt the protein on a HiPrep desalting column using an FPLC 
equipment (GE Healthcare): sodium citrate 20 mM, pH 3.4; sodium acetate 20 mM, 
pH 4.6; MOPS 20 mM, pH 7.0. Final protein concentration was measured by optical 
density at 280 nm using an extinction coefficient of 58718 M-1 cm2 for OvPrP (wt ad 
mutants) and MoPrP, and an extinction coefficient of 18005 and 23505 M-1 cm2 for 
∆OvPrP and for ∆OvPrP_I206W, respectively, deduced from the aminoacid 
sequence. 
The generation of oligomers from OvPrP and MoPrP was performed in sodium citrate 
20 mM, pH 3.4. Both protein solutions, at a concentration of 100 µM were incubated 
in a thermocycler Perkin Elmer GenAmp2400  and heated at 60 °C for 12 hours and 
at 50°C for 8 minutes for OvPrP and MoPrP, respectively. Then the samples were 
cooled down to 15 °C and eluted with sodium citrate 20mM, pH 3.4 on a TSK 
4000SW (60 x 0.78 cm) column. Homogeneous fractions of each oligomer were 
collected. 
 
• Fluorescence experiments 
Fluorescence spectra were recorded at 20 °C on a Jasco 6200 spectrofluorimeter 
with a 2 mm x 10 mm optical path-length cuvette. An excitation wavelength of 285 
nm was chosen and for all the experiments the protein concentration range used was 
20-30 µM in sodium acetate 20 mM, pH 4.6.  
Concentration of MB varied from 0 up to a molar ratio PrP:MB of 1:5. Each solution of 
the mixture PrP-MB was prepared independently without successive additions of MB 
in the PrP solution to avoid complications due to dilution effects within titration type 
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experiments. Each measurement was repeated in triplicate and appropriate blanks 
corresponding to the buffer were subtracted to correct the fluorescence background.  
It was used the Stern-Volmer equation to evaluate the type of quenching resulting 
from fluorescence experiments performed (Lakowicz, 1999).   
                                             


= 1 + 	 []1 + []                  Eq.1 
where F0 and F are the fluorescence intensities before and after the addition of the 
quencher respectively. The first factor on the right-hand side describes the static 
quenching, resulting by formation of a complex between quencher and fluorophore, 
with Keq as the equilibrium constant of the binding reaction. The second factor is 
related to the dynamic quenching, resulting from encounters of quencher and 
fluorophore during the fluorescence lifetime where kq is the bimolecular quenching 
constant, τ0 is the lifetime of the fluorophore in the absence of quencher and [Q] is 
the concentration of the quencher.  
 
• Surface Plasmon Resonance 
The SPR experiments were performed using a Biacore T100 system (GE Healthcare, 
Uppsala, Sweden). The full-length OvPrP and the truncated ∆OvPrP were 
immobilized on a CM5 using a standard amine coupling procedure, using HBS-EP 
buffer (HEPES 10 mM, NaCl 150 mM, EDTA 3 mM, 0.005% Surfactatnt P20, pH 7.4) 
as running buffer. The PrP forms were immobilized through activation of the sensor 
chip with 60 µL of N-hydroxysuccinimide (NHS) and N-ethyl-N-(dimethylaminopropyl) 
carbodiimide (EDC), followed by 30 µL injection of PrP forms diluted in 10 mM 
sodium acetate buffer pH 5.0. Unreacted activated groups were blocked by a 15 µL 
injection of 1 M ethanolamine.  
Various concentrations of MB were prepared in running buffer up to 500 µM, since 
the completely regeneration of the sensor surface was not possible at higher 
concentrations. Then, MB was injected over the flow cell of the chip for 1 minute at a 
flow rate of 30 µL/min. Data were corrected using a blank sensor chip as control. The 
analysis of the SPR sensorgram was made using BIAevaluation software.  
 
• Circular Dichroism 
CD spectra were recorded with a Jasco J-815 spectropolarimeter equipped with a 
Peltier type temperature control system (Model PTC-423S). The instrument was 
calibrated with an aqueous solution of d-10-(+)-camphorsulfonic acid at 290 nm. 
Molar ellipticity per mean residue, [θ] in deg cm2 dmol-1, was calculated from the 
equation: [θ] = [θ]obs·mrw/10·l·C, where [θ]obs is the ellipticity measured in degrees, 
mrw is the mean residue molecular weight, 109 Da, C is the protein concentration in 
g L-1 and l is the optical path length of the cell in cm. ). Far-UV CD spectra of full-
length OvPrP in absence and presence of MB were recorded in the range 260 ÷ 190 
nm at 20 °C, using a 0.2-cm optical path length quartz cuvette. The protein 
concentration used was 6 µM in sodium acetate 15 mM, pH 4.6. Each CD spectrum 
was obtained by averaging 3 scans collected with a time constant of 4 s, a 2-nm 
bandwidth, and a scan rate of 5 nm min-1. The baseline was corrected by subtracting 
the buffer spectrum. Thermal denaturation curves of full-length OvPrP with and 
without MB were recorded over the 20 ÷ 90 °C temperature range and by monitoring 
the CD signal at 222 nm. All curves were obtained using a scan rate of 1.0 °C min-1. 
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Reversibility of the denaturation was evaluated by recording, after cooling to 20 °C, 
the spectra of samples subjected to a first temperature scan. 
For all CD measurements, concentration of MB varied from 0 up to a molar ratio 
PrP:MB of 1:20. Each solution of the mixture PrP-MB was prepared independently.  
 
• Size exclusion chromatography 
The oligomerization pathways of each PrP forms were analyzed using Akta FPLC 
chromatography equipment (GE Healthcare) on a TSK 4000SW (60 x 0.78 cm) 
column. The column was previously calibrated for molecular mass using a Gel 
Filtration High Molecular Weight calibration kit (GE Healthcare) constituted by 
ovalbumin (44 kDa), conalbumin (75 kDa) and aldolase A (158 kDa). Before each 
run, the column was equilibrated with at least two column volumes of elution buffer 
and each run was performed at room temperature. The elution buffer was sodium 
citrate 20 mM, pH 3.4 and the eluent flow was 1 mL min-1. The elution profile was 
monitored at two UV absorption wavelengths (280 nm and 215 nm). The 
concentration of proteins used was 40 µM and each protein solution was incubated 
at 50 °C at different incubation time, ranging from 0 to 90 minutes. 
 
• Static light-scattering Experiments  
The static light-scattering kinetics experiments were performed on a homemade 
device with four lasers beams (407, 473, 533, and 633 nm) using a 2 mm cuvette. 
The oligomerization of OvPrP, MoPrP and the mutants OvPrPH190A and 
OvPrPH190KI208M was monitored at 50 °C. The concentration of protein samples 
was in the range 30 ÷ 50 µM in 20 mM citrate sodium, pH 3.4 or MOPS 20 mM, pH 
7.0, depending on the pH condition tested. To estimate the percent decrease of the 
SLS intensity signal in the presence of MB with respect to the one of the protein 
without MB, the SLS values, at the maximum recorded time, were considered for 
each curve. 
For depolymerization experiments, O1 and O3 oligomers obtained from SEC 
purification were incubated, at a concentration of 8 µM, in the SLS device at 75 °C 
and 55 °C, respectively. Signal processing was achieved by a homemade MatLab 
program. 
 
• Differential scanning calorimetry 
DSC thermograms were obtained by a MicroCal DSC instrument with cell volumes of 
0.5 mL, at a scan rate of 60 and 90 °C/hour. All the experiments were performed with 
the full-length OvPrP at 50 µM, using three different pH conditions: sodium citrate 20 
mM, pH 3.4, sodium acetate 15 mM, pH 4.6 and MOPS 20 mM, pH 7.0. For each 
condition, at least two thermograms were recorded with and without MB at a molar 
ratio PrP:MB of 1:4. DSC thermograms were analyzed with ORIGINLab software. 
Deconvolution of DSC curves obtained at pH 7.0 was achieved by a homemade 
MatLab program applying the Lumry–Eyring model (Sanchez-Ruiz, 1992). To 
estimate the percentage of oligomers formed in the absence and in the presence of 
MB, we calculated the area of the deconvoluted peaks corresponding to the second 
transition. 
 
• PrP fibrillization and electron microscopy 
All solvents and solutions prepared for fibril formation were filtered using 0.02-µm 
filters prior any usage. Lyophilized HuPrP and OvPrP were dissolved in MES 50 mM, 
pH 6.0. The fibrillization reaction was started diluting the PrP stock solution (44 µM) 
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to a final concentration of 22 µM in 2.0 M GdnHCl and 0.5 mM MES, pH 6.0. For the 
samples with methylene blue, MB was dissolved in water to a final concentration of 
22 ÷ 220 µM. All the samples were incubated at 37 °C. 
The kinetics of fibril formation was monitored using a ThT binding assay. During 
incubation at 37 °C, aliquots of the solutions were collected at regular  time intervals 
and diluted in  sodium acetate 10 mM, pH 5.0 to a PrP final concentration of 0.3 µM. 
Then, ThT was added to a final concentration of 10 µM. For each sample, emission 
spectra were recorded using a Jasco 6200 spectrofluorimeter with a 2 mm x 10 mm 
optical path-length cuvette and an excitation wavelength of 445 nm. Both excitation 
and emission slits were 5 nm. Spectra were averaged upon three measurements (n) 
and the fluorescence intensity at emission maximum (482 nm) was determined. To 
evaluate if MB could interfere with the ThT emission, fluorescence spectra of the 
solutions containing alternatively only ThT and both ThT and MB were recorded, at 
the maximum concentration used for the samples PrP-MB. The emission of ThT was 
the same with and without MB. 
Fibril morphology was analyzed by TEM using a Zeiss EM902 (80kV) microscope. 
Briefly, 10 µL of the protein samples were adsorbed onto carbon-coated Formvar 
grids (Agar Scientific). Then, each grid was washed three times with water, stained 
with 2% uranyl acetate and finally air-dried.  
 
 
2.3 Results 
 
 
Interaction between the native monomeric PrP and methylene blue. 
 
In order to evaluate if there is a specific binding of prion protein with MB at pH 4.6, 
we used different approaches, namely, Trp fluorescence and SPR. In the prion 
primary structure, there are seven tryptophan residues, all located within the N-
terminal domain. This domain is highly flexible and lacks any identifiable secondary 
structure (Donne et al., 1997; Riek et al., 1997), leading to a complete exposure of all 
the Trp residues. This particular arrangement of the tryptophans in a restricted region 
of the protein allows to identify the binding region of prion protein to MB. Indeed, for 
fluorescence experiments we used the full-length OvPrP (23-234) and the truncated 
form ∆OvPrP (103-234) with the mutation I206W, since the C-terminal domain lacks 
tryptophan. In ∆OvPrP, a Trp was placed at position 206 replacing the residue Ile, 
that in the 3D structure is exposed on the protein surface. 
 
Figure II.2 shows the fluorescence spectra recorded for the full-length OvPrP and 
∆OvPrP_I206W in the presence of MB at increasing molar ratio PrP:MB up to 1:5. 
The quenching phenomena of MB on the full-length OvPrP and ∆OvPrP results in a 
decrease of the intensity fluorescence with the increase of MB concentration. Such 
effects are indicative of fluorescence quenching and can be used to characterize the 
PrP-MB interaction by the well-known Stern-Volmer equation (Lakowicz, 1999). 
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Figure II.2 Fluorescence titrations for the interaction of prion protein with MB. A) Spectra related to the 
full-length OvPrP with MB; B) Spectra related to ∆OvPrP_I206W with MB 
 
Figure II.3 shows the Stern-Volmer plot of the PrP proteins quenching caused by the 
presence of methylene blue. The Stern-Volmer plot was found to be linear for both 
the full-length OvPrP and ∆OvPrP_I206W, which means that only a dynamic 
quenching occurs. 
 
It has to be taken into account that the full-length OvPrP embodies seven Trp and all 
of them contribute to the Stern-Volmer equation with their own dynamic and static 
constants. In general, when there are more fluorophores in a protein, if the difference 
between the quenching constants is not large, the Stern-Volmer plots may appear 
approximately linear (Calhoun et al., 1986). Thus, for the full-length OvPrP all the 
tryptophans are dynamically quenched by MB with similar dynamic quenching 
constants, that is reliable since the N-terminal domain of the protein is not structured 
and all the Trp are similarly exposed.  
 
Figure II.3 Stern-Volmer plot of the full-length and the truncated PrP quenching caused by the 
presence of MB 
 
Because both full-length and truncated OvPrP fluorescence intensity progressively 
decrease with increasing concentrations of MB, without reaching saturation, MB does 
not establish a specific interaction with PrP. 
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It is noteworthy that fluorescence measurements provide only information about the 
structural integrity of the immediate environment of the fluorophores, thus, SPR 
experiments have been performed to further study the interaction between PrP and 
MB. The full-length OvPrP and ∆OvPrP were immobilized on the sensor surface chip 
and various concentrations of MB were injected over the sensor chip up to 500 µM.   
 
The SPR sensorgrams obtained for the full-length OvPrP, shown in Figure II.4A as 
example, demonstrated that, albeit the signal responses increase with increasing MB 
concentration, the responses remain constant within a few seconds and returns to 
the baseline very rapidly after dissociation. Reliable kinetic constants cannot be 
obtained by fitting the SPR sensorgrams with any models available in the 
BIAevaluation software. A similar behavior was observed with ∆OvPrP. 
 
In Figure II.4B is reported the SPR response curve of the full-length OvPrP versus 
MB concentration. The linear dose-response curve suggests that no saturation is 
reached, and this precludes the possibility to determine the dissociation constant 
value (KD). These results may be indicative of multiple binding sites and/or a low 
affinity for OvPrP (Hosokawa-Muto et al., 2008).  
 
 
Figure II.4 SPR experiments for the interaction of the full-length PrP with MB. A) Time evolution of 
SPR response at various MB concentrations up to 500 µM. B) Dose response curve of the SPR 
response versus MB concentration 
 
Finally, 15N-HSQC spectra of the 15N-labeled ∆OvPrP in the presence of MB up to a 
molar ratio PrP:MB of 1:10 were recorded by Dr. Annalisa Pastore at the National 
Institute for Medical Research-MRC (The Ridgeway London, United Kingdom). No 
chemical shift changes of nitrogen resonance frequencies were observed in the 
presence of MB (data not shown), in agreement with fluorescence and SPR data. 
 
To analyze the effects of MB on the stability of PrP, CD and DSC experiments were 
also performed, at pH 4.6, and results are shown in Figure II.5. The inset in Figure 
II.5A, shows the normalized CD spectra recorded for the native monomeric protein 
with and without MB, up to a molar ratio PrP:MB of 1:20. All spectra show a 
characteristic α-helical structure and are perfectly superimposable. Furthermore, 
thermal denaturation curves were recorded by monitoring the molar ellipticity at 222 
nm (Fig. II.5A) going up to a molar ratio PrP:MB of 1:20. In all cases, there is no 
change on the melting temperature of the unfolding process. Either in the presence 
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or in the absence of MB, the unfolding process was reversible with complete 
recovery, after cooling, of the secondary structure of the protein (data not shown). 
 
   
 
Figure II.5 Analysis of the stability effects on prion protein mediated by MB at pH 4.6. A) CD thermal 
unfolding of OvPrP in the absence and in the presence of MB up to a molar ratio PrP:MB of 1:20 (In 
the inset are displayed the corresponding CD spectra). B) DSC thermograms recorded for OvPrP in 
the absence and in the presence of MB at a molar ratio PrP:MB of 1:4 
 
Similar results were obtained from DSC experiments (Fig. II.5B). Indeed, the DSC 
thermogram related to PrP in the presence of MB at a molar ratio PrP-MB of 1:4, 
showed no variations of Tm (69.1 °C ± 1 °C) with respect to the thermogram obtained 
in the absence of MB. 
 
Effects of methylene blue on the kinetics of PrP polymerization and depolymerization. 
 
In previous works, it has been shown that the thermal treatment of either OvPrP and 
MoPrP leads to the formation of oligomers, although the oligomerization pathway is 
not the same, with oligomer ratio differing as a function of PrP type (Eghiaian et al., 
2007). In particular, the thermal refolding of the OvPrP, in acidic (pH < 4.5) 
conditions, induces the formation of three different oligomers referred to as O1, O2 
and O3 corresponding to 36, 24 and 12 mers, respectively. In addition, it was shown 
that only O1 is able to fibrilize giving rise to a fiber-like aggregate, referred to as P0. 
The thermal refolding of MoPrP predominantly leads to the formation of the oligomer 
O3, with small amounts of O1 and O2 (Chakroun et al., 2010).  
 
In order to evaluate the effect of MB on the oligomerization process of PrP, we 
analyzed, through SLS, the kinetics of the oligomerization for both OvPrP (wt and 
properly selected mutants) and MoPrP in the presence of MB, at pH 3.4 and 7.0. The 
PrP mutants were selected on the following criteria: i) to evaluate the influence of MB 
on the oligomerization rate of the PrP mutants that give rise to only one type of 
oligomer and, ii) to evaluate the influence of MB on the oligomerization rate of the 
type of PrP that leads to the formation of higher aggregates. For the first aim, wt-
MoPrP and the mutant OvPrP_H190A were selected, as they lead to the formation of 
only O3 and O1 oligomer, respectively (Chakroun et al., 2010), using wt-OvPrP as 
control. On the other hand, the influence of MB on aggregates was evaluated through 
the design and the production of a new mutant, OvPrP_H190KI208M, which leads to 
the formation of P0 fibrillar assemblies.  
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In Figure II.6 the SEC profiles of all the PrP forms, obtained at pH 3.4, at 50 °C and 
at various incubation times (See Experimental Procedures, Section 2.2), are shown 
together with the schematic oligomerization reaction. The chromatogram referred to 
wt-OvPrP showed the formation of the three oligomers O3, O2 and O1 (Fig. II.6A), 
whereas MoPrP and the mutant OvPrP_H190A showed the formation of only one 
oligomer, O3 and O1 respectively (Fig. II.6B,C), as previously reported (Chakroun et 
al., 2010). The new mutant OvPrP_H190KI208M is characterized by the formation of 
P0 fibrils assemblies, in addition to the oligomer O3 (Fig. II.6D).  
 
 
 
 
Figure II.6 Oligomerization pathways obtained by thermal treatment, at pH 3.4 and at various 
incubation times. A) SEC profiles of wt-OvPrP; B) SEC profiles of wt-MoPrP; C) SEC profiles of 
OvPrP_H190A; D) SEC profiles of OvPrP_H190KI208M. The color curves correspond to increasing 
incubation times from 0 to 90 minutes. 
 
In Figure II.7, the kinetic curves of all PrP protein forms tested in the presence of MB 
at pH 3.4 are shown. In all cases, the kinetic profiles obtained in the presence of MB 
differed from those obtained using the protein alone, and the higher the MB 
concentration was, the more the SLS intensity signal decreased. The estimation of 
the SLS signal decrease, performed at the maximum recorded time, is indicative of 
the oligomerization rate. In particular, the decrease suggests that at molar ratio 
PrP:MB of 1:1, the signal of OvPrP, MoPrP and OvPrP_H190A decreased about 10 
% and at molar ratio PrP:MB of 1:3 about 18 % with respect to the protein without 
MB. The decrease of the SLS intensity signal of the variant OvPrP_H190KI208M was 
17 % and 30 % lesser with respect to the protein alone, at molar ratios PrP:MB of 1:1 
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and 1:3, respectively. This general behavior clearly shows the MB influence on the 
PrP oligomerization rate.  
 
 
 
Figure II.7 Effect of MB on the kinetics of the PrP oligomerization, at pH 3.4. A) SLS curves of wt-
OvPrP; B) SLS curves of MoPrP; C) SLS curves of OvPrP_H190A; D) SLS curves of 
OvPrP_H190KI208M 
 
It has been shown that in neutral conditions, the thermal treatment of wt-OvPrP leads 
to an oligomerization pattern in which the formation of O1 oligomer, rather than O2 
and O3 oligomers, is favored and further heating produces the formation of 
aggregates (Prigent et al, 2011). For comparison, SEC profiles related to the 
oligomerization pathways of OvPrP, at pH 3.4, 4.5 and 7.1, is displayed in Figure II. 
8A.  
 
SLS kinetic experiments on wt-OvPrP, at pH 7.0, showed a drastically slow down of 
the kinetics in the presence of MB, already at a molar ratio of MB:PrP equal to 1 (Fig. 
II.8B). It is noteworthy that the SLS intensity signal of OvPrP in the presence of MB 
was about 40 % lesser than the one of the protein alone at the end of the measure. A 
conclusive finding of SLS polymerization experiments is that PrP oligomerization rate 
is affected by MB.  
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Figure II.8 A) Comparison of the SEC profiles corresponding to the oligomerization pathways of 
OvPrP at pH 3.4, 4.5 and 7.1; B) SLS kinetic curves describing the effects of MB on the 
oligomerization of OvPrP, at pH 7.0. 
 
At this junction a question arises: does MB directly interact with oligomers or with 
intermediate species? If MB interacted with PrP oligomers they should undergo some 
changes in their properties and behavior such as depolymerization, that is a well 
characterized one-step process that leads to monomers generation (Eghiaian, 2007). 
To address this question, we carried out depolymerization experiments on the two 
most representative oligomers O1 and O3. They were obtained and purified 
respectively from OvPrP and MoPrP, and their depolymerization was monitored by 
SLS in the presence of MB and at a molar ratio PrP:MB of 1:4. The SLS curves, 
shown in Fig. II.9, indicate that the depolymerization rate of both oligomers is the 
same with and without MB, excluding the possibility of a direct interaction between 
MB and PrP oligomers. 
 
 
Figure II.9 SLS kinetics of the depolymerization of O3 oligomer (A), and O1 oligomer (B) at pH 3.4 
 
 
The unfolding process of PrP in the presence of methylene blue. 
 
It was previously reported that the thermal unfolding of OvPrP within the pH interval 
4.5<pH>7.0 showed two peaks interpreted as a polymerization and depolymerization 
phenomena (Rezaei et al., 2002). Thus, the effects of MB on the oligomerization 
process of PrP was also studied by DSC, recording the thermograms at pH 3.4 and 
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pH 7.0, in the presence of MB. In Figure II.10, the DSC thermograms recorded for 
OvPrP, in the absence and the presence of MB at a ratio PrP:MB of 1:4, are shown. 
The denaturation process, at both pH, consists of two transitions, in agreement with 
previous data (Rezaei et al., 2002). 
 
  
 
 
Figure II.10 Unfolding of OvPrP followed by DSC at two different pH in the absence and in the 
presence of MB, at a molar ratio PrP:MB of 1:4. A) DSC thermogram at pH 3.4; B) DSC thermogram 
at pH 7.0; C) Deconvolution of the DSC curves obtained at pH 7.0, with and without MB. Continuous 
lines correspond to the experimental Cp data. Symbols represent the predicted Cp curves of each 
transition peak in which the global curves can be deconvoluted. 
 
At pH 3.4, the first transition occurs around 47 °C and the second one around 94 °C 
(Fig. II.10A). For both thermograms, with and without MB, these temperatures are 
preserved and the area of both peaks is similar, even if a small reduction on the area 
of the second peak was observed in the presence of MB.  
  
Interestingly, at pH 7.0, the DSC thermogram of OvPrP without MB showed a first 
transition temperature around 66 °C and a second transition temperature around 88 
°C (Fig. II.10B). In the presence of MB, the DSC thermogram was markedly different 
compared to that one of the protein only. Indeed, both peak area decrease, in 
particular, the second peak is considerably reduced. Therefore, to compare the 
oligomers amount formed during the first transition in the absence and in the 
presence of MB, thermograms have been deconvoluted, as shown in Figure II.10C. 
Particularly, deconvolution of the first peak shows no significant differences with and 
without MB. Differently, deconvolution of the second peak reveals meaningful 
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differences in both the surface area and the transition temperature. Indeed, in the 
presence of MB, the peak area, which is proportional to the total protein 
concentration, is reduced by about 28 % and the transition temperature (84 °C) is 
about 4 °C lower in comparison to the protein alone (88 °C), in good agreement with 
the Lumry–Eyring equation (Sanchez-Ruiz, 1992). As result from DSC experiments, 
MB significantly interferes with polymerization of PrP and particularly limits the 
amount of oligomers formed along the polymerization pathway, at the physiologic pH 
7.0. 
 
Effect of methylene blue on PrP fibrillization 
 
Finally, the action of MB on fibril formation was studied. HuPrP and OvPrP fibrils 
were generated at pH 6.0 in the absence (as control) and in the presence of MB. The 
PrP fibril formation was monitored using a ThT binding assay. In Figure II.11 the 
kinetics of fibril formation is shown for HuPrP and OvPrP, with and without MB, at 
different molar ratios.  
 
 
Figure II.11 ThT binding assay for PrP fibril formation in the absence and in the presence of MB at low 
PrP:MB molar ratios, as indicated. A) ThT fluorescence of HuPrP; B) ThT fluorescence for OvPrP. 
Results represent means ± s.d (n=3). 
 
For both HuPrP and OvPrP, in the absence of MB, the ThT signal gradually rises with 
a sigmoidal shape, indicating the formation of PrP fibrils. In contrast, the fibril 
formation was completely inhibited by the presence of MB, at molar ratios PrP:MB 
equal or lesser than 1:2.  
 
In the range 1:0 ≤ PrP:MB ≤ 1:1, there is no inhibition of fibril formation, but a longer 
lag phase is observed at equimolar concentration of MB relative to PrP, compared to 
the control (Fig. II.12).  
A B 
Prion protein and Methylene blue  
 
 
Figure II.12 ThT binding assay for PrP fibril form
ratios, as indicated. A) ThT fluorescence
A valuable confirmation that the fibril formation is suppressed by MB, at molar ratios 
lesser than 1:2, was obtained by 
fibrillar structures were observed in the absence of MB, (Fig. 
hand, very little fibrillar material was observed for samples incubated with MB at 
molar ratios PrP:MB lower than
 
Figure II.13 TEM images of HuPrP fibrils formed in the absence of
presence of MB at molar ratios HuPrP:MB of 1:2 (
formed in the absence of MB (control) (
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 of HuPrP; B) ThT fluorescence of OvPrP. 
means ± s.d (n = 3). 
 
TEM images. For both HuPrP and OvPrP, typical 
II.13A
 1:2 (Fig. II.13B-D,F).  
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The EM images of the samples HuPrP and OvPrP in the presence of MB, at 
equimolar concentration, confirm the results obtained by ThT fluorescence assays, 
showing the formation of PrP fibrils also for the samples containing MB, even if 
decrease on the fibril amount was detected 
that MB efficiently prevents the amyloidogenesis of PrP, at a PrP:MB ratio equal to 
1:2.  
 
Figure II.14 TEM images related to HuPrP fibrils without MB (control)
HuPrP:MB of 1:1 (B), OvPrP fibrils without MB (control) (
 
MB does not specifically interact with the native monomeric PrP
The potential anti-prion agents hitherto 
the prionogenesis. In fact, they can act in a specific step of the
mechanism, interacting with different PrP forms and blocking the chain reaction. 
Indeed, many of these compounds antagonize the PrP conversion 
state stabilization of the protein by a direct interaction with the native PrP 
conformation (Vogtherr et al., 2003; 
molecules, as Congo red, reinforce PrP
so that the partial denaturation essential for 
occur (Caspi et al., 1998)
transconformation of PrP, we first stu
PrP using fluorescence, SPR and NMR approaches. To this purpose, we used both 
the full-length PrP (103-234) and the deleted protein (103
39 
(Fig. II.14). These findings demonstrate 
 
 
 (A), HuPrP fibrils at a molar ratio 
C), and OvPrP fibrils at a molar ratio 1:1 (
Scale bar: 0.5 µm. 
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Results from both fluorescence and SPR showed that MB does not specifically 
interact with the native conformation of both full-length and truncated PrP. In addition, 
NMR data shows no interaction of MB with ∆OvPrP.  
 
CD spectra at room temperature, and both DSC and CD thermal unfolding 
experiments carried out at pH 4.6 (which is the optimal pH for prion protein) on the 
full-length OvPrP in the presence of MB showed that neither the secondary structure 
or the stability of the protein is pertubated by MB. Collectively, all results demonstrate 
that MB does not have any effect on the native monomeric form of PrP. 
 
MB interferes with PrP oligomerization but not with depolymerization 
 
It has been underlined the importance of the polymerization process during PrP 
conversion for the acquisition of amyloidogenic properties (Rezaei, 2008). In fact, all 
the PrPC -> PrPSc mechanism models include at least a polymerization step (Griffith, 
1967; Come et al., 1993). Therefore, the kinetic formation of PrP oligomers in the 
presence of MB was analyzed by SLS. In particular, using PrP from various species, 
and different kind of mutants under various experimental conditions, we studied the 
effects of MB on different oligomerization pathways of the prion protein.  
 
Taking into account that OvPrP undergoes parallel unfolding/refolding processes 
upon heating, and thus, each oligomer directly originates from the native state 
(Eghiaian, 2007), our SLS data on the PrP oligomerization demonstrate that MB is 
able to slow down the formation rate of all oligomers, independently. In particular, MB 
reduces the SLS intensity signal of the PrP variant OvPrP_H190KI208M, at pH 3.4 
and wt-OvPrP at pH 7.0, that give rise to aggregates in addition to O1 oligomer 
(Eghiaian, 2007). In the latter case a decrement of SLS signal of 40 % was observed, 
at the end of the measurements. The above results from SLS support the hypothesis 
of a direct action of MB on a partial or completely unfolded transient state that 
precedes the formation of oligomers, either at pH 3.4 or at the physiological pH 7.0. 
This hypothesis could explain the diverse observed effects of MB on the 
oligomerization of the various PrP forms, that are characterized by distinct pathways.   
 
Furthermore, depolymerization experiments performed on the purified oligomers in 
the presence of MB did not show a variation on the kinetics, indicating that MB does 
not interact with the oligomers, but acts as a simple spectator in this process. It is 
noteworthy that depolymerization is a one-step process, without the formation of 
intermediate states or intermediate oligomers (Eghiaian, 2007). Therefore, 
considering the action of MB on the kinetics of PrP oligomerization, together with the 
fact that there is not a direct specific interaction neither with the α-monomeric PrP or 
the oligomers, we conclude that MB may specifically target the partially unfolded 
intermediates that precede the formation of the oligomers. In fact, many experimental 
data have provided evidence for the existence of a partially unfolded state that 
precedes the formation of oligomers (Kuwata et al., 2002; Rezaei et al., 2005; 
Eghiaian, 2007; Jenkins et al., 2008). 
 
MB limits the amount of oligomers and suppresses the fibril formation 
 
DSC thermograms at pH 3.4 and 7.0 revealed a different action of MB on the PrP 
conversion depending on the pH, and hence, depending on the PrP oligomerization 
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pathway, in agreement with SLS experiments. The unfolding process of OvPrP in 
acidic (pH < 4.5) and neutral (pH > 6.0) conditions gives rise to two peaks on the 
DSC thermograms (Rezaei et al., 2002). This multimolecular process was explained 
assuming that the endothermic unfolding of the protein is immediately followed by an 
irreversible polymerization in the first transition and an irreversible depolymerization 
in the second one. Following this assumption, the second transition on the 
thermograms should be directly related to the amount of oligomers formed during the 
first transition. Thereby, DSC experiments provided a direct proof that MB is able to 
reduce the amount of oligomer formed during polymerization, at pH 7.0 (Eghiaian, 
2007; Eghiaian et al., 2007). The second peak area decrement is related to a fewer 
amount of oligomers formed during the first transition, corresponding to a net 
oligomer loss of about 28 %.  
 
The experimental evidences presented here support the idea that MB has a dual 
effect both on the kinetics and the thermodynamics of the prion conversion. MB is 
able to decrease the oligomerization rate of all PrP oligomers independently, and 
significantly decreases the amount of oligomers. It is worth point out that the ability to 
decrease the PrP oligomerization rate is an advisable feature of this compound, 
since MB can be therapeutically useful to enhance the incubation period in prion 
diseases. 
 
Finally, we investigated the effect of MB on the PrP fibrillization by promoting fiber 
formation of recombinant PrP. Our experiments on fibrillization of both HuPrP and 
OvPrP, with and without MB, carried out by means of ThT assay and TEM, 
successfully demonstrated a complete inhibition of the fibril formation in the presence 
of MB, at a molar ratio PrP:MB of 1:2 or lesser. However, TEM images provided 
evidence for a little reduction of the fiber formation, with respect to the control, 
already at an equimolar PrP:MB ratio.  
 
Data of the the actual PrP form (oligomer and/or amyloid fibrils) that carry the toxicity 
and the infectivity on prion diseases are still matter of debate. However, fibrils 
obtained from recombinant PrP are reported to be toxic and also infectious (Legname 
et al., 2004; Lee et al., 2011), thus the effectiveness of MB also on the PrP 
fibrillization is a relevant feature, being fiber formation an essential step of the 
conversion process.  
 
Possible mechanism of action of MB on the PrP conversion 
 
MB belongs to a new class of inhibitor compounds that can prevent the 
oligomerization and fibrillization of proteins associated to amyloidogenic diseases. In 
fact, the action of MB was evaluated for several proteins, including Aβ, 
polyglutammine and TDP-43 (Necula et al., 2007; Gura, 2008; Yamashita et al., 
2009).  
 
Although many studies have reported the beneficial effects of MB on other 
amyloidogenic proteins, this molecule has been rarely considered for studies on prion 
conversion. In a previous work, MB showed no inhibition effect on PrPSc formation, 
together with high toxicity in neuroblastoma ScN2a cells (Korth et al., 2001). Anyhow, 
the authors have considered that some of the compounds tested, that could not be 
reliably examined because of their cytotoxicity forward ScN2a cells, might be 
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effective anti-prion drugs. Therefore, nowadays it would be worthwhile to conduct 
further studies, preliminarily in vitro. More recently, positive data were obtained about 
MB treated prion-filtered red cells utilized for neonatal exchange transfusion to 
reduce the risk of variant Creutzfeldt-Jakob disease transmission (Hornsey et al., 
2010). 
 
Several works, that already tested MB on other amyloidogenic proteins, have 
attempted to explain the mechanism by which MB interferes with the 
amyloidogenesis. In fact, MB might have distinct modes of anti-aggregation action. It 
has been reported that MB inhibits the Aβ40 aggregation (Taniguchi et al., 2005). 
Differently, Necula et al. reported that MB inhibits Aβ42 oligomerization but promotes 
fibrillization, suggesting that oligomer and fibril formation are distinct and competing 
pathways (Necula et al., 2007). Another protein, that has to be taken into account in 
AD, is the tau protein and MB was shown to be able to block the tau-tau binding 
interaction inhibiting tau filament formation (Wischik et al., 1996; Taniguchi et al., 
2005). It was also shown that MB could be useful for the treatment of TDP-43 
proteinopathies. In this case, MB may bind to dimers and oligomers of TDP-43 and 
thereby inhibit fibril formation (Yamashita et al., 2009). All these studies lead to 
presume a general action of MB on those proteins that are correlated to misfolding 
diseases. However, it is worth pointing out that the mechanism underlying 
oligomerization and fibril formation still requires clarification, and could occur by 
different pathways for each disease-associated amyloid-forming proteins.  
 
As far as PrP oligomerization and fibrillization is concerned (Griffith, 1967; Come et 
al., 1993), structural analysis and MD simulations revealed that OvPrP 
oligomerization requires a full detachment of the unfolded S1-H1-S2 segment from 
the H2-H3 α-helical bundle and the type of oligomer produced is controlled by the site 
where this protein expansion takes place (De Simone et al., 2007; Eghiaian et al., 
2007). On this basis, we put forward a mechanism that might explain how MB 
antagonizes PrP oligomerization and fibrillization. Taking into account that MB slows 
down the oligomerization rate of all oligomers, but reduces the amount of only O1 
oligomer, MB may modulate the PrP structural expansion in a reaction dependent 
manner i) by reducing local structural fluctuations of the intermediates that precede 
O2 and O3 oligomer, and thus, slowing down their formation rate, and ii) by 
stabilizing the intermediate state that leads to O1 oligomer formation through 
hydrophobic and electrostatic interactions, and thus, preventing the formation of this 
oligomer (Fig. II.15). Moreover, it was shown that O1 is the only oligomer able to 
fibrilize giving rise to a fiber-like aggregate (Eghiaian et al., 2007), thus, it is 
conceivable to presume that this oligomer may be the responsible for the fibril 
assemblies formation. Therefore, the stabilization of the intermediate which precedes 
O1 oligomer by a direct interaction with MB, could explain also the complete 
suppression of fibrillization.  
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Figure II.15 Proposed mechanism of action of MB on the oligomerization/fibrillization of PrP. The PrP 
oligomerization process starts from a structural protein expansion leading to the formation of distinct 
intermediates, denoted by I, that precede each oligomer (A). MB may interact with the intermediates 
that precede each oligomer (B), (i) by slowing down the formation rate of all oligomers, and in addition 
(ii) by reducing the amount of the O1 oligomer and hence suppressing the fibrillization. 
 
Currently, there are growing evidences that in other brain amyloidoses, soluble 
oligomers, as well as insoluble fibrils are toxic (Stefani et al., 2003; Lee et al., 2011). 
In particular, it has been reported that the oligomers generated from recombinant PrP 
are neurotoxic, in vitro and in vivo (Simoneau et al., 2007). On the other hand, PrP 
fibrils were shown to be infectious in vivo (Legname et al., 2004). Therefore, the 
action of MB on both PrP oligomers and fibrils is a highly valuable mark, since MB 
would act in both the PrP forms that are related to prion toxicity and infectivity, 
respectively.   
 
To sum up, this thesis work is the first that shows the effective action of MB on the 
PrP conversion, in vitro. We demonstrate that MB can slow down the formation of 
PrP oligomers and limit the amount of higher assemblies. Finally, we demonstrate 
that MB is able to completely suppress the formation of PrP fibrils. As oligomerization 
and fibrillization are essential steps in the PrPC to PrPSc conversion, MB acts as an 
antiprion agent. As a consequence, our findings deserve the evaluation of MB for in 
vivo studies and preclinical testing also for prion disease. 
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Chapter III Prion Protein and Aptamers 
 
 
3.1 Nucleic-acid-binding properties of prion protein 
 
 
The concept that a protein is the causative agent for TSEs challenged the traditional 
paradigm that disease transmission results solely from an agent that carries genetic 
information. Many independent studies all failed to identify specific nucleic acids in 
the scrapie agent, including viroid-like molecules, as well as to demonstrate any 
infectivity associated with nucleic acids extracted from the brains of infected animals 
(Marsh et al., 1974). This is also consistent with the exceptional resistance of the 
agent against physical, chemical and enzymatic treatments that degrade nucleic 
acids (Ward et al., 1974; Alper et al., 1987).  
 
Although no additional molecule implicated in the pathogenesis has been found in 
PrPSc samples, the presence of a cofactor is still not completely ruled out. It has been 
suggested by several groups that an additional, as yet unknown, factor might initiate 
or modulate the PrPC-to-PrPSc conversion (Telling et al., 1995; Nandi et al., 1999; 
Cordeiro et al., 2001). Several host macromolecules have been suggested as 
candidates for conversion catalysts: cellular adhesion molecules, nucleic acids, basal 
membrane molecules and sulfated glycans. These molecules have been reported to 
interact with PrPC and to induce or modulate its conversion into a β-sheet-rich 
structure that shares many features with the infectious PrP (Caughey et al., 1994; 
Cordeiro et al., 2001; Horonchik et al., 2005). 
 
The nucleic acids DNA and RNA form an interesting group of PrP molecular partners 
and several scientists have demonstrated that PrP can bind small NAs in vitro and in 
vivo with varying affinities (Beaudoin, 2008; Gomes, 2008b; Mercey, 2006). 
Moreover, the interaction of PrP with DNA or RNA can lead to conformational 
changes both to the protein and to the NA molecule (Cordeiro et al., 2001; Adler et 
al., 2003), which could suggest a biological significance of PrP binding to nucleic 
acids.  
 
Anyhow, if the proteinaceous nature of the TSE agent now seems firmly established, 
the involvement of nucleic acids in triggering the initial polymerization events remains 
a possible scenario. In addition, mysteries still obscure the status and biological 
functions of the cellular protein, the knowledge of which could help understand many 
aspects of the pathophysiology of prion diseases (Marc, 2010). These open 
questions have also motivated the studies of prion protein’s interaction with nucleic 
acids.  
 
3.1.1 Are the nucleic acids involved in the physiology and/or in the pathology of prion 
protein? 
 
The nucleic acid-binding properties of the prion protein (both RNA and DNA) might 
have broader implications either for its native function or for disease.  
From a structural point of view, the 3D-structure of mouse PrP in complex with an 18 
bp double-stranded DNA (dsDNA) was derived from SAXS and NMR measurements 
(Lima et al., 2006). In particular, NMR HSQC spectra revealed changes that are 
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clustered in two major domains: one in the disordered N-terminal part of PrP and the 
other in the C-terminal globular domain. Another in silico study (Tjong et al., 2007), 
predicted that the PrP globular domain recognizes DNA mainly through the α-helix 
H1. As result, both PrP domains show the ability to bind DNA. 
 
On the other hand, an NMR study of the interaction between murine rPrP and a 
synthetic RNA sequence (SAF9343–59) revealed that part of the N-terminal domain 
has undergone modifications upon RNA binding (Gomes et al., 2008b). Moreover, a 
rPrP mutant lacking residues 23–90 was not able to bind RNA, demonstrating that 
the amino-terminal region is crucial for RNA interactions (Gomes et al., 2008a; Gomes 
et al., 2008b).  
 
Physiology of the nucleic acid binding to PrP. 
It is worth mentioning that the nucleic acid segments (DNA or RNA) that have been 
hitherto described to bind or affect PrP conversion are very different from those of a 
genomic NA. The described NA-dependent effects occur via sequences with 
unknown cellular functions and that are also much smaller than those that could carry 
enough genetic information. So is there any in vivo functional implication for the NA 
binding properties of PrPC? The in vitro studies showed nanomolar affinities for some 
complexes with DNA or RNA, suggesting that these molecules represent interesting 
candidates for in vivo PrP binding (Cordeiro et al., 2001; Takemura et al., 2006). In 
fact, PrP shares similarities with nucleic acid binding proteins (Gabus et al., 2001) 
and has a mapped DNA-binding region on its globular domain (Lima et al., 2006). 
Therefore, several findings point to a physiological role for PrP as an NA-binding 
protein.  
 
Furthermore, the idea of an NA chaperoning properties possessed by PrP has 
recently emerged, since NA-binding by PrPC can lead to structural rearrangements in 
both binding partners, with folding/refolding of the NA and folding/oligomerization of 
the protein (Nandi et al., 1999; Gabus et al., 2001). This hypothesis could be 
supported also by the fact that, so far, no specific NA sequence was recognized by 
PrP and the RNA-chaperoning activity includes specific and non-specific RNA (Clodi 
et al., 1999). Moreover, with the capacity to bind both small RNAs and DNAs, PrP 
might exert its function by participating in the gene regulation array at the post-
transcriptional level, acting as a NA chaperone (Bera et al., 2007). 
 
Finally, it is worth mentioning that a general overview of nucleic acids so far studied 
suggests that long molecules of RNAs and DNAs generally induce the formation of 
large nucleoprotein aggregates, while the interaction with short RNAs or DNAs 
results in a soluble or oligomerized β-sheet PrP (Cordeiro et al., 2001; Gabus et al., 
2001; Gomes et al., 2008b). This has led to speculate that the transition of PrP to a 
beta-rich structure could represent a physiological mechanism. On the contrary, 
some DNA and RNA molecules seem to prevent or stop PrP aggregation in infected 
cells (Silva et al., 2010). This capacity has been explored in possible therapeutic and 
diagnostic strategies for prion disease. 
 
Pathology of the nucleic acid binding to PrP. 
Besides the potential physiological role of the PrP-NA complexes, one of the most 
intriguing features of the interaction between PrP and NAs is the finding that some 
NA sequences can act as catalysts for the formation of a scrapie-like PrP 
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conformation. Indeed, previous works have shown that the binding of PrP to small 
double-stranded NA sequences increases the β-sheet content of the protein and, 
depending on the PrP:NA molar ratio, protein aggregates can be formed (Cordeiro et 
al., 2001). These aggregates are mainly amorphous although, under some 
conditions, NA binding can promote partial unfolding of PrP, triggering formation of 
an amyloid-like structure that resembles PrPSc in its resistance to proteinase-K 
digestion (Deleault et al., 2003; Gomes et al., 2008b). Moreover, highly structured 
RNAs can also convert human PrPC into PrPSc-like forms (Adler et al., 2003), and 
some RNA aptamers bind with high specificity to PrPSc (Rhie et al., 2003). 
 
An interesting study brought compelling evidence to the hypothesis that NAs might 
catalyze PrP conversion, with the use of PMCA technique. PMCA occurs through the 
incubation of PrPC with an excess of PrPSc, either from brain homogenates or from a 
purified source (Deleault et al., 2007). Using this approach, with a preparation 
containing only native PrPC and co-purified lipid and mouse liver RNA, it was 
obtained successful PMCA propagation of PrPSc molecules. The conversion was 
confirmed by the observation of the disease occurrence after inoculation of the de 
novo PrPSc molecules formed into mice (Wang et al., 2010). This seminal work 
shows that infectious prions can be formed from a minimal set of components 
including synthetic NA, stressing the possible role of nucleic acids in PrPSc 
generation. These results led to propose the hypothesis of NA-catalyzed PrP 
conversion (Cordeiro et al., 2005). Accordingly, host NAs might catalyze the PrPC-
>PrPSc conversion by acting as a scaffold or surfaces and thereby facilitating the 
interaction between PrPC and PrPSc molecules. From the energetic point of view, NA 
molecules would act by lowering the free-energy barrier between PrPC and PrPSc, 
thus triggering conversion.  
 
Figure III.1 shows the template assistance model of PrP conversion together with the 
models proposed for the catalyst action and/or molecular chaperone of NAs on the 
PrPC-to-PrPSc conversion (Cordeiro et al., 2005). In the NA-catalyst models, the 
formation of large aggregates of PrPSc would need the presence of exogenous PrPSc 
(or generated from spontaneous conversion of PrPC into PrPSc), which would rescue 
the already converted PrPSc from the NA. The freed NA would then be able to 
catalyze another conversion, amplifying the process (Silva et al., 2008). 
 
However, in vitro studies showed the dependency of the extent of aggregation on the 
molar ratio between PrP and NA, so that an apparently irreversible process, in the 
direction of PrP aggregation, predominates within a high PrP to NA ratio (Cordeiro et 
al., 2001). However, the precise mechanism behind this catalyzed conversion is still 
not completely understood and further studies must be done in order to determine 
how NAs play in the PrP conversion mechanism.  
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Figure III.1 Models for nucleic acid-mediated prion propagation. The models propose how a NA (gray) 
can act on the PrPC (blue) to PrPSc (red) conversion. A) Template-assisted refolding model. PrPSc 
interacts directly with PrPC (i) and helps the latter to assume the PrPSc-like conformation (ii). Formed 
PrPSc is able to catalyze conversion of more PrPC into the infectious species (iii). B) Binding of NA by 
PrPC (i) induces the acquisition of the β-sheet-rich conformation (ii). Following the addition of PrPSc 
oligomers (iii), larger aggregates are formed and the nucleic acid is released from the complex (iv). It 
is then able to catalyze another conversion event (v). C) Formation of the PrPC–NA complex (i) would 
act as a scaffold for binding of PrPSc to the protein part of the complex (ii), leading to conversion into 
scrapie-like conformation and giving rise into the net conversion of more PrPSc (iii). The NA could be 
released from the complex, after PrPSc formation (iii) being able to contribute to further conversion (iv), 
or could be irreversibly incorporated into the infectious aggregated particle (v). After (Silva et al., 2008) 
 
3.1.2 Prion protein and DNA/RNA aptamers 
 
Originally, the term “aptamer” designated synthetic RNA or DNA molecules selected 
from combinatorial libraries to specifically bind small molecules or proteins. SELEX is 
the most employed in vitro method used to isolate, starting from a very large pool of 
random sequences, one or a few families of nucleic acid sequences that satisfy the 
selection criteria (Tuerk et al., 1990). Indeed, in the search for nucleic acids that 
could bind with high affinity and specificity to prion protein, several authors used 
SELEX method. This method has allowed to identify DNA and/or RNA sequences 
capable to bind PrPC and/or PrPSc.  
 
To the purpose of isolating aptamers that could distinguish PrPC from its pathological 
isoform PrPSc, Weiss et al. were the first authors to carry out the SELEX method in 
the prion field, with the selection of various RNA aptamers able to bind to the 
recombinant Syrian golden hamster PrP (Weiss et al., 1997).  
Beside the highly specific ligands that can be selected by SELEX method, PrP has 
been shown to bind a variety of DNAs or RNAs, that have proved very useful in 
covering many aspects of the PrP-nucleic acids interaction. 
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Therefore, a question arises regard the selected DNA and RNA aptamers by SELEX 
hitherto studied: Do these aptamers share a common sequence or a structural motif? 
Unluckily, a sequence analysis of the reported PrP specific-aptamers reveals no 
obvious sequence motif for DNA and RNA aptamers. Anyhow, a comparison of the 
RNA- or DNA-ligands that were isolated from independent laboratories has revealed: 
i) conserved sequence patterns that were present in a few independently obtained 
aptamers, and ii) a relatively frequent structural feature consisting of a guanine 
quadruplex. Regarding the shared sequence of the aptamers, some of them were 
characterized by the following pattern: AAG(A or G)(C or U)GUCGGGG-N0-1-
UUGGCA-N0-1-AA, where N0-1 is zero or one nucleotide (Marc, 2010). In other cases, 
the aptamers presented repeated guanine triplets (GGG….GGG….GGG…GGG). 
Anyhow, in both cases, the sequence contains repeated guanine duplets or triplets. 
Besides the common sequence, these aptamers share also a common structure. 
Indeed, they can adopt a guanine quadruplex-structure (Weiss et al., 1997). Many 
works have reported that this structure seems necessary for the interaction, since its 
disruption, by replacing the guanosine with uridines, completely abolishes the 
interaction with PrP. Thus, G-quadruplexes may represent a common recognition 
motif (Gatto et al., 2009). Guanine-quadruplexes are a structural motif composed of 
two or more tetrads of coplanar guanosines (G-quartets) that are stacked on top of 
each other (Keniry, 2000).  
 
It is worth mentioning that beside G-quadruplexes, other structural motifs have been 
described in RNA- and DNA-aptamers raised against PrP (Adler et al., 2003; Mercey 
et al., 2006; Takemura et al., 2006). In some cases, the requirement of these 
structures for PrP-binding has been probed by various methods. However, the 
absence of any obvious relation between them, precludes the identification of a 
consensus structural pattern. 
 
From a structural point of view, taking together the results of several studies, the 
interaction of PrP with nucleic acids seems to involve at least three distinct sites in 
the protein: two of them located at the ends of the unstructured N-terminal domain, 
and the third in the C-terminal globular part. In particular, there are two lysine clusters 
located in the N-terminal domain of PrP that were assigned as possible binding sites 
of NAs. The first one encompasses the residues K25KRPKPGGGW34 in OvPrP and it 
was reported to be the major nucleic-acid binding site (Mercey, 2006 ;Weiss, 1997). 
NAs could interact with these aa through charge interaction with low specificity and 
high affinity. The second binding site in PrP for nucleic acids is another lysine cluster  
(W101NKPSKPKT110 in sheep PrP) (Lima et al., 2006; Mercey et al., 2006). 
Interestingly, both lysine-clusters contain alternating proline and basic residues, a 
feature that is reminiscent of the binding motifs found in proteins that are known to 
interact with nucleotides and nucleic acids. The binding to this second lysine cluster 
does not rely solely on charge interaction but may also involve stacking interactions 
with tryptophan residue 101. In fact, the overlapping peptide K103PSKPKTNM112, 
lacking residue W101, did not bind in spite of its three basic lysine residues.  
 
Beside these two interaction sites in its disordered N-terminal domain, the structured 
C-terminal domain of PrP also contributes to nucleic acid binding. Studies based on 
SAXS and NMR spectroscopy have shown that the globular and unstructured 
domains of PrP are both involved in the interaction with nucleic acids. A comparison 
of the chemical shifts between the NMR spectra of free and DNA-bound hamster PrP 
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point to several residues in the structured domain from arginine 136 to alanine 224, 
that interact with E2DBS, a 18 bp DNA (Lima et al., 2006). Therefore, each of these 
three sites in PrP may cooperate in binding nucleic acids through either of the two 
main modes through which proteins are known to interact with nucleic acids: i) 
binding to the groove of a nucleic-acid helix, through charge interactions with the 
backbone, and/or ii) sequence-specific recognition of unstacked bases into binding 
pockets of the protein (Shulman-Peleg et al., 2008). 
 
Finally, regarding the recognition of PrP toward nucleic acid, most of the aptamers 
that have been raised against PrP from one species, also recognized PrP from other 
species (Weiss et al., 1997; Mercey et al., 2006; Takemura et al., 2006). This is not 
unexpected, considering the high conservation of PrP polypeptide sequence, which 
is close to 100% in the PrP regions involved in nucleic acid binding. In addition, most 
of these aptamers recognize both PrPC and its pathological isoform PrPSc, except for 
some of them that show some specificity towards PrPSc or the β-oligomeric isoform of 
recombinant PrP, as a result of the selection process (Weiss et al., 1997; Rhie et al., 
2003). Considering the interaction from the other side, PrP was shown to bind a large 
variety of nucleic acids that were either identified through SELEX, or tested 
individually. As no obvious consensus sequence or structural pattern could be 
extracted from the comparison of these ligands, NA aptamers include both single-
stranded and double stranded DNAs, as well as RNAs with diverse structures. 
However, this diversity should not lead to the conclusion that PrP binds any nucleic 
acid with no specificity, since modifications of RNA or DNA aptamer often reduce 
binding (Takemura et al., 2006). Moreover, most of the nucleic acid-binding proteins 
do not bind only one well defined sequence, but may instead functionally interact with 
more than one structural or sequential pattern, suggesting that the large group of 
NAs capable to bind PrP do not rule out a physiological meaning of this interaction.  
 
3.1.3 D12 and R12 aptamers against prion protein 
 
In a previous work, RNA aptamers against recombinant bPrP and its amyloidogenic β 
isoform (bPrP-β) were obtained by means of SELEX method (Tuerk et al., 1990) from 
RNA pools containing a 55-nt randomized region (Murakami et al., 2008). The 
recombinant amyloidogenic prion protein, bPrP-β, was generated through chemical 
treatment of recombinant bPrP, with the assumption that bPrP- β resembles PrPSc in 
terms of structural and biochemical properties (Baskakov et al., 2002).  
 
Interestingly, all RNAs contained tandem GGA repeats, mainly four continuous GGA 
triplet repeats (GGA)4. These RNA aptamers showed high affinity to both bPrP and 
bPrP-β and moreover, were able to detect PrPC in a bovine brain homogenate on 
northwestern blotting assay (Murakami et al., 2008). Since the conserved region 
(GGA)4 plays an important role for specific binding to bPrP and bPrP-β, the authors 
minimized the selected aptamers to a 12-nt RNA, r(GGA)4, in order to evaluate if this 
region is the minimal sequence required to keep the interaction with the PrP. In this 
manner, they could demonstrate that the minimized 12-nt RNA retained the binding 
ability toward bPrP and bPrP-β and thus, the conserved core sequence of tandem 
GGA repeat (GGA)4 is the region relevant for this binding. Moreover, it is worth 
mentioning that the appearance of the tandem GGA in anti-PrP RNA aptamers is 
relatively high, thus GGA repeat must be meaningful for specific binding to 
PrP(Weiss et al., 1997; Proske et al., 2002; Gatto et al., 2009). This is further 
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confirmed by experiments in which substitutions were applied in the conserved 
region (GGA)4. The results revealed a decrease of the binding ability of the aptamer 
mutants toward bPrP-β while a moderate decrease in binding affinity was observed 
with bPrP (Murakami et al., 2008).  
 
Another intriguing feature of the aptamers containing a GGA repeat is the ability to 
adopt a unique quadruplex structure in the presence of K+ ions (Kettani et al., 2000). 
NMR experiments, performed under physiological K+ conditions, have been made on 
the 12-nt RNA r(GGA)4, (R12), and 12-nt DNA d(GGA)4, (D12), showing that one R12 
molecule folds into an intramolecular parallel quadruplex with a G:G:G:G tetrad plane 
and a G(:A):G:G(:A):G hexad one. Then, two R12 quadruplexes form a dimer in a 
tail-to-tail manner, through hexad–hexad stacking (Mashima et al., 2009). 
Analogously, one D12 strand forms a quadruplex with four G-G segments aligned 
parallel to each other, and then two D12 quadruplex form a dimer in a tail-to-tail 
manner (Matsugami et al., 2001). Although the R12 structure shares several 
common features with the structure formed by the DNA counterpart molecule, 
remarkable differences between the R12 and D12 structures have also been noted. 
In Figure III.2 both structures of R12 and D12 are schematically shown. The R12 
quadruplex comprises a G(:A):G:G(:A):G hexad plane in addition to a G:G:G:G tetrad 
plane, while the D12 quadruplex comprises a G(:A):G(:A):G(:A):G heptad plane in 
addition to a G:G:G:G tetrad plane; the dimerization occurs through heptad-heptad 
staking (Mashima et al., 2009). Moreover, the dyad axis correlating two monomers is 
along the A3-A9 direction for R12, but is perpendicular to the A3-A9 direction for 
D12. 
 
 
Figure III.2 Schematic representation of the R12 structure (A) and the D12 structure (B). A dyad axis 
correlating the two monomers is indicated for each structure. 
 
The quadruplex fold, adopted by PrP-binding aptamers, seems an essential feature 
for the PrP recognition. Indeed, a work on RNA aptamers, selected against 
recombinant Syrian golden hamster PrP, reported that the G quartet scaffold is 
required for the interaction with PrP, since the replacement of guanosine with uridine 
completely hampers the binding with PrP (Weiss et al., 1997). 
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Summarizing, DNA and RNA aptamers must have two essential features to be able 
to specifically interact with both α-rich PrP isoform and β-PrP: i) the presence of a 
minimal sequence core of four tandem GGA repeat (GGA)4, and ii) a G quadruplex 
architecture. 
 
In this context, taking into account the minimal sequence of both DNA and RNA 
aptamers required for a specific interaction with PrP, calorimetric, spectroscopic and 
SPR studies were here performed in order to characterize thermodynamically, 
kinetically and structurally the interactions between OvPrP and both D12 and R12. 
Moreover, structural investigations were conducted using various PrP domains in 
order to obtain insight into the PrP regions involved in the interaction and the nature 
of the forces that drive these bindings.  
 
 
3.2 Experimental procedures 
 
 
• Sample preparation 
The full-length PrP from sheep PrP (23-234) and the truncated form ∆OvPrP (103-
234) were produced as described in Section 2. 2. The buffer used to desalt the 
protein, on a HiPrep desalting column, was MES 15 mM pH 6.0, KCl 70 mM. Protein 
concentration was measured by optical density at 280 nm with the procedure 
described in Section 2.2.  
Aptamers were purchased from PRIMM (Milan). The aptamer samples were 
prepared by dissolving the lyophilized compound in MES 15 mM, KCl 70 mM at pH 
6.0. The solution has been annealed by heating at 95 °C for 5 min and slowly cooling 
to room temperature. The concentration of the dissolved oligonucleotide has been 
evaluated by UV measurement at 95 °C, using as molar extinction coefficient the 
value calculated by the nearest-neighbor model (Cantor et al., 1970) for the 
sequence d(GGAGGAGGAGGA), r(GGAGGAGGAGGA) and d(TGGGGT). 
The unfolded D12 solutions were obtained by dialysis against MES 15 mM pH 6.0, to 
remove the K+ ions. 
 
• Isothermal Titration calorimetry. 
ITC experiments were carried out at 298 K using a high-sensitivity CSC-5300 Nano-
ITC microcalorimeter from Calorimetry Science Corporation (Lindon, Utah) with a cell 
volume of 1ml. Only after reaching the baseline stability, the experiments were 
launched. In each titration experiment, volumes of 10 µL of a solution containing D12, 
R12 and d[(TGGGGT)4] at a concentration of 80÷130 µM were injected into a solution 
with the prion protein in the same buffer (MES 15 mM pH 6.0 KCl 70 mM), using a 
computer-controlled 250 µL microsyringe. The OvPrP forms were prepared at a 
concentration of 16 µM. In order to allow the system to reach the equilibrium, we 
applied a time interval of 300 or 400 s between each ligand injection. Heat produced 
by ligands dilution was evaluated by performing a control experiment, titrating each 
ligand into the buffer alone. The interaction heat for each injection was calculated 
after correction for the heat of ligand dilution. The corrected heat values were plotted 
as a function of the molar ratio aptamer:PrP, to give the corresponding binding 
isotherms. The resulting isotherms were fitted to a single set of identical sites model 
employing a nonlinear least-squares minimization algorithm to a theoretical titration 
curve, using the program Bindwork from Calorimetry Science Inc. ∆bH° (reaction 
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enthalpy change in kJ mol−
sites) were the fitting parameters. The Gibbs energy and the entropic contribution
were calculated using the relationships 
298 K) and −T∆bS° = ∆bG° 
 
• Surface Plasmon Resonance.
For technical and instrument details see Section 2.2. SPR experime
performed immobilizing the
surface of a CM5 chip, using a
R12 aptamers, as well as 
concentrations (from 200 nM to 
running buffer. OvPrP covalently immobiliz
removed bound analytes using the mobile phase buffer Glycine
injected 180 s after the analyte injection. 
chip as control.  
The SPR sensorgram for each protein
fitting using BIAevaluation software
reaction models were applied to perform complete kinetic analysis of the protein 
sensorgram. The fitting was performed in such
the statistical closeness of curve
ideally to be below 10. The 
(conformation change) model 
where A is the immobilized protein, 
aptamer complex and AB* represents the complex after the conformational change.
 
• Circular Dichroism. 
For technical and instrument details see Section 2.2. 
250 nm) were carried out in 
optical path length cell. CD titration was performed
OvPrP, keeping the concentration of PrP constant (10 
concentration of the aptamers up to a molar ratio PrP/aptamer of 1:2. 
Each solution of the mixture PrP
successive additions of the aptamers
to dilution effects within t
constant of 4 s, a 2 nm band width, and a scan rate of 
averaged over at least three scans. The baseline was corrected by subtracting the 
buffer spectrum. 
 
 
 
 
 
 
 
 
 
 
 
52 
1), Kb (binding constant in M−1), and n (number of binding 
∆bG° = −RT ln Kb, (R = 8.314 J
− ∆bH°. 
 
 full-length OvPrP and ∆OvPrP domain 
 standard amine coupling procedure. 
d[(TGGGGT)4], were injected as analytes
50 µM) and using MES 15 mM, pH 6.0 KCl 70 mM as 
ed chip was subsequently regenerated by 
 
Data were corrected using a blank sensor 
-aptamer interaction were analyzed by curve
 provided with the Biacore device
 a way that the χ2 value
-fitting, became the lowest. It was recommended 
best fitting was achieved by the two
which is described by the following equation:
 
B is the aptamer, AB represents 
Far-UV measuremen
MES 15 mM pH 6.0 KCl 70 mM at 20 °C using a 0.1 cm 
 on the full-length and truncated 
µM), and increasing the 
-aptamer was prepared independently
 in the PrP solution to avoid complications due 
itration experiments. CD spectra, recorded with a time 
20 nm min
 
 
 mol−1 K−1, T = 
nts were 
on the sensor 
Then, D12 and 
 at various 
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-
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, representing 
-state reaction 
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, without 
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3.3 Results 
 
 
Binding analysis of the interaction between prion protein and quadruplex structures 
 
In order to study the kinetics and the thermodynamics of the binding between OvPrP 
and both D12 and R12 aptamers, we used ITC and SPR. Various PrP forms were 
investigated to identify the regions involved in the interaction with both DNA and 
RNA, as well as the type of interactions that take place. In particular, the following 
PrP proteins were used: i) the full-length OvPrP (23-234), and ii) the deleted ∆OvPrP 
(103-234) which partially lacks the unstructured N-terminal part. All experiments were 
conducted at pH 6.0. It is worth mentioning that the full-length PrP contains all the 
three potential binding sites, i.e., the two lysine clusters (aa 25-34 and 101-110 in 
OvPrP) in the N-terminal region and the third site consisting of various aa located in 
the structured C-terminal domain, whereas the deleted form (∆OvPrP) lacks the first 
lysine cluster (Fig. III.3). 
 
 
 
Figure III.3 Schematic representation of the OvPrP forms used. A) Full-length OvPrP (23-234); B) 
∆OvPrP (103-234). The areas in the sequence, depicted in red, and the related numbers, correspond 
to the putative PrP binding sites for NAs. 
 
Since for this study, only the ovine prion protein species was used, the protein is 
reported as PrP, for simplification. 
 
Thermodynamic data obtained by ITC experiments 
 
The integrated heat data, along with the corresponding raw ITC profiles (insets) 
obtained by ITC measurements for the titration of the full-length PrP and ∆PrP with 
both D12 and R12, are shown in Figure III.4. The raw data for all the titration 
experiments indicate an exothermic interaction, based on the positive values 
observed for the peaks. Thermodynamic parameters, obtained from the fitting of the 
binding isotherms, are summarized in Table III.1, with the exception of the system 
full-length PrP and D12, from which no thermodynamic parameters were derived. 
Indeed, although the corresponding raw ITC has the typical profile of an exothermic 
reaction, precipitation was observed at the end of ITC experiments, precluding the 
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possibility to obtain the thermodynamic parameters related to this system. Differently, 
no precipitation was detected for the interaction between the full-length PrP and R12, 
as well as for ∆PrP with both D12 and R12 aptamers. For the determination of the 
thermodynamic parameters, both D12 and R12 aptamers were considered to be 
dimeric.  
 
 
Figure III.4 ITC titration experiments. Binding isotherms and raw ITC profiles (insets) for full-length 
PrP with D12 (A) and R12 (B); and for ∆PrP with D12 (C) and R12 (D). 
 
The ITC data for R12 binding to full-length PrP indicate the formation of a 1:1 protein-
aptamer complex with the highest binding affinity (Kb = 1.3 x 107 M-1). Another kind of 
complex is formed with the truncated protein, since the binding stoichiometry of 
∆PrP, with both D12 and R12, was 1:0.5 with similar Kb values. Comparison of the 
thermodynamic constants related to the interaction of the full-length and the 
truncated protein with R12 show that Kb is one order of magnitude higher for the full-
length PrP than for ∆PrP. Anyhow, the values of the Gibbs energy variations indicate 
that, from a thermodynamic point of view, the interaction of prion protein with the 
aptamer molecules is strongly favored at 25 °C. 
 
The favorable enthalpy variation values (from -86.2 to -68.4 kJ mol-1) and the 
unfavorable entropies (from -49 to -32 kJ mol-1) indicate that, in all cases, the binding 
processes are enthalpically driven. Anyhow, R12 binding to ∆PrP has a lesser 
favorable enthalpy (∆bH° = -68.4 kJ mol-1) as compared to the other systems.  
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Table III.1 Thermodynamic parameters for the interaction of the full-length PrP and the truncated PrP 
with D12 and R12 aptamers, and d[(TGGGGT)4] determined by ITC at 25 °C and pH 6.0.  
 
 n Kb (M-1) ∆bH° (kJ mol-1) T∆bS° (kJ mol-1) ∆bG° (kJ mol-1) 
PrP + D12 ND ND ND ND ND 
∆PrP + D12 0.5 ± 0.1 
(3.1 ± 0.2) 
x106 
-86.2 ± 2.0 -49 ± 2 -37 ± 2 
PrP + R12 0.9 ± 0.2 
(1.3 ± 0.1) 
x107 
-81.6 ± 1.0 -41 ± 2 -41 ± 2 
∆PrP + R12 0.5 ± 0.1 
(2.2 ± 0.3) 
x106 
-68.4 ± 1.0 -32 ± 2 -36 ± 2 
PrP + 
d[(TGGGGT)4] 
0.5 ± 0.2 
(5.2 ± 0.1) 
x106 
-76.4 ± 1.0 -38 ± 2 -38 ± 2 
               ND = not determined 
 n = number of PrP binding sites 
 
We tested also the interaction of the full-length PrP with the truncated sequence of 
Tetrahymena telomeric DNA, d(TGGGGT), which forms a parallel tetramolecular 
quadruplex in the presence of K+ ions, containing four equivalent grooves (Laughlan 
et al., 1994). Although this sequence differs from the sequence of D12 and R12 
(containing four GGA repeated triplets), it still contains contiguous guanine and, 
furthermore, folds in a G-quadruplex, [d(TGGGGT)4]. 
In Figure III.5A the schematic structure of a parallel tetramolecular G-quadruplex is 
shown. Raw ITC data relative to the interaction of the full-length PrP with 
[d(TGGGGT)4] showed a similar profile to those obtained with both D12 and R12 
aptamers (Fig. III.5B). 
 
 
Figure III.5  A) Schematic structure of a parallel tetramolecular G-quadruplex. B) Binding isotherm and 
raw ITC data (inset) for titration of the full length PrP with d[(TGGGGT)4]. 
 
 
The thermodynamic parameters obtained from ITC titration revealed a high affinity of 
PrP also toward this quadruplex (Kb = 5.2 x 106 M-1), but with a binding stoichiometry 
A B 
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of 1:0.5 (Table III.1). The binding enthalpy change is in between the values 
corresponding to the interaction of R12 with the full-length and the truncated PrP.  
ITC results suggest that the high affinity of PrP toward these nucleic acids is 
presumably due to the presence of contiguous guanines in the sequence. Moreover, 
PrP seems to specifically interact with DNA and RNA that fold into quadruplex 
structures. To confirm the specificity of PrP toward the quadruplex DNA and RNA, 
D12 was unfolded by removing K+ ions from the solution, and an ITC titration was 
performed using only ∆PrP, to avoid difficulties due to precipitation with the full-length 
PrP. As shown in Figure III.6, the heat changes obtained upon addition of the 
unfolded D12 correspond to the heat of the ligand dilution. Therefore, the results fully 
demonstrated the failure of ∆PrP interaction with the unfolded D12, lacking the 
quadruplex structure. 
 
 
Figure III.6 ITC titration experiments related to the binding of ∆PrP with the unfolded D12. A) Raw ITC 
profile; B) Plot of heat change on ligand addition against the ligand:PrP molar ratio. 
 
Kinetic and binding data obtained by SPR experiments 
 
To validate the ITC data and to get insights into the kinetics of the interactions, SPR 
experiments were performed testing the interaction of both D12 and R12 aptamers 
with the same PrP forms used for ITC experiments. In particular, the PrP proteins 
were immobilized on different channels of a sensor chip and solutions of various 
concentrations of D12 and R12 were injected over the surface chip.  
 
As previously mentioned, the interaction of D12 with the full-length PrP leads to 
precipitation, thus, no information was obtained by ITC analysis. In contrast, SPR 
experiments allowed the estimation of the affinity of this interaction, since the binding 
reaction occurs in a solution-independent manner. In Figure III.7, the SPR 
sensorgrams corresponding to the interaction of D12 and R12 aptamers with both the 
immobilized full-length and truncated PrP, are shown.  
 
A B 
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Figure III.7 Time Evolution of the SPR sensorgrams obtained at various concentrations of the 
aptamers (in the range from 0.5 µM to 50 µM). Sensorgrams related to the full-length PrP with D12 (A) 
and R12 (B). Sensorgrams related to ∆PrP with D12 (C) and R12 (D). Each SPR sensorgrams is 
reported with the corresponding fit (dot lines), based on a two state reaction model which includes a 
conformational change. 
 
All SPR sensorgrams were analyzed, by applying various kinetic models. The best 
fits were yielded with the two state reaction model that takes into account a 
conformational change upon complex formation. The two states reaction model can 
be described by two steps: i) the formation of the initial protein-aptamer complex, and 
ii) the subsequent conformation rearrangement that can take place on the protein 
and/or on the aptamers (Fig. III.8). Thus, SPR experiments allowed not only to 
kinetically characterize these systems, but also to obtain structural information 
regarding the systems studied. Indeed, these results are in agreement with previous 
studies in which structural variations for both PrP and NAs were reported. 
 
From the fitting of the SPR sensorgrams, the association (kon1, kon2) and dissociation 
rate constant (koff1, koff2) of the two reaction steps were derived. In Table III.2 the 
kinetic constants for the PrP-aptamers interactions are summarized. 
A B 
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Figure III.8 Separation of individual components of the actual SPR curves characterizing the 
interactions PrP-aptamers: formation of the complex PrP-aptamer (in magenta); conformational 
changes upon complex formation (in red); contribution of bulk and drifts (in green) 
 
The association rate constants (kon1) related to the first interaction step were 
significantly higher with respect to those obtained for the second step (kon,2), for the 
full-length and the truncated PrP with D12 and R12, respectively. In more detail, the 
kon,1 values, for both the full-length and the truncated PrP, are within the same order 
of magnitude (103), either for the interaction with D12 and R12, revealing a fast 
association phase of these aptamers to PrP. Analogously, koff,2 values are very 
similar among all the systems, indicating that the dissociation process is relatively 
slow. 
 
Table III.2 Kinetic parameters for the interaction of the full-length PrP and the truncated PrP with D12, 
R12, and d[(TGGGGT)4] determined by SPR. The values of KD were determined by the dose response 
curves. 
 
kon,1 
(M-1 s-1) koff,1 (s
-1) kon,2 (s-1) koff,2 (s-1) KD (M) 
PrP + D12 (5.4 ± 0.1) x 103 
(1.0 ± 0.1) x 
10-1 
(3.6 ± 0.1) x 
10-2 
(5.9 ± 0.5) x 
10-3 
(2.8 ± 0.3) 
10-6 
∆PrP + D12  (6.7 ± 0.1) x 103 
(5.1 ± 0.2) x 
10-2 
(2.7 ± 0.3) x 
10-2 
(5.1 ± 0.7) x 
10-3 
(4.3 ± 0.4) 
10-6 
PrP + R12  (1.8 ± 0.3) x 103 
(9.9 ± 0.2) x 
10-1 
(4.0 ± 0.2) x 
10-2 
(5.7 ± 0.6) x 
10-3 
(2.9 ± 0.5) 
10-6 
∆PrP + R12 (7.1 ± 0.3) x 103 
(5.4 ± 0.1) x 
10-2 
(2.8 ± 0.2) x 
10-2 
(5.7 ± 0.7) x 
10-3 
(4.8 ± 0.5) 
10-6 
PrP + 
d[(TGGGGT)] 
(6.0 ± 0.7) x 
104 
(8.8 ± 0.1) x 
10-2 
(1.4 ± 0.1) x 
10-2 
(1.5 ± 0.6) x 
10-3 
(1.3 ± 0.5) 
10-5 
∆PrP + 
d[(TGGGGT)] 
(8.8 ± 0.2) x 
103 
(1.9 ± 0.2) x 
10-1 
(1.9 ± 0.2) x 
10-2 
(1.4 ± 0.5) x 
10-2 
(1.8 ± 0.5) 
10-5 
    
To determine the binding dissociation constant, the dose response curves were 
obtained by plotting the SPR responses at equilibrium against aptamer 
concentration, from which it was possible to estimate the KD values (Table III.2). The 
dose response curves for the interaction of the full-length PrP and ∆PrP with D12 
and R12 are depicted in Figure III.9. The values of the binding constants are within 
the micromolar range and are very similar among all the systems. These results 
suggest that the binding of PrP with D12 and R12 aptamers occurs through 
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interactions with both the N-terminal and C-terminal domain, and thus, it is 
conceivable to presume that all the three binding sites reported in PrP for nucleic 
acids are involved in these bindings. 
 
  
Figure III. 9 SPR binding analysis. Dose-response curves for the interaction of the full-length PrP with 
D12 (A) and R12 (B). Dose-response curves for the interaction of ∆PrP with D12 (C) and R12 (D). 
 
SPR experiments were performed to kinetically characterize also the interaction of 
the full-length and the truncated PrP with the tetramolecular quadruplex 
d[(TGGGGT)4]. In Figure III.10, the corresponding sensorgrams are shown.  
 
 
Figure III.10 SPR sensorgrams corresponding to the interaction of the quadruplex d[(TGGGGT)4] with 
the full-length PrP (A), and ∆PrP (B) together with the fit obtained applying the two state reaction 
model (dot lines). 
A B 
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As for D12 and R12, the SPR sensorgrams relative to the interaction between PrP 
and d[(TGGGGT)4] were best fitted by the two state reaction model, giving rise to 
kinetic constants that follow a similar trend as that related to the interaction between 
PrPs and D12 and R12.  
 
The fitting of the dose response curves (Fig. III.11) led to KD values of one order of 
magnitude higher than those determined for D12 and R12, indicating a lower affinity 
of PrP toward the quadruplex d[(TGGGGT)4]. Moreover, the values obtained for both 
PrP forms are very similar, suggesting that the interaction of PrP with the quadruplex 
d[(TGGGGT)4] may be mediated by the two binding sites present in the deleted PrP 
used in this study and does not involve the first lysine cluster in the N-terminal part.  
  
 
Figure III. 11 SPR binding analysis. A) Dose-response curves for the interaction of the full-length PrP 
with d[(TGGGGT)4]. B) Dose-response curves for the interaction of ∆PrP with d[(TGGGGT)4]. 
 
Finally, SPR experiments were performed using the unfolded D12, and the results 
obtained were in good agreement with ITC data, supporting the conclusion that the 
binding of DNA and RNA aptamers to PrP requires not only specific sequences, with 
GG repeats, but also the fold into quadruplex structures. 
 
Structural analysis of the interaction between prion protein and quadruplex 
structures. 
 
As previously reported, in some cases, the interaction between DNA or RNA 
aptamers and prion protein led to changes either on the protein and/or on the nucleic 
acid structure (Cordeiro et al., 2001; Adler et al., 2003). SPR experiments, here 
performed, have revealed that the interaction of prion protein with D12 and R12 
aptamers, could give rise to structural rearrangements of one or both the 
components of the complexes. Therefore, to evaluate whether PrP or the aptamers 
undergo structural changes upon interaction, CD titration experiments were carried 
out, with the only exception for the system full-length PrP-D12, as this interaction 
leads to precipitation, precluding any structural analysis.  
 
The DNA and RNA aptamers here studied are characterized by the same sequence 
consisting of four tandem GGA repeats (GGAGGAGGAGGA). These aptamers are 
able to adopt an intramolecular and parallel G-quadruplex structure in the presence 
of K+ ions and at pH near neutrality. Thus, in order to determine whether free 
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aptamers interfere with the protein CD spectra, far UV CD spectra were registered, in 
the wavelength range 320-200 nm, for both D12 and R12 aptamers (Fig. III.12).  
 
 
Figure III.12 CD spectra registered for D12 (in red) and R12 (in blue) aptamers in a solution 
containing K+ ions at pH 6.0 
 
In both cases, CD spectra showed a positive peak at about 265 nm and another one 
at about 209 nm. These CD profiles are typical for parallel G-quadruplex folds. 
Therefore, for the CD titration analysis, it must be taking into account that D12 and 
R12 aptamers present a significant CD signal in the wavelength range where the 
secondary structure of the proteins is evaluated. Thus, for each experiment, it was 
evaluated whether the CD spectrum, corresponding to the complex PrP-aptamer, 
overlap with that one of the aptamer alone at the same concentration.  
 
In the case of the interaction between ∆PrP and D12, titration experiments revealed 
no changes of the secondary structure of D12 (Fig. III.13A). Indeed, it was possible 
to subtract the CD spectra referred to the aptamer alone with that one corresponding 
to the complex ∆PrP-D12, and the resulting CD spectra showed a progressive 
decrease of the α-helical content of PrP (Fig. III.13B). 
 
Interestingly, in the molar ratio range 0.3 ≤ ∆PrP:D12 ≤ 1 (considering the aptamers 
as dimers), even if there is a detectable loss of secondary structure of PrP, the CD 
signal remains almost constant. A molar ratio ∆PrP:D12 of 1:2, leads to a further loss 
of α-helical structure of prion protein. 
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Figure III.13 CD spectra related to the titration of ∆PrP with D12 up to a molar ratio ∆PrP:D12 of 1:2. 
A) CD spectra corresponding to ∆PrP alone, D12 alone, complex ∆PrP-D12 and the subtracted CD of 
∆PrP-D12. B) CD spectra of ∆PrP:D12 complex obtained by subtraction of CD spectra of D12 alone. 
 
Differently, CD spectra related to the interaction of the full-length PrP with R12, 
showed a loss of secondary structure for both PrP and R12 aptamer (Fig. III.14A,B). 
In this case, it was not possible to subtract the CD spectra of the RNA alone from the 
one corresponding to the complex. Anyhow, since the CD signal of R12 at 209 nm is 
very low at molar ratios within the interval 1:0≤PrP:R12≤1:0.3 (Fig. III.14C), it is 
reliable to ascribe the signal decrease observed to an actual loss of protein 
secondary structure. 
 
 
 
Figure III.14 A) CD spectra, in the wavelength range 330 ÷ 200 nm, related to the titration of the full-
length PrP with R12 up to a molar ratio of 1:2. B) CD spectra, in the wavelength range 330 ÷ 240 nm, 
related to the complexes PrP-R12. C) CD spectra corresponding to the R12 alone at the same 
concentrations used for titration with the full-length PrP.  
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Considering the wavelength range 330 ÷ 240 nm, it is possible to evaluate the 
structural variation of the RNA, without the interference of CD signal from the protein. 
In fact, there is a complete loss of the secondary structure of R12, up to an equimolar 
ratio of R12 relative to PrP. For a molar ratio PrP-R12 of 1:2, a CD signal at 265 nm 
is observed. In Figure III.14B, the CD spectra of R12 alone at the same concentration 
used for the solution PrP-R12, at molar ratio of 1:2, is shown. Even if a CD signal is 
observed at this molar ratio, the signal is lower compared to that one corresponding 
to R12 alone. Thus, this could be due to the unbounded R12 present in solution. In 
fact, ITC experiments showed a binding stoichiometry PrP:R12 of 1:1, which could 
explain the CD signal at a molar ratio below the stoichiometry value. 
 
A similar behavior was observed for the interaction of ∆PrP with R12. In fact, also in 
this case, both proteins and R12 lose secondary structure (Fig. III.15), even if the 
structural loss of R12 is lower with respect to the complete loss of the quadruplex 
architecture, found in the interaction with the full-length PrP. This difference could be 
explained considering that in the interaction of R12 with ∆PrP, many contacts are 
missing, leading to a partially misfold of the quadruplex structure. On the contrary, 
R12 can fully interact with all the binding sites present on the full-length PrP.  
 
  
Figure III.15 A) CD spectra, in the wavelength range 330 ÷ 200 nm, related to the titration of ∆PrP 
with R12 up to a molar ratio of 1:2. B) CD spectra, in the wavelength range 330 ÷ 240 nm, related to 
the complexes ∆PrP-R12.  
 
Interestingly, at an equimolar concentration of R12 relative to ∆PrP, CD signal of R12 
is observed (Fig. III.15B). From a comparison with the ITC data, the binding 
stoichiometry resulted for this system was 1:0.5 (protein:aptamer), thus, we can 
deduce that both proteins and R12 partially lose secondary structure up to a molar 
ratio ∆PrP:R12 of 1:0.5. Below this molar ratio, the CD signal observed corresponds 
to free R12 molecules in solution. 
 
Morphological analysis 
 
Since the interaction between the full-length PrP with D12 leads to precipitation upon 
addition of the aptamer, a question has arisen about the nature of this precipitate: 
Does the addition of D12 into the solution of PrP lead to the formation of amorphous 
aggregates, or might D12 induce a conformational variation of the protein, forming 
fibrils-like structure? To answer to this question, transmission electron microscopy 
images were collected for the solution containing the complex PrP-D12. Figure III.16 
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Figure III.16 TEM images corresponding to 
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Although several binding studies have been conducted between these aptamers and 
PrP, no thermodynamic and kinetic characterization so far has been reported. In this 
regard, ITC and SPR technologies are complementary techniques to obtain a 
complete understanding of bimolecular interactions. From one side, ITC directly 
measures the binding enthalpy change and the stoichiometry for the formation of a 
complex, and thus it allows to distinguish between the enthalpic and entropic 
contribution to the association process. This reveals the nature of the forces that 
drive the binding and can provide insight into the nature of the intermolecular 
contacts formed. From the other side, SPR is capable of determining the rate 
constants of an interaction, and allows further rationalization of the contribution of 
individual structural features to the interaction. 
 
The results here obtained clearly demonstrate that: i) the interaction of PrP with both 
D12 and R12 is different, from the viewpoint of the nature of the forces that drive the 
formation of PrP-aptamer complexes, ii) the interaction between the full-length PrP 
and R12 aptamer occurs through the formation of a 1:1 complex in which one 
molecule of PrP interacts with one R12 dimer molecule, iii) the interaction with the 
full-length prion protein presumably involves three binding regions in the protein.  
 
Unluckily, only the stoichiometry of the binding between the full-length PrP and R12 
was determined, since addition of D12 caused amorphous aggregate formation. This 
phenomenon precluded the derivation of the thermodynamic parameters. Although 
we could not extrapolate ITC binding parameters for the interaction of D12 with the 
full-length PrP, the aggregate formation is a clue to understand how DNA and RNA 
interact in a different way, and thus, could have different influences on prion biology. 
Anyhow, the diverse behavior of D12 and R12 with respect to the binding with the 
full-length PrP can be attributed to the differences in the structure between R12 and 
D12, described in Section 3.1.3. 
  
From ITC and SPR data, it emerges that the binding features of D12 and R12 differ 
among the PrP forms here considered. First of all, the binding stoichiometry resulted 
from ITC experiments was 1:1 (protein-aptamer) for the interaction of R12 with the 
full-length PrP, while a value of 1:0.5 was obtained for the interaction of both 
aptamers with ∆PrP (the aptamers are in the dimeric form). Previous work has 
reported three different binding sites in PrP for nucleic acids; in particular two binding 
sites located at the ends of the unstructured N-terminal domain, and the third in the 
C-terminal globular part. Indeed, two lysine clusters, located in the N-terminal domain 
of PrP, encompass the residues K25KRPKPGGGW34 and W101NKPSKPKT110 in ovine 
PrP (Lima et al., 2006; Mercey et al., 2006). Regarding the C-terminal domain 
several studies point to several residues in the structured domain from arginine 136 
to alanine 224 (Lima et al., 2006).  
It is worth point out that in this work, two PrP forms were used: the full-length PrP 
(23-234), in which all the three binding sites reported for nucleic acids are present, 
and a deleted PrP (103-234), lacking only one binding sites, namely, the first lysine 
cluster. Taking in consideration the ITC and SPR results obtained for both PrP forms, 
we can conclude that the interaction with D12 and R12 involved the three binding 
sites of PrP. Moreover, from stoichiometry data, it is conceivable to presume that, 
since D12 and R12 are dimers, the binding occurs through the interaction of each 
monomer with the N-terminal and C-terminal domain, respectively. These findings 
are further confirmed by the different values of the binding enthalpy changes 
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obtained for the interaction of R12 with both full-length and deleted PrP. Indeed, the 
more negative ∆bH° obtained for the interaction with the full-length protein with 
respect to that one obtained for ∆PrP indicates that R12 can establish a higher 
number of contacts since all the dimeric structure is involved in the interaction. 
 
Another important feature, derived from ∆bH° values, is related to the interaction of 
∆PrP with both aptamers. In fact, these values are markedly different, suggesting a 
distinct intermolecular contact pattern in the complex formation. Anyhow, the 
electrostatic interactions between the positive charges of the lysine clusters and the 
negative charges of the phosphate groups of the aptamers must be the main factor 
for the high affinity between PrP and both D12/R12 aptamers. Moreover, it was 
suggested for the ovine PrP-aptamer system that the stacking interaction of the 
aptamers with a tryptophan residue, located in the second lysine cluster, may also 
contribute to the binding (Mercey et al., 2006). D12, as well as R12, has two 
G:G:G:G tetrad planes at the top and bottom of its dimer structure. These planes are 
suitable for the stacking interaction with the tryptophan residues.  
 
It is worth mentioning that, differently from previous works in which R12 interaction 
with bPrP resulted to be stronger than the one with D12 (Murakami et al., 2008), our 
results indicate that the affinity of both aptamers toward ovine PrP is comparable. 
The different results could be related to the diverse PrP species considered. Anyhow, 
the Kb values resulted from ITC titration of R12 with both the full-length and the 
truncated PrP revealed a stronger interaction of this aptamer toward the full-length 
PrP rather than with ∆PrP, might be due to the lack of the first lysine cluster in the 
deleted protein. 
 
Another important feature that seems necessary for aptamer binding properties 
toward prion protein is the folding in a quadruplex architecture. This requirement was 
confirmed by using the sequence d[(TGGGGT)4], which can adopt a tetramolecular 
quadruplex structure in presence of K+ ions. The ITC thermodynamic parameters 
corresponding to the system full-length PrP-(TGGGGT)4 are roughly comparable to 
those obtained for the full-length PrP and R12, even if the quadruplex d[(TGGGGT)4] 
has a lower affinity toward the full-length compared to R12. Moreover, d[(TGGGGT)4] 
interacts with the full-length PrP with a binding stoichiometry of 1:0.5 (protein-NA). 
Taking into account that the quadruplex d[(TGGGGT)4] does not form a dimer, it 
might form a complex in which two PrP molecules interact with one molecule of 
d[(TGGGGT)4]. Differently to ITC, SPR measurements were conducted using both 
the full-length and the deleted protein, and the KD values obtained are very similar for 
both the PrP forms, indicating that the interaction with this quadruplex is mediated by 
the C-terminal domain and could involved one or both binding sites present in the 
delete protein.  
 
The binding study of the quadruplex d[(TGGGGT)4] with PrP endorsed the affinity of 
the GG-containing sequences versus PrP and the need of a quadruplex folding. In 
fact, in a quadruplex structure the arrangement of the negatively charged phosphate 
groups is unique and different from those of canonical structures such as an A-form 
duplex. This particular rearrangement, together with the highly density of negative 
charges, are supposed to be responsible for the high affinity of these aptamers 
toward PrP (Mashima et al., 2009).  
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One of the most intriguing aftermaths of nucleic acid binding to PrP is the structural 
variation underlying the complexes formation. Although ITC titrations directly 
measure the enthalpy change of the binding reaction, this value contains all the 
components of the interaction at equilibrium, such as solvation or desolvation effects, 
buffer ionization effects and conformational changes in the reactants during complex 
formation, and these contributions cannot be distinguished (Horn et al., 2002). 
Conversely, SPR experiments allow the measure of the direct binding interaction and 
a kinetic characterization which takes into account possible structural variations of 
the components of the binding reaction. Indeed, the SPR experiments related to the 
interaction of the full-length and the truncated PrP with D12 and R12 revealed a 
binding reaction consisting of two steps: i) the formation of the initial protein-aptamer 
complex, and ii) the conformational rearrangement that may take place on the protein 
and/or on the aptamers upon complex formation.  
 
CD experiments confirmed the structural changes that occur upon interaction of PrP 
with these aptamers. In particular, CD titration showed that PrP undergoes structural 
rearrangements upon addition of D12 or R12 aptamers. On the other hand, D12 did 
not show a structural variation when interacting with ∆PrP, whereas R12 completely 
or partially loses its quadruplex architecture upon binding with the full-length or the 
truncated PrP, respectively. These findings reveal an important binding feature that 
differentiates the type of interaction of D12 and R12 with prion protein and may 
explain the precipitation phenomena observed upon addition of D12 into the full-
length PrP solution. However, these changes in structure of the prion protein when 
complexed to the nucleic acid would have a biological feedback since this feature is 
typical of nucleic acid chaperones (Gabus et al., 2001; Cristofari et al., 2002; Silva et 
al., 2008). 
 
Finally, in this work we want to highlight the possibility to use DNA and RNA 
aptamers for diagnostic purpose. Indeed, the high specificity of DNA and RNA 
aptamers toward PrP can be used to enrich PrP from biological samples. RNA 
aptamers have been successfully used for concentration of PrPC and PK-resistant 
PrP taken from serum, urine (Zeiler et al., 2003) and brain homogenate (Davidowitz 
et al., 2005). Several aptamers, designed for this aim and immobilized on a column 
cartridge, efficiently bound PrPC and PrPSc. This device was able to concentrate PrP 
from biological fluids, thus showing its potential in improving the current diagnostic 
tests by lowering the detection threshold (Zeiler et al., 2003). A similar principle was 
recently tested using magnetic nanoparticles functionalized with a PrP-specific DNA 
aptamer (Takemura et al., 2006). In spite of their experimentally demonstrated 
potential, to our knowledge these aptamer-based tools have not yet been 
commercially developed. We hope that in the future this strategy could be applied as 
diagnostic tools in double ligand assay systems. 
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Chapter IV Prion Protein and Aldolase C 
 
 
4.1 The glycolytic enzyme Aldolase 
 
 
As mentioned in the Chapter I, the prion protein is able to interact with many 
partners, including proteins, nucleic acids and glycosaminoglycans. Several studies 
have been dedicated to the description of the PrP interaction with various 
macromolecules and the investigation of their role in prion biology. The interactome 
studies may help to clarify the elusive function not only of the prion protein but also of 
its biological partners. 
 
Prion protein is mostly a plasma membrane-anchored extracellular glycoprotein, 
whose localization within the cell is represented by a small fraction. Despite this, the 
number of identified intracellular partners of PrP is comparable to that of its 
membranal or extracellular interactors. One of these intracellular proteins that has 
been identified as a possible biological partner of PrP is aldolase C, one of the three  
isozymes belonging to the aldolases family. Strom and co-workers have found, 
through a proteomic approach mainly based on mass spectrometry combined with 
far-Western immunoblotting and 2D gel electrophoresis, that mouse PrP may interact 
with heterogeneous nuclear ribonucleoprotein (hnRNP) and Aldolase C (Strom et al., 
2006). Indeed, on ligand blots, purified recombinant PrP23–231 bound both the 
proteins from the cytosolic fraction of brain homogenate obtained from Prnp-knockout 
mice.  
Very recently, this interaction has acquired a greater significance since it was found 
that enzymes involved in the glucose metabolism are diversely regulated during the 
pathology of prion diseases (Watts et al., 2009; Gawinecka et al., 2010).  
 
Fructose-1,6-(bis)phosphate aldolase are ubiquitous enzymes of the glycolytic and 
gluconeogenic pathways. These enzymes catalyze the reversible cleavage of 
fructose-1,6-(bis)phosphate (Fru-1,6-P2) and fructose-1-phosphate (Fru-1-P) to 
dihydroxy-acetone phosphate (DHAP) and either glyceraldehyde-3-phosphate (G3P) 
or glyceraldehyde, respectively. There are two distinct classes of aldolases: Class I 
aldolases, which are present in animals and higher plants and use covalent catalysis 
through a Schiff-based intermediate; and a class II aldolases, which are present in 
most bacteria and fungi and require a divalent metal cation as a cofactor for their 
enzymatic activity (Rutter, 1964). 
 
Among the class I enzymes found in mammals, there are three tissue-specific 
isozymes of aldolase that have similar molecular masses and catalytic mechanisms: 
aldolase A, aldolase B and aldolase C. The A isozyme is essentially ubiquitous in all 
mammalian tissues but is predominantly expressed in muscle and red blood cells. 
Mutations of the corresponding gene have been associated to haemolytic anaemia 
and myopathy (Yao et al., 2004). The B isozyme is found in liver, kidney and small 
intestine and mutations in the gene cause fructose-intolerance, a hereditary disorder 
(Tolan, 1995). The C isozyme is expressed mainly in the brain, i. e., in hippocampal 
neurons and in the Purkinje cells of the cerebellum. No gene variants have been 
found in this tissue.  
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The aldolase isozymes are similar in sequence, with 66% identity between human A 
and B, 68% identity between B and C, and 78% identity between A and C (Rottmann 
et al., 1987). Despite the sequence similarity, they have different catalytic properties, 
and thus they are involved in different physiological roles. In fact, the three isozymes 
differ in their affinity for the two physiological substrates, Fru-1,6-P2 and Fru-1-P. 
These differences correspond to the demonstrated function of liver aldolase in the 
aldol cleavage of Fru-1-P during the metabolism of fructose by this tissue. Other 
catalytic differences suggest aldolase B is tailored for a role in gluconeogenesis while 
aldolase A is more effective in a degradative glycolytic capacity. In contrast, the 
physiological role of the glycolytic AldoC is not well-understood. 
  
X-ray crystallographic structures of human muscle aldolase A (Gamblin et al., 1991), 
human liver aldolase B (Dalby et al., 2001) and human brain aldolase C (Arakaki et 
al., 2004) demonstrate that these enzymes are structurally similar. The enzyme is 
homotetrameric, with a subunit molecular mass of 36 kDa (Fig. IV.1A). The subunits 
are arranged in the tetramer with a local 222 symmetry. The enzyme has a tertiary 
structure characteristic of the TIM barrel class of proteins, consisting of eight 
alternating α helices and parallel β-strands, where the Schiff-base lysine is located in 
the central cavity of the barrel. The C-terminal end is highly mobile and its movement 
allows the entrance of the substrate and the exit of the reaction product. In Figure 
IV.1B the 3D structural superposition of the three aldolase isozymes is shown, 
indicating a highly similar fold. 
 
 
Figure IV.1 A) Ribbon diagram representation of aldolase C tetramer; PDB accession code 1XFB. B) 
3D structure superposition of the three aldolase enzymes: AldoC is depicted as a coil overlaid (in blue) 
with the ribbon structure of AldoA (red) and AldoB (green). 
 
Aldolase enzymes not only play a key role in glycolysis, but also bind to 
macromolecules unrelated to glycolysis such as F-actin (Wang et al., 1996), vacuolar 
H+-ATPase (Lu et al., 2001), cell surface adhesions (Jewett et al., 2003), and tubulin 
(Karkhoff-Schweizer et al., 1987). Thus, aldolase may be used for other functions in 
the cell, a concept that has been described as “moonlighting”. Studies have shown 
that aldolases associate with target proteins in a tissue-specific manner (Kusakabe et 
al., 1994). 
 
A B 
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Regarding aldolase C, the ratio of the specificity constants (kcat/Km) for the two 
hexose substrates is in between those of isoenzymes A and B. Although AldoA and 
AldoB have well-defined roles in glycolysis and gluconeogenesis, the physiological 
role of AldoC remains elusive. It has been suggested that the occurrence of AldoC in 
some tissues can substitute for aldolase B in fructose metabolism (Funari et al., 
2005). Moreover, aldolase C has been implicated in establishing subsets of neurons 
during cerebellar development (Ahn et al., 1994) or during differentiation of 
progenitor cells in the subventricular zones of the developing brain (Staugaitis et al., 
2001). 
 
Finally, the identification of aldolase C macromolecular interactors might open new 
perspectives that could shed light on the mechanisms underlying neuronal function 
and dysfunction. 
  
4.1.1 The possible physiological role of the PrP-AldoC complex 
 
Strom and co-workers speculated that the interaction of PrPC with aldolase C could 
explain the loss of cerebellar Purkinje cells in aged PrP0/0 mice (Yamaguchi et al., 
2004), a hypothesis supported by the localization of aldolase C in Purkinje cells. 
 
Interestingly, there are many evidences that correlate aldolase C, and in general 
glycolytic enzymes, with the pathological pattern of prion diseases. In fact, a study of 
the cerebrospinal fluid (CSF) protein pattern, from patients with sporadic Creutzfeldt-
Jakob disease (sCJD), showed that the major alteration in CSF proteome was 
observed in proteins involved in the glycolysis pathway or involved in glucose 
metabolism (Gawinecka et al., 2010). Moreover, it has been shown that the 
expression levels of AldoC in the brains of scrapie-infected mice significantly 
increase (Jang et al., 2008).  
 
Aldolase C seems to be related also to other neurodegenerative diseases. AldoC is 
able to specifically interact with the light neurofilament mRNA (Cañete-Soler et al., 
2005), which is not transcripted in neurons of patients afflicted with amyotrophic 
lateral sclerosis (Ge et al., 2003). Thus, the modulation of the expression levels of 
NF-L by AldoC might have important consequences for understanding causal 
mechanisms underlying neurodegeneration. Another implication was found in 
Huntington’s diseases (HD); in particular, HD affected mice showed higher activities 
of some glycolytic enzymes, leading to the suggestion that the neuronal damage in 
HD tissue may be associated with increased energy metabolism at the tissue level 
giving rise to modified levels of various intermediary metabolites with pathological 
consequences (Oláh et al., 2008).   
 
Ultimately, previous results obtained on the correlation of aldolase C with prion 
protein require further clarifications, especially in view of the possible role that 
aldolase C might have on prion pathology. Therefore, taking into account that no 
information about the strength of the binding between prion protein and aldolase C 
was reported, in this work we have carried out a detailed quantitative analysis of the 
binding of PrP to aldolase C by SPR; indeed we determined the thermodynamic and 
kinetic binding constants. Moreover, our interaction study was extended to the other 
two aldolase isoenzymes, AldoA and AldoB, to investigate whether the binding was 
sequence specific or not. Interestingly, we identified the PrP C-terminal domain as 
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the binding region for aldolases. Moreover, the results obtained indicate that the 
interaction between PrP and aldolases occurs through a 3D-structural recognition, 
rather than a sequence recognition. 
 
4.2 Experimental procedures 
 
 
• Protein production and storage 
The full-length PrP from sheep PrP and the truncated form ∆PrP (103-234) were 
produced as described in Section II. 2. The lyophilized protein was directly dissolved 
in buffer sodium acetate 10 mM, pH 5.0. Final protein concentration was measured 
by optical density at 280 nm as described in Section 2.2. The aldolase enzymes were 
supplied by the group of Prof. F. Salvatore and Prof. P. Buono, at CEINGE. The 
enzymes remained stable at 4 °C in Tris-HCl 20 mM, pH 7.4, for at least 2 weeks, 
and for at least 1 month at -20 °C in 40 %(v/v) glycerol/ Tris-HCl 20 mM, pH 7.4. 
Glycerol was removed by subjecting the sample dialysis, using Tris-HCl 20 mM pH 
7.4, NaCl 150 mM. The concentration of aldolases samples was measured by optical 
density at 280 nm using an extinction coefficient of 36370, 33390, 36245 M-1 cm2 for 
the isozyme A, B and C, respectively, deduced from amino acid sequence. 
 
• Circular Dichroism. 
For technical and instrument details see Section 2.2. Far-UV measurements (190-
250 nm) were carried out in sodium acetate 10 mM, pH 5.0 at 20 °C using a 0.1 cm 
optical path length cell and a protein concentration of 0.2 mg·mL-1 for all proteins. CD 
spectra, recorded with a time constant of 4 s, a 2 nm band width, and a scan rate of 5 
nm·min-1, were signal-averaged over at least three scans. The baseline was 
corrected by subtracting the buffer spectrum.  
 
• Size-exclusion chromatography with multiangle light scattering 
SEC was performed using AKTA FPLC equipment on a Superdex 200 10/300 GL 
column. For further details regarding the calibration and equilibration of the columns, 
see Section 2.2. The elution buffer was Tris-HCl 20 mM pH 7.4, NaCl 100 mM. The 
eluent flow was 0.5 mL min-1. A total of 0.1÷0.2 mg of proteins were loaded.  
Size-exclusion chromatography with multiangle light scattering (MALS) experiments 
was carried out with the AKTA system coupled to a three-angle (45°, 90° and 135°) 
Wyatt Minidown EOS light scattering instrument linked to a Wyatt Optilab 
refractometer (Wyatt Technology Corp., Santa Barbara, CA). These experiments 
served to determine the molecular mass aldolase C. Molecular masses, 
polydispersity and root mean square radius calculations were made by ASTRA 
software, which is supplied with the light scattering device, using a dn/dc value of 
0.185 mL g-1. 
 
• Surface Plasmon Resonance. 
For technical and instrument details see Section 2.2. Both full-length and truncated 
PrP were immobilized with the same procedure previously described (Section 2.2). 
Aldolase A, B and C solutions at various concentrations (from 10 nM to 10 µM) were 
injected in the running buffer as analytes. Also denaturated aldolases were used as 
analytes. Aldolases were denatured trough incubation of the solutions at relatively 
high temperatures, and the loss of structure was evaluated by CD. PrP covalently 
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immobilised chip was regenerated using the mobile phase buffer [Glycine 10mM 
(pH2.5)], injected 180 s after the analyte injection. 
Kinetic binding analysis was performed and kinetic constants were calculated from 
the sensorgrams using the same software as described in Section 2.2. The full 
binding cycle for each aldolase concentration is well described by a 1:1 interaction 
model.  
 
 
4.3 Results 
 
 
Some bio-physical features of Aldolase C 
 
A comparison among the three aldolases fold shows the high structural similarity 
(Fig. IV.1B). Indeed, the relatively high sequence identity and the same 
tridimensional structure, leads to suppose the comparable chemico-physical features 
for the three aldolases.  
 
To well-characterized the PrP-AldoC binding, a structural analysis has been 
performed on purified human aldolase C by several biophysical approaches, since in 
literature, very little is known about aldolase C chemico-physical properties. First, 
secondary structure analysis was conducted by recording CD spectra of aldolase C 
samples in the far-UV region (190-250 nm) at pH 7.4 and 20 °C (Fig. IV.2A). Far-UV 
CD spectra are characterized by the presence of two minima (at 208 and 222 nm) 
and one maximum (at 195 nm) which are typical fingerprints of α/β proteins (Cantor 
et al., 1970). Secondary structure analysis by means of the self-consistent method, 
implemented in the Dichroweb server, resulted in 38% α-helix and 13% β-sheet; such 
estimates are in line with those determined from the X-ray structure of human 
aldolase C (Arakaki et al., 2004). 
   
Figure IV.2 Structural analysis of aldolase C by circular dichroism. A) Far-UV CD spectra recorded  
at 20 °C and pH 7.4. B) CD thermal denaturation curve followed at 222 nm. 
 
Moreover, temperature induced denaturation was performed, by following the molar 
ellipticity at 222 nm (Fig. IV.2B). Thermal denaturation curve of aldolase C presents a 
sigmoidal shape with a single inflection point, corresponding to Tm value of 51.5 °C. 
The CD spectra of denatured species at 80 °C are typical of random coil. The 
spectrum of cooled samples after denaturation is virtually identical to that of the 
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denatured protein at 80 °C, thereby indicating the irreversibility of the unfolding 
process. 
 
For comparison, in Table IV.1 the melting temperature reported in literature and 
obtained by the same methodology for aldolase A and B are listed, together with the 
Tm of aldolase C here obtained. Aldolase C has a melting temperature in between 
those reported for aldolase A and B. 
 
Table IV.1 Comparison of the Tm here obtained for aldolase C with previously reported Tm for aldolase 
A and B 
Human Aldolases Tm (°C) References 
Aldolase A 54.2 (Esposito et al., 2005) 
Aldolase B 50.0 (Malay et al., 2002) 
Aldolase C 51.5 ±0.5  
 
The quaternary structure of aldolase C was analyzed by SEC coupled with a multi-
angle light scattering. The SEC profile, shown in Figure IV.3A, revealed that aldolase 
C elutes at 11.9 mL and the protein is in the tetrameric form. The presence of 
aldolase C was confirmed loading the fraction collected by SEC on a SDS/PAGE 
(Fig. IV.3A). The resulting molecular mass, obtained by MALS data, was 164 kDa 
(within 0.7%). A representative profile obtained by MALS measurements of aldolase 
C is shown in Figure IV.3B.  
 
 
Figure IV.3 Quaternary structure analysis of aldolase C by SEC-MALS. A) SEC chromatogram carried 
out at pH 7.4 and SDS-PAGE analysis of the fraction collected by SEC. B) Representative SEC-MALS 
profile in which the molecular mass is shown. The experimental data are represented by dots and the 
fitting of experimental data is shown by a red line. 
 
PrP-Aldolases interaction resulting from SPR measurements 
 
To evaluate the kinetics and the binding affinity of the interaction between aldolases 
and PrP (both full length and truncated forms), SPR technology was utilized. During 
the experiments, we observed a strong non-specific interaction between aldolases 
and the sensor chip CM5, hampering an accurate measurement of the binding. We 
spent several efforts in finding the experimental conditions suitable for a reliable 
measurement. Finally, we found that the addition of the enzyme substrate, fructose-
1,6-bisphosphate, eliminated nonspecific interactions between aldolases and CM-
A 
B 
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dextran. We speculate that because the natural substrate of aldolase is a sugar, this 
enzyme is prone to interact with this class of molecules, and thus, may interact with 
the carboxymethylated dextran surface of the sensor chip. In the presence of 
fructose-1,6-bisphosphate, the enzyme is saturated by its natural substrate, for which 
the enzyme has a greater affinity, preventing the interaction with the matrix of the 
sensor chip.  
 
Kinetic and binding experiments were carried out immobilizing, on the sensor chip, 
the full-length and the C-terminal PrP and injecting aldolase C at various 
concentrations in the presence of its substrate Fru-1,6-P2. Analogously, with the aim 
to investigate the specificity of the PrP interaction with aldolases, kinetic and binding 
experiments were carried out also for the interaction of prion protein with the other 
two isozymes: AldoA and AldoB.  
 
In Figure IV.4, SPR sensorgrams related to the binding of aldolases with the 
immobilized full-length PrP are shown. The sensorgrams registered for the binding of 
the three isozymes with ∆PrP are very similar (data not shown). SPR sensorgrams 
were used to calculate the corresponding kinetic constants kon and koff (Table IV.2) by 
a global fit of the response data collected during the association and dissociation 
phases.  
 
 
Figure IV.4 SPR sensorgrams corresponding to the interaction of aldolases with the full-length PrP 
together with the fit obtained applying the 1:1 binding model (dot lines). A) Aldolase A; B) Aldolase B; 
C) Aldolase C  
 
A B 
C 
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Kinetic data indicated that the values of kon obtained for the binding of all aldolases 
with the full-length PrP are within the same order of magnitude (103), as well as the 
values obtained for the system aldolases-∆PrP (104). It is worth noting that the kinetic 
association constant relative to the interaction of aldolases with ∆PrP, are one order 
of magnitude higher compared to those obtained with the full-length PrP, indicating a 
faster association with the C-terminal part of the prion protein. Regarding the kinetic 
dissociation constant, the values are similar for the binding of the three isozymes to 
the full-length PrP, whereas these values change significantly for the truncated 
protein. In fact, koff is smaller for the system ∆PrP-AldoB, suggesting a slower 
dissociation process for this complex.  
 
Table IV.2 Kinetic and binding analysis of the interaction data between aldolases and PrP. The values 
of KD were determined by the dose response curves. 
 
Ligand kon (1/Ms) koff (1/s) KD (M) 
Full-length PrP immobilized 
AldoA (5.4 ± 0.2) x 103 (1.0 ± 0.2) x 10-3 (4.9 ± 0.4) x 10-6 
AldoB (9.7 ± 0.2) x 103 (3.2 ± 0.3) x 10-3 (3.4 ± 0.4) x 10-6 
AldoC (6.4 ± 0.1) x 103 (8.3 ± 0.1) x 10-3 (9.9 ± 0.3) x 10-6 
∆PrP immobilized 
AldoA (1.3 ± 0.3) x 104 (1.5 ± 0.2) x 10-3 (1.3 ± 0.4) x 10-6 
AldoB (6.4 ± 0.2) x 104 (6.9 ± 0.1) x 10-5 (4.2 ± 0.5) x 10-6 
AldoC (5.3 ± 0.1) x 104 (2.1 ± 0.1) x 10-4 (3.6 ± 0.3) x 10-7 
 
To determine the binding dissociation constant, SPR sensorgrams at each 
concentration of aldolase isoenzymes were used to plot the dose-response curve, 
from which it was possible to estimate the KD values (Table IV.2). The dose response 
curves for the interaction of the full-length PrP and AldoA, B and C are depicted in 
Figure IV.5. The values of KD are comparable for the binding of all the aldolases with 
the full-length PrP and ∆PrP, with the only exception of the system ∆PrP-AldoC, 
which is one order of magnitude lower. These results indicated that aldolases interact 
with PrP mainly through the C-terminal domain of the protein. 
 
Finally, to study the influence of the folded state of aldolases to the interaction with 
PrP, SPR measurements were carried out with the unfolded aldolases (see 
experimental procedures). In fact, since the affinity of aldolases toward the full-length 
PrP is comparable, we presumed that a 3D-structural recognition drives the 
interaction between aldolases and prion protein. The results obtained did not show 
an interaction with prion protein. 
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Figure IV.5 SPR binding analysis. Dose-response curves for the interaction of the full-length PrP with 
AldoA (A) AldoB (B) and AldoC (C). 
 
 
4.4 Discussion 
 
 
In recent years, a number of different methods have been used for the identification 
of PrP-binding molecules. A complex picture is emerging of PrPC as a multifunctional 
protein, able to interact with a large ensemble of biological macromolecules and, 
thus, to participate in several cellular processes. 
 
Based on a previous work, where the authors showed the interaction between mouse 
prion protein with aldolase C (Strom et al., 2006), we confirmed that PrP and AldoC 
interact in vitro. We monitored the formation of the PrP-AldoC complex by SPR, 
deriving all the kinetic and binding parameters. Moreover, we used both full-length 
and truncated PrP, which lacks of the N-terminal region to investigate the binding 
region of prion protein to aldolase C. Both kinetic and binding constants related to the 
binding of aldolase C with both the full-length and the truncated PrP indicate that the 
interaction occurs through the structured C-terminal region of PrP, spanning residues 
103-234. In fact, the interaction of aldolase C with the ∆PrP is characterized by a 
faster association and a slower dissociation process, with a higher binding affinity, 
compared to the kinetic and binding data obtained for the full-length.  
The interaction study was extended to the other aldolase isozymes, namely aldolase 
A and B, that share a relatively high sequence identity and a similar 3D structure with 
A B 
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the aldolase C. In fact, the bio-physical analysis of aldolase C, here performed, has 
confirmed the similarity among the aldolase isozymes. The SPR experiments have 
demonstrated that also AldoA and AldoB interact with both full length and truncated 
forms of PrP, similarly to AldoC. It is worth noting that the interaction of aldolase A 
and B with ∆PrP has kinetic and binding properties similar to those corresponding to 
the interaction with the full-length. The results obtained lead to presume that the PrP 
interacting region for aldolases is the C-terminal folded domain, whereas the N-
terminal unstructured domain does not participate in the interaction. 
 
On the basis of the results obtained, it is reasonably to suppose that the binding 
process between PrP and all aldolase isozymes is based on a 3D-structural 
recognition and presumably do not involve primary structure recognition. This 
assumption is supported by the following remarks: i) PrP-aldolase interactions were 
observed in SPR experiments, in which all the proteins involved were in a folded 
state accordingly to the far-UV CD spectra recorded for each protein immediately 
before SPR measurements; ii) Not only do assume human aldolases the same fold 
but also an essentially identical binding site architecture for PrP, being the SPR 
experiments performed in the presence of substrate Fru-1,6-P2; iii) SPR 
measurements performed with the unfolded aldolases did not reveal any interaction.  
 
Anyhow, the interaction of prion protein with aldolase C seems to be related to the 
loss of cerebellar Purkinje cells in aged PrP0/0 mice (Yamaguchi et al., 2004). As 
aldolase C and PrP colocalized in Purkinje cells, their interaction in normal 
cerebellum may be required to maintain the long-term survival of these cells, while 
the absence of PrPC in PrP0/0 mice may explain the death of cerebellar Purkinje cells 
in these mice (Strom et al., 2006). It is also worth mentioning that neurotoxicity of 
doppel (Dpl), the PrPC homologue, in Purkinje cells of a line of PrP-null mice, Ngsk 
Prnp0/0, varies according to aldolase C expression.  
 
Further evidences for a physiological correlation of PrPC and aldolase C come from 
various studies that connect the glycolytic enzymes to prion diseases. In fact, in BSE-
infected mouse brain was found an enhanced level of a long aldolase C mRNA 
transcript (Dandoy-Dron et al., 2000). Moreover, the expression of proteins involved 
in the glycolytic pathway was found altered in sCJD patients (Gawinecka et al., 
2010). 
 
Interaction studies could add, to the current knowledge, more information about the 
possibility that PrPC may be part of large multi-molecular complexes, depending on 
the cellular context and environment, and thereby contribute to diverse cellular 
functions. Resolving the complexity of PrPC partners and the functional interactions in 
neuronal cells should lead to a better understanding of the neurospecificity of PrPC 
function. Further research is required to determine the relationship between PrPC and 
its biological ligands, how the absence of the interaction is compensated, and 
whether the loss-of-function of PrP-interactors is related to prion diseases. 
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Chapter V Conclusion 
 
 
Prion diseases have occurred in humans and animals for many years. The first cases 
of human prion disease, CJD, were reported in the 1920s (Creutzfeldt, 1920; Jakob, 
1921). The number of human and animal diseases recognized as TSEs has 
increased steadily and now includes many other variants that may arise either 
spontaneously, via inheritance of a predisposing mutation, or by way of infection, with 
an incidence of 1:1milion. Acquisition of disease by infection has drawn intense 
interest among both scientists and the general public, especially in light of the 
outbreak of BSE (“mad cow” disease) in the United Kingdom (Wells et al., 1995) and 
indications that BSE can likely be transmitted to humans, resulting in a new variant of 
CJD (Caughey et al., 2001).  
 
Although excellent progresses have been achieved, several important questions in 
the prion field remain unanswered. Most conspicuously, both the physiological 
function of PrPC and the molecular pathways leading to the fatal neurodegeneration 
in prion diseases remain unknown. The complete knowledge of the biological 
meaning of PrP and the mechanism of prion replication could build a bridge toward 
the understanding of fundamental cellular processes that involved this protein and its 
biological partners, and the development of easily implementable diagnostic tools 
and effective therapies against prionopathies. These unresolved questions could 
have a significant impact on other protein misfolding disorders. 
 
In this thesis work, we aimed to add one more piece to the fascinating field of prion 
protein, by studying the interaction of PrP with three different molecules: a small 
molecule, methylene blue; DNA and RNA aptamers; and a glycolytic enzyme, 
Aldolase C. This in vitro binding study brought further information on the significance 
of these interactions to PrP, and on how they may modulate the behavior of both PrP 
native and oligomer/fibrils states.  
 
Among the wide repertoire of small molecules that have been studied for prion 
diseases or for other misfolding diseases, the addition of a new potential compound 
against prionopathies is not suitable, due to the great number of reported compounds 
that have shown somehow to have an effect on prion conversion but they remained 
at an in vitro level, without further development. This could be ascribed to the fact 
that some of these compounds do not satisfy the requirements to act in CNS and to 
be used as a drug for human and animals. For all these reasons, we have sought a 
molecule which has known toxicological properties, because already used for 
medical treatments, and is able to target the misfolded proteins in the brain. To this 
aim, we found that methylene blue is one of the oldest drugs used, and, more 
interesting, it was already shown to be effective for other amyloidogenic-associated 
diseases. Thus, it is conceivable to presume that MB, also in a synergistic 
mechanism with other compounds, could act as a general anti-aggregation 
compound against many proteinopathies. Our results strongly encourage further 
studies on animal models for future perspective in clinical trials. 
 
Beside the research of compounds that could act as antagonist of prionopathies, the 
development of effective diagnostic tools, that allow the early detection of the 
occurrence of the diseases, is a currently compelling need. DNA and RNA aptamers 
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have been demonstrated to specifically interact with prion protein, and, in some 
cases, distinguish between the normal and the pathogenic isoform of prion protein. 
Although many NA sequences were found to interact with PrP, a common shared 
sequence containing contiguous guanine was observed for some of these aptamers, 
in addition to a common fold in a G-quadruplex architecture. Our study of the binding 
between prion protein and some GG-containing aptamers that fold in G-
quadruplexes, have endorsed the importance of these two requirements to maintain 
the specificity with PrP. Aptamers are gaining more interest not only because they 
can help to better understand the biological function of PrP, but also because they 
can be used to enrich PrP from biological samples, and thus, can be a potent tool for 
diagnostic purposes. 
 
As far as the PrP physiological role is concerned, one of the most used approaches 
to try to resolve this conundrum, is the study of the interaction partners that could 
regulate specific actions of PrP, within the cells. Aldolase C, one of the three 
isoforms of  the glycolytic enzyme aldolase, was found to interact with prion protein. 
Although, it is not yet clear if this interaction occurs in vivo, the understanding of the 
mechanism of recognition between these proteins may help to understand some 
unresolved mechanisms observed in the cell, also considering the very recent results 
that correlate the glucose metabolism-associated enzymes to prion pathologies.  
 
We are aware that in most cases, investigations bring more questions than answers, 
but they add further steps toward a deeper understanding of the mechanisms that 
drive the living processes.  
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Appendix I Other protein-misfolding diseases: the case of phenylalanine 
hydroxylase 
 
 
The protein folding is described as a complex process in which a polypeptide chain 
reaches its native structure by searching the conformational space through a 
multidimensional energy surface (Dobson, 2003). Failure to fold correctly, or to 
remain correctly folded, will give rise to the malfunctioning of living systems and 
hence to diseases. Some of these diseases result from proteins with a high 
propensity to misfold, and thus, escaping all the protective mechanism of the cells 
and forming amyloid fibrils that are deposited in the extracellular space. In this group 
fall those diseases as Alzheimer’s and Parkinson’s diseases and prionopathies (Chiti 
et al., 2006). In other cases, diseases arise from a loss of the biological function due 
to an incorrect folding of the proteins. Mutations are the most frequent causes of the 
increased tendency of the proteins to misfold, leading to reduced in vivo function. 
Among mutation-induced misfolding diseases, PKU (caused by mutations in PAH) is 
considered a paradigm of misfolding metabolic diseases (Gregersen et al., 2006).  
 
The human inborn error of metabolism PKU (OMIM# 261600) is caused by a 
dysfunction of the liver enzyme PAH (EC 1.14.16.1). PAH catalyzes the rate-limiting 
step in L-phenylalanine (L-Phe) catabolism in liver, using tetrahydrobiopterin (BH4) 
and dioxygen as additional co-substrates. PKU mutations are associated with 
impairment of PAH activity, leading to accumulation of L-Phe in plasma (that is, 
hyperphenylalaninemia – HPA) and neurological damage in untreated patients 
(Scriver et al., 1994). Since the introduction of a dietary treatment fifty years ago, 
PKU has been the prototype for a treatable genetic disease and, later, for genetic 
screening in human populations.  
 
About two-thirds of PKU mutations are caused by single amino acid changes in the 
PAH sequence. A large proportion of all missense mutations, including many of the 
most common mutations found  in patients, display stability and folding defects when 
they are expressed in vitro (Waters, 2003). These variant PAH proteins are found to 
aggregate when expressed in prokaryote systems, where they appear as both 
soluble and insoluble aggregates (Leandro et al., 2010). But the presence of amyloid 
fibrils or insoluble aggregates has never been reported in the liver of PKU-affected 
individuals, and PKU has, in fact, been classified as a cytosol-associated protein-
misfolding disease. The current understanding of PKU is related to a loss-of-function 
mechanism associated with increased degradation rather than aggregation of the 
mutants (Waters, 2006). 
 
The full-length PAH gene encodes a protein of about 52 kDa (452 amino acids) that 
in the mature form is assembled as a homotetramer. Each subunit consists of three 
functional domains: a flexible N-terminal regulatory domain (residues 1-142); a 
catalytic domain (residues 143-410) which includes binding sites for iron, substrate 
and cofactor; and a C-terminal oligomerization domain (residues 411-452) which 
includes a tetramerization motifs (residues 427-452). The crystal structure of PAH 
has revealed that the tetrameric oligomers are dimers of dimers in which the 
interaction between the two dimers is mediated by a C-terminal ‘arm’ (Fusetti et al., 
1998).  
 
Phenylalanine hydroxylase 
 
 
81 
 
Recombinant variant proteins containing prevalently missense mutations have been 
analyzed and characterized in vitro. Each exerts a distinct effect on the behavior of 
the PAH protein, which in many cases predicts the biochemical phenotype 
(Zschocke, 2003). The effects of a specific mutation on protein function have been 
studied by various approaches. It is now established that, in most PKU cases, the 
loss of PAH function is due to decreased stability (Mallolas et al., 1999) increased 
susceptibility toward aggregation and degradation of PAH mutant proteins (Leandro 
et al., 2010), thermodynamic instability and/or folding efficiency (Pey et al., 2007). 
 
PAH protein function and its involvement in the PKU diseases is one of the main field 
studied by the group of Prof. Salvatore and his co-workers (Prof. Daniele) at the 
research institute CEINGE. In this regard, they previously carried out a molecular 
analysis of the PAH gene in HPA patients from Southern Italy, and identified and 
characterized several novel mutations (Daniele et al., 2007; Daniele et al., 2008; 
Daniele et al., 2009). During my thesis work, in collaboration with the afore-
mentioned group, I carried out a bio-physical study on the wt-PAH protein and some 
PAH natural mutants, p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N,  p.A403V,  
p.Q419R, to obtain further information about the molecular basis of PKU. To this aim, 
biophysical characterization of PAH proteins was performed by size-exclusion 
chromatography, light scattering and circular dichroism, thereby providing novel data 
on this group of mutant proteins. Our study demonstrate that the oligomerization 
process and conformational stability are altered by mutations, thus affecting the 
physiological behavior of the enzyme and endorsing the hypothesis that 
oligomerization and folding defects of PAH variants are the most common causes of 
HPA, particularly as regards mild human phenotypes. 
 
 
For more information see the article enclosed: 
 
Cerreto, M., Cavaliere, P., Carluccio, C., Amato, F., Zagari, A., Daniele, A. and 
Salvatore, F., 2011. Natural phenylalanine hydroxylase variants that confer a mild 
phenotype affect the enzyme's conformational stability and oligomerization 
equilibrium. Biochim. Biophys. Acta. 1812, 1435-1445. 
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Appendix II List of publication, communications and research activity in scientific 
institutions abroad and in Italy 
 
 
Publications: 
 
• Cerreto, M., Cavaliere, P., Carluccio, C., Amato, F., Zagari, A., Daniele, A. 
and Salvatore, F., 2011. Natural phenylalanine hydroxylase variants that 
confer a mild phenotype affect the enzyme's conformational stability and 
oligomerization equilibrium. Biochim. Biophys. Acta. 1812, 1435-1445.  
 
Manuscripts in preparation: 
 
• Cavaliere, P., Torrent, J., Prigent, S., Pouwels, K., Granata, V., Pastore, A., 
Rezaei, H. and Zagari, A. Inhibition insights into PrP oligomerization and 
fibrillization by methylene blue.  
 
• Cavaliere, P., Pagano, B., Granata, V., Prigent, S., Rezaei, H., Giancola, C. 
and Zagari, A. High affinity binding of quadruplex DNA and RNA aptamers to 
ovine prion protein.  
 
Proceedings: 
 
• Cerreto, M., Cavaliere, P.,  Zagari, A., Daniele, A., Salvatore, F. “Mutation 
Q301P promotes structural instability and formation of high molecular mass 
oligomers in the phenylalanine hydroxylase enzyme”. FEBS J., vol 278 
supplement 1,  p.100. 36th FEBS Congress Torino-Italy, 25-30 June 2011 
 
• Cavaliere, P., Prigent, S., Pastore, A., Rezaei, H., Zagari, A. “Effects of 
Methylene Blue on the Oligomerization Pathway of Prion Protein”. Prion J., vol 
5 supplement 1-20,  pp. 34. PRION 2011 Congress Montreal-Canada, 16-19 
May 2011 
 
Communications: 
 
• Pagano, B., Cavaliere, P., Granata, V., Prigent, S., Rezaei, H., Zagari, A., 
Giancola, C. “Biophysical characterization of interaction between prion and G-
quadruplex forming aptamers”. Abstract book, pp.54. Third International 
Meeting on G-quadruplex and G-assembly Sorrento-Italy, 28 June-01 July 
2011  
 
• Cerreto, M., Cavaliere, P., Carluccio, C., Zagari, A., Daniele, A., Salvatore, F. 
“Characterization of the biochemical, biophysical and structural phenotypes of 
seven PAH natural variants identified in patients affected by 
Hyperphenylalaninemias”. Abstract Book, pag. 524. 42° National Congress 
SIBioc Roma-Italy, 05-08 October 2010 
 
• Cavaliere, P., Cerreto, M.,. Carluccio, C., Cappuccio, A., Daniele, A., Zagari, 
A., Salvatore, F. “Natural phenylalanine hydroxylase mutants provoke 
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conformational instability and oligomerization defects of the enzyme”. Abstract 
Book, pag. 119. The EMBO meeting 2010 Barcelona-Spain, 04-07 September 
2010 
 
•  Cavaliere, P., Granata, V., Zagari, A. “Binding of Methylene Blue to Prion 
Protein Oligomers By Surface Plasmon Resonance”. Abstract Book, pag. P33. 
IX  National Congress of Supramolecular chemistry Parma-Italy, 06-09 
September 2009 
 
Research activity in Scientific Institutions abroad and in Italy: 
 
• From April 2009 to April 2011, excluding periods spent in France, the research 
activity on phenylalanine hydroxylase and on the interaction between prion 
protein and aldolase C were partially carried out at CEINGE- Biotecnologie 
avanzate Scarl, Naples-Italy. These projects were headed by Prof. F. 
Salvatore and carried out in collaboration with Prof. P. Buono and Prof. A. 
Daniele; 
 
• From March to July 2010, September to December 2010, and June to August 
2011, the research activity on the effects of methylene blue on the 
oligomerization and fibrillization of PrP was carried out at INRA “Institute 
National de la Recherche Agronomique”, Jouy en Josas-Paris-France, in 
collaboration with Dr. H. Rezaei; 
 
• From November 2010 to May 2011, part of the research activity on the 
interaction between PrP and DNA and RNA aptamers was carried out at the 
Department of Chemistry, University of Naples “Federico II”, Naples-Italy, in 
collaboration with Prof. C. Giancola. 
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Hyperphenylalaninemia
Phenylalanine hydroxylaseHyperphenylalaninemias are genetic diseases prevalently caused by mutations in the phenylalanine
hydroxylase (PAH) gene. The wild-type PAH enzyme is a homotetramer regulated by its substrate, cofactor
and phosphorylation. We reproduced a full-length wild-type protein and seven natural full-length PAH
variants, p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V, and p.Q419R, and analyzed their biochemical
and biophysical behavior. All mutants exhibited reduced enzymatic activity, namely from 38% to 69% of wild-
type activity. Biophysical characterization was performed by size-exclusion chromatography, light scattering
and circular dichroism. In the puriﬁed wild-type PAH, we identiﬁed the monomer in equilibrium with the
dimer and tetramer. In most mutants, the equilibrium shifted toward the dimer and most tended to form
aggregates. All PAH variants displayed different biophysical behaviors due to loss of secondary structure and
thermal destabilization. Speciﬁcally, p.F382L was highly unstable at physiological temperature. Moreover,
using confocal microscopy with the number and brightness technique, we studied the effect of BH4 addition
directly in living human cells expressing wild-type PAH or p.A403V, a mild mutant associated with BH4
responsiveness in vivo. Our results demonstrate that BH4 addition promotes re-establishment of the
oligomerization equilibrium, thus indicating that the dimer-to-tetramer shift in pA403V plays a key role in
BH4 responsiveness. In conclusion, we show that the oligomerization process and conformational stability are
altered by mutations that could affect the physiological behavior of the enzyme. This endorses the hypothesis
that oligomerization and folding defects of PAH variants are the most common causes of HPAs, particularly as
regards mild human phenotypes.iopterin; CD, circular dichroism;
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Phenylketonuria (PKU, Online Mendelian Inheritance in Man
database: 261600) and its hyperphenylalaninemia (HPA) variantsrepresent the most common inherited disorder of amino acid metab-
olism transmitted by an autosomal recessive mode [1]. The primary
cause of HPA is a dysfunction of phenylalanine hydroxylase (PAH: EC
1.14.16.1). In the liver, this enzymemetabolizes L-Phenylalanine (L-Phe)
to L-Tyrosine (L-Tyr) using (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin
(BH4) as coenzyme. More rarely, forms of HPAs can also be caused by a
lack of the BH4 cofactor due to defective cofactor biosynthesis and
regeneration [2]. Untreated PKU patients present an abnormal pheno-
type, with growth failure, microcephaly, seizures and permanent
neurologic damage because their body ﬂuids contain elevated levels of
L-Phe and its neurotoxic metabolites (phenylpyruvate, phenylacetate
and phenylactate) [1,3].
The major manifestations of the disease, which start at birth, are
prevented by severe dietary restriction of L-Phe [4] and, in selected
cases, by BH4 supplementation, which reduces L-Phe levels and
increases L-Phe tolerance in HPA patients [5]. Several new therapeutic
strategies based on the biochemistry and pathogenetic features of
PKU are currently being investigated [6,7].
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encompassing 171 kb. The full-length PAH cDNA encodes a protein of
about 52 kDa (452 amino acids) that in the mature form is assembled
as a homotetramer. Each subunit consists of three functional domains:
a ﬂexible N-terminal regulatory domain (residues 1–142); a catalytic
domain (residues 143–410) that includes binding sites for iron,
substrate and cofactor; and a C-terminal oligomerization domain
(residues 411–452) with dimerization (residues 411–426) and
tetramerization motifs (residues 427–452) [8] (Fig. 1). The crystal
structure of PAH has revealed that the tetrameric oligomers are
dimers of dimers in which the interaction between the two dimers is
mediated by the C-terminal ‘arm’ [8].
The tetrameric and dimeric forms of PAH are in equilibrium [9,10]
and have different catalytic properties because the tetramer, but not
the dimer, demonstrates a positive kinetic cooperativity with respect
to L-Phe [11]. In particular, substrate activation results in conforma-
tional changes involving the tertiary as well as the quaternary
structure [12] and drives the tetramer–dimer equilibrium toward
the tetrameric form [13]. Further regulation mechanisms require
binding of BH4 [12] and phosphorylation [14].
The clinical and metabolic features associated to HPA are complex
[15] and various genotype–phenotype correlation studies have been
performed [16–18]. In addition, at molecular level, about 600
mutations have been identiﬁed, most of which are point mutations
scattered throughout the whole PAH gene (http://www.pahdb.mcgill.
ca), although frequencies differ among populations and geographic
areas [16–18].
Recombinant variant proteins containing prevalently missense
mutations have been analyzed and characterized in vitro; each
mutation exerts a distinct effect on the behavior of the PAH protein,
which in many cases allows the prediction of the biochemical
phenotype [19–21]. The effects of a speciﬁc mutation on protein
functions have been studied with different approaches, i.e., enzyme
assay, in vivo isotopic studies and in vitro expression. Moreover, the
crystal structures of human and rat PAH [8,22] provided the structural
basis of HPA [23]. It is now established that, inmost HPA cases, the loss
of PAH function is due to decreased stability [21,24], increased
susceptibility toward aggregation and degradation of PAH mutant
proteins [19,24,25], thermodynamic instability [26] and/or folding
efﬁciency [27]. About 75% of PAH mutations, characterized by high
residual activity, have been found to be associated with BH4Fig. 1. Full-length composite model of the PAH monomer structure and distribution of
the HPA-related missense mutations studied in this paper. The N-terminal regulatory
domain is shown in blue, the catalytic domain in red and the tetramerization domain in
green. The Fe ion is shown as a cyan sphere at the center of the catalytic domain; the
mutation sites are marked as yellow balls.responsiveness, both in vitro [28–30] and in vivo [4,5]. It has recently
been speculated that pharmacological doses of BH4 may augment the
conformational stability and the amount of functional PAH [31].
We previously carried out a molecular analysis of the PAH gene in
HPA patients from Southern Italy, and identiﬁed and characterized
several novel mutations [32–34]. In the present study, we analyzed
the wild-type PAH protein and some PAH natural mutants to obtain
further information about the molecular basis of HPAs and the
mechanism of BH4 responsiveness. To this purpose, we reproduced,
by in vitro mutagenesis, the wild-type and seven natural variants of
PAH: p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V, and
p.Q419R, and characterized the biophysical–biochemical properties of
the above-mentioned puriﬁed full-length proteins in order to
understand the impact of each mutation on the activity, oligomeric
structure and stability of PAH. In addition, we investigated the
mechanism underlying BH4 responsiveness using p.A403V, which is
one of the most frequent mutations in our geographic area [32], and is
associated with a BH4-responsive mild phenotype [35].
2. Material and methods
2.1. Construction of PAH expression plasmid and site-directed
mutagenesis
PAHwild-type andmutant constructs were obtained by modifying
the pMAL Xa PAH plasmid, kindly provided by Drs CR. Scriver and P.
Waters (McGill University-Montreal Children's Hospital Research
Institute, Montreal, Canada), to digest the fusion protein MBP-PAH
with enterokinase (Ek) [9]. The Ek site was inserted downstream the
sequence encoding the factor Xa site, by site-directed mutagenesis
using the primers 5′gatgacgatgacaagtctactgcggtcctgg3′ and 5′
gccctaactcccttccctactgctactgttc3′ and the Quick Site-directed muta-
genesis kit (Stratagene, CA, USA). GFP was ampliﬁed by PCR from
pEGFP-N1 (Clonetech, CA, USA) using the primers: 5′acattaggtac-
cagccatggtgagcaagggcgag3′ and 3′ gtagatgaattctccaccacccttgtacagctcg
5′ and cloned into pcDNA3 (Invitrogen, Carlsbad, CA) using Kpn1
and EcoR1 sites. PAH cDNA was ampliﬁed from pMAL Xa Ek PAH
by using the primers: 5′catcattgaattctccactgcggtcctgg3′ and 3′
cgtaatgcggccgcttactttattttctggag 5′ and cloned downstream GFP,
using EcoR1 and Not1 sites. Sequence analysis conﬁrmed the correct
frame.
Mutations were introduced into pMAL Xa Ek PAH and pCDNA3-
GFP-PAH using mutagenic primers and the Quick Site-directed
mutagenesis kit (Table 1). The modiﬁed plasmid and the mutant
clones were sequenced to verify the introduction of each single
mutation. Commercial MBP was obtained from New England Biolabs
(Ipswich, MA, USA).
2.2. Expression, puriﬁcation and N-terminal sequencing of the
PAH protein
pMAL Xa Ek PAH expression plasmids were transformed into
Escherichia coli BL21 cells and the colonies were selected using Luria-
Broth plates with ampicillin (0.1 mgmL−1). Bacteria were grown to
2×108 cells/mL (A600nm~0.5) and overexpression of wild-type and
variant MBP-PAH fusion proteins was induced with 1 mM isopropylthio-
β-D-galactoside (IPTG) for 16 h at 37 °C. Cells were harvested by
centrifugation and treated according to the instruction manual of the
pMAL protein fusion and puriﬁcation system (New England Biolabs). The
fusion proteinwas digested overnight at room temperaturewith Ek (New
England Biolabs) to obtain wild-type and mutant forms of PAH without
the MBP tag, using 0.5 ng of enzyme for each 50 μg fusion protein. The
mixturewas then applied to ahydroxyapatite column (1 cm×10 cm, Bio-
Rad Laboratories, CA, USA) and subjected to several washes with 20 mM
sodiumphosphate, 200 mMNaCl (pH7.2). Proteinswere thenelutedwith
0.5 MNa phosphate, pH 7.2 and subsequentlyMBPwas isolated from the
Table 1
The seven mutant forms of PAH reproduced in vitro as recombinant products and analyzed. The primer pairs used to produce the pMAL Xa Ek PAH plasmid.
Mutant forms of PAH Mutagenic primers (forward) Mutagenic primers (reverse)
Ek site 5′GATGACGATGACAAGTCTACTGCGGTCCTGG3′ 5′GCCCTAACTCCCTTCCCTACTGCTACTGTTC3′
p.I65M 5′ACCTGACCCACATGGAATCTAGACCTTCTC3′ 5′GAGAAGGTCTAGATTCCATGTGGGTCAGGT3′
p.N223Y 5′CATGAAGATTACATTCCCCAGCTGGAAGAC3′ 5′GTCTTCCAGCTGGGGAATGTAATCTTCATG3′
p.R297L 5′TGTTTTCAGATCTCAGCTTTGCCCAGTTTT3′ 5′AAAACTGGGCAAAGCTGAGATCTGAAAACA3′
p.F382L 5′ACTGTCACGGAGTTGCAGCCCCTGTATTAC3′ 5′GTAATACAGGGGCTGCAACTCCGTGACAGT3′
p.K398N 5′GCCAAGGAGAACGTAAGGAACTTTGCTGCC3′ 5′GGCAGCAAAGTTCCTTACGTTCTCCTTGGC3′
p.A403V 5′GAAAGTAAGGAACTTTGTTGCCACAA3′ 5′CCGAGGTATTGTGGCAACAAAGTTCC3′
p.Q419R 5′ATACACCCGAAGGATTGAGG3′ 5′CCTCAATCCTTCGGGTGTAT3′
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by size-exclusion chromatography with a HiLoad 16/60 Superdex 200
column (GE Healthcare, UK). Protein concentrations were determined
spectrophotometricallywith the use of the absorption coefﬁcient A280 or
the dye-binding Bradford assay (Bio-Rad Laboratories). The N-terminal
aminoacid sequenceofPAHwasdeterminedbyEdmandegradationonan
automated Procise H49 sequencer (Applied Biosystems, MA, USA).
It has been reported [36] that, during the various steps of
recombinant protein production, some labile Asn residues are
deamidated: however, any possible deamidation of these residues,
which would in the activity assay produce substrate inhibition, would
most likely be the same in the presence of wild-type and of the variant
forms of PAH we have employed.
2.3. Concentration and storage of proteins
The concentration of proteins was determined both by the micro
BCA protein assay and spectrophotometrically. The ﬁnal protein
concentration was measured based on optical density at 280 nm
using, for the extinction coefﬁcient, a value of 49,780, 66,350 and
115,630 M−1 cm−1 for PAH, MBP and the fused wild-type MBP-PAH
respectively, deduced from the amino acid composition of the protein.
We used a SpeedVac concentrator (Thermo Scientiﬁc, Rockford, IL,
USA) to concentrate the protein solutions because ultra-ﬁltration led
to considerable sample loss. All protein samples, if not utilized within
few days, were stored at −20 °C in their elution buffer (see below).
2.4. PAH activity and thermal inactivation assay
Enzymatic activity analysis was carried out on a whole equilibrium
mixture of oligomeric species of puriﬁed full-length wild-type and
mutant PAH (see Supplementary Table S1). The activity was assayed
in the presence of 0.25 μCi L-[14C] Phe (Amersham, Buckinghamshire,
UK; 460 μCi/mmol); 0.25 mM cold L-Phe, 1.3 units of beef liver
catalase; 0.8 mM BH4; 250 mM Tris HCl pH 7.8, 1 μg of protein;
ﬁnal volume: 100 μL. The reaction was conducted at 25 °C with
an incubation time of 1 h [32–34]. After centrifugation at room
temperature andmaximum speed, an aliquot of each supernatant was
applied on a thin-layer chromatography system and the amount of
[14C] radio-labeled L-Phe converted to [14C] radio-labeled L-Tyr was
measured. The mean PAH activities were calculated from three sets of
experiments. The residual activities of mutant PAH enzymes were
expressed as a percentage of wild-type enzyme activity. The same
assay was used for the thermal inactivation analysis of the wild-type
protein and of the p.F382L mutant. Thermal inactivation of both
proteins was determined by measuring the decay of tyrosine
production as a function of temperature in the 32–58 °C range.
2.5. Electrophoresis and immunoblotting
SDS/PAGE was performed at 100 V (2 h) in a 10% (w/v)
polyacrylamide gel. The puriﬁcation of all proteins was veriﬁed after
staining with Colloidal Coomassie. The absence of MBP contamination
in all preparations was determined by western blot analyses.Immunoblotting was performed using afﬁnity-puriﬁed rabbit anti-
hPAH [32–34] and mouse anti-MBP (New England Biolabs) as primary
antibodies. The enhanced chemiluminescence system from Amersham
(GE Healthcare) was used for immunodetection.
2.6. Size-exclusion chromatography with multiangle light scattering
Size-exclusion chromatography (SEC) was performed using Akta
FPLC chromatography equipment (GE Healthcare) on a Superdex 200
10/300 GL column. The column was previously calibrated for
molecular mass using a Gel Filtration High Molecular Weight
calibration kit (GE Healthcare) constituted by ovalbumin (44 kDa),
conalbumin (75 kDa) and aldolase (158 kDa). Before each run, the
column was equilibrated with at least two column volumes of elution
buffer and each run was performed at both 4 °C and room
temperature (20–23 °C). The elution buffer was Tris–HCl 20 mM pH
7.4, NaCl 100 mM (buffer A) and, in a few cases, Na-phosphate 20 mM
pH 7.0, KF 150 mM (buffer B).
The eluent ﬂow was 0.5 mL min−1. Only freshly prepared or
recently defrosted proteins were loaded on the column because
storage at 4 °C for more than one week led to sample aging. A total of
0.1÷0.2 mg of proteins were loaded. At room temperature, the
elution proﬁle was monitored at three UV absorption wavelengths
(280 nm, 215 nm and 258 nm). At 4 °C, UV absorption was measured
only at 280 nm. The chromatograms were deconvoluted by Unicorn
software, supplied with the FPLC device, to calculate the percentage of
single species. All chromatograms were normalized in the (0.0÷1.2)
range.
At roomtemperature, size-exclusionchromatographywithmultiangle
light scattering (MALS) experiments was carried out with the AKTA
systemcoupled toa three-angle (45°, 90° and135°)WyattMinidownEOS
light scattering instrument linked to a Wyatt Optilab refractometer
(Wyatt Technology Corp., Santa Barbara, CA). These experiments served
to determine the sizes of oligomers of wild-type and mutant PAH.
Molecular masses, polydispersity and root mean square radius
calculations were made by ASTRA software, which is supplied with
the light scattering device, using a dn/dc value of 0.185 mL g−1.
2.7. Circular dichroism
Circulardichroism(CD) analysiswasperformedoncommercialMBP,
on the fused wild-type MBP-PAH tetrameric sample and on the most
abundant species of cleaved PAH proteins after SEC puriﬁcation. In the
case of the cleaved wild-type PAH, CD experiments were performed
with both the tetrameric form and the whole equilibrium mixture. A
2-day dialysis at 4 °C against Tris–HCl 20 mM pH 7.4 (buffer C) was
conducted to eliminate NaCl before CDexperiments. All CD spectrawere
recorded with a Jasco J-810 spectropolarimeter equipped with a Peltier
temperature control system(model PTC-423-S). The spectropolarimeter
was calibrated with an aqueous solution of D-10-(+)-camphorsulfonic
acid at 290 nm. The molar ellipticity per mean residue, [θ] in deg cm2
dmol−1, was calculated from the equation [θ]=[θ]obs mrw (10 l C)−1,
where [θ]obs is the ellipticity measured in degrees, mrw is the mean
residue molecular weight (111.5 Da), C is the protein concentration in
Fig. 2. Enzymatic activity of the PAHmutants expressed as percentage of wild-type PAH
activity. The activity was measured by the amount of [14C] Tyr produced by [14C] Phe as
analyzed by thin layer chromatography. Mean values and the standard deviation
derived from three sets of independent experiments for each construct are shown
expressed as percentage of wild-type PAH activity. The experimental assay conditions
are reported in Section 2.4.
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(ultraviolet) measurements (190–260 nm) were carried out at 20 °C
using a 0.2 cmoptical path length cell and a protein concentration in the
range 0.10–0.15 mg mL−1. CD spectra, recordedwith a time constant of
4 s, a 1-nm bandwidth, and a scan rate of 20 nmmin−1, were signal
averaged over at least three scans. The baseline was corrected by
subtracting the buffer spectrum. Thermal denaturation curves were
recorded over the 20–80 °C temperature range and by monitoring the
CD signal at 222 nm.After preliminary trialswithin the scan rate interval
of 0.5÷2.0 °C min−1, all curves were recorded using a 0.2-cm path
length cell and a scan rate of 1.0 °C min−1. Irreversibility of the
denaturation was veriﬁed by recording, after cooling to 20 °C, the
spectra of samples subjected toaﬁrst temperature scan.All denaturation
curves were normalized in an interval of 0.0÷1.0. The Tm values were
determined from the ﬁrst derivatives of the denaturation curves after
noise reduction by using the standard analysis program provided with
the instrument.
2.8. Cell culture
HeLa cellswere grown inD-MEMhigh glucosemedium (Invitrogen)
containing 10% heat inactivated fetal bovine serum (Invitrogen), 1%
penicillin/streptomycin, at 37 °C in 5% CO2. Transfections of both wild-
typePAHand thep.A403Vmutantwere carriedout using theProFection
Mammalian Transfection System (Promega, WI, USA) in accordance
with the manufacturer's protocol. Cells were plated on 35-mm glass
bottom dishes (MatTek, MA) for imaging.
2.9. Confocal microscopy and number and brightness analysis
Constructs containing GFP-PAH fusion proteins were transfected
in HeLa cells and experiments were started 18 h after transfection. To
evaluate BH4 responsiveness, transfected cells were treated with
60 μM BH4 in aqueous solution. Analyses were performed 6 h later.
Number and brightness (N&B) analysis was performed according to
Gratton and colleagues [37,38] using a Zeiss LSM 510 META confocal
microscope. Cells grown for 4 days on bottom glass dishes were
imaged in vivo in CO2-independent medium (150 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 1 mMMgCl2, and 20 mM Hepes, pH 7.4). Fifty frame
time series were acquired with a LSM 510META equipped with a plan
apo 63× oil-immersion (NA 1.4) objective lens using the following
settings: 488 nm Argon laser, 25% of output power, 1.5% transmission,
505–550 nm emission, gain equal to 850, offset 0.1, and digital gain 1.
Scanning parameters were: 512×512 frame window, 25.61 μs/pixel
dwell time, no average, zoom 6×, ROI (x,y) 256×64, and pinhole
corresponding to 1 μmoptical slice. Data from each cell were analyzed
with the simFCS software (Globals Software, East Villa Grove, IL
61956, USA). Brieﬂy, data analysis was performed pixel-by-pixel over
time to calculate variance and average intensity. Correction was
applied to take into account the analog detection of ﬂuorescence by
the photomultiplier tubes of the confocal microscope. Brieﬂy, the
correction parameters S, offset and sigma0 were determined, for each
experiment, by plotting the measured average intensity (bIN) vs
average variance (bVarN) of 50 frame time series acquired using same
settings as above, but setting 4 different values of laser transmission
percentages. Moreover, ﬁlters and beam splitters were conﬁgured to
obtain reﬂection images to detect the deﬁned amount of light
originating directly from the laser. The obtained plots were linearly
interpolated and the equation of straight line (R≥0.99) was used to
extract the parameters S and offset based on the following equation:
bVarN=S∗b IN+offset∗S. The parameter sigma0 was estimated from
time-series acquired with laser off, as the half maximum width of the
histogram peak of the “dark”-counts. Its value was constantly lower
than 0.1, and consequently was approximated to zero in all the
calculations. Brightness (B) was calculated pixel by pixel from thefollowing equation B=V(x,y)/(S∗ Ix,y), where I = Im-offset (Im:
measured average ﬂuorescence).
The number of molecule subunits constituting each oligomer was
calculated with the following calibration procedure: the brightness of
monomeric GFP and of GFP-based molecules made by two or three GFP
moieties fused in tandeminexpressionvectorpcDNA3.1andexpressed in
HeLa cellsweremeasuredwith the same experimental settings described
above. The measured B values for monomeric, dimeric and trimeric GFP
and the corresponding number of subunits were linearly interpolated to
obtain the experimental equation describing the dependence of
brightness on thenumberofGFP subunits: B=k×nsub+c. This equation
was used to calculate the unknown number of GFP subunits correspond-
ing to the measured brightness. The following formula B=sum (Bi2 ni)/
sum(Bi ni) provides the brightness ofmultiple species (Bi)whose number
is ni in a single pixel, is combined in the measured brightness (B). This
formula is used to interpret non integer subunit values obtained by the
above procedure.
2.10. Structural analysis
The effect of themutations on the 3D structure was investigated by
analyzing the structural environment of each substituted residue in
the PAH crystal structures deposited in the Protein Data Bank (PDB).
Since no crystal structure of any full-length enzyme is available,
various models were used: tetrameric human PAH lacking residues
1–117 (pdbcode 2pah); dimeric truncated human PAH lacking
residues 1–117 and 425–452 (PDB code 1kw0); and the dimeric rat
PAH, from residue 19 to 427 (pdbcode 1phz), which encompasses the
regulatory domain. A composite monomeric model that included the
three domains was built by superimposing the secondary structure
elements of the respective catalytic domains of the rat (1phz) and
human structures (2pah and 1kw0). The structural superposition was
performed using the program O [39].
3. Results
3.1. Enzymatic activity analysis of wild-type and mutant forms of PAH
Wemeasured the enzymatic activity of the equilibriummixture of
the wild-type and mutant forms of PAH to investigate the effect of the
mutations on catalytic activity. As shown in Fig. 2, the residual
activities of the mutant PAH enzymes, expressed as a percentage
of wild-type enzyme activity, were: 38±3% (p.I65M), 48±14%
(p.N223Y), 60±12% (p.R297L), 69±11% (p.F382L), 58±9%
(p.K398N), 43±4% (p.A403V) and 63±5% (p.Q419R). In our
conditions, we found in multiple experiments that isolated oligomeric
species are not stable and evolve toward the equilibriummixture (see
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tetramers and dimers was not possible to be measured with accuracy.
3.2. Oligomerization equilibrium of wild-type and mutant forms of PAH
The oligomerization equilibrium for the fused MBP-PAH protein,
the puriﬁed cleaved wild-type protein, and the missense mutants was
analyzed by SEC (Fig. 3a,b). SEC runs were carried out at both 4 °C and
room temperature. The elution proﬁle was essentially the same at
both temperatures, therefore only the data at room temperature are
reported. Unless speciﬁed otherwise, SEC measurements were carried
at a constant pH of 7.4 (buffer A). The SEC proﬁles revealed that wild-
type and most of the mutant forms of PAH elute as tetramers and
dimers although monomers and aggregates are also present,
depending on the mutation of the protein. Fig. 3a shows the SEC
proﬁles of proteins in which the tetramer is the most abundant
species, i.e., the fused protein, the cleaved wild-type PAH and mutant
p.R297L. Fig. 3b shows the proﬁles of the wild-type PAH (as reference)
and of mutants p.I65M, p.N223Y, p.F382L, p.K398N, p.A403V and
p.Q419R in which dimer is the dominant species. The peaks
corresponding to tetramer, dimer and monomer species elute at
11.5 mL, 13.1 mL and 14.7 mL respectively (Fig. 3a,b).Fig. 3. Chromatographic proﬁles of the PAH natural variants and immunoblotting of wild-ty
and normalized in the 0.0÷1.2 interval. All curves are shifted along the ordinate axis by 0.05n
and other mutant recombinant PAH proteins. All curves are shifted along the ordinate axis by
the single curves. c)Western blot analysis using the anti-PAH antibody of each of the fraction
forms, possibly multimeric; peak T) tetramer; peak D) dimer; peak M) monomer. Western b
MBP antibodies.The presence of the PAH protein was conﬁrmed in each of the
fractions obtained by SEC (Fig. 3a) after separation by SDS/PAGE and
Western blot analysis using anti-PAH serum (Fig. 3c). This result
demonstrates the existence of a monomeric form of the PAH enzyme.
This formwas probably underestimated in previous studies because it
was masked by MBP. Western blot analysis also showed that samples
did not contain MBP after cleavage (Fig. 3c).
The percentage of PAH oligomeric species is reported in Fig. 4 (see
also Supplementary Table S1). The tetramer and dimer species of the
wild-type PAH were separately collected and stored for less than one
week at 4 °C. Subsequently, SEC analysis of tetramers and dimers
showed that the tetramer shifts back toward the dimer and the
monomer, while the dimer is fairly stable, since about 90% of the
protein applied was recovered in the dimeric form (data not shown),
according to literature data [21].
All chromatographic runs were done in conjunction with MALS.
The masses resulting from MALS measurements in wild-type PAH
mutants were 203 kDa (within 1%) and 102 kDa (within 3%) for
tetramer species and dimer species, respectively. Because of the small
quantities of monomer, we were not able to calculate its molecular
mass. A representative proﬁle of wild-type PAH obtained from MALS
is shown in Fig. 5.pe PAH. a) Size exclusion chromatographic (SEC) runs carried out in buffer A (see text)
, n integer (1≤n≤5), with respect to the wild-type PAH curve. b) SEC runs of wild-type
0.05n, n integer (1≤n≤5), with respect to the wild-type PAH curve, to better visualize
s in panel a obtained fromwild-type (depicted as a black curve in a); peak A) aggregated
lot analysis of the wild-type PAH monomer (peak M of panel a) with anti-PAH or anti-
Fig. 4. Percentage of the molecular species of the recombinant wild-type PAH protein and its mutants. The histograms indicate a) the percentage of tetramers and dimers, and b) the
percentage of aggregate and monomers of recombinant wild-type PAH, MBP-PAH, p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V and p.Q419R. All data with standard
deviations were calculated on at least triplicate runs carried out at 20 °C.
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The dominant oligomeric species of wild-type PAH and mutants,
collected after gel ﬁltration and dialyzed against buffer C, were
analyzed by CD. The CD spectra of all samples were recorded in the
far-UV region (190–250 nm), in buffer C, pH 7.4, at 20 °C. Fig. 6a
shows the normalized spectra for wild-type PAH and selected
mutants, together with the spectrum for the fused wild-type MBP-
PAH. In the spectra of Fig. 6a, the maximum centered at 195 nm and
the two broad minima centered at 208 and 222 nm are indicative of
the presence of both α and β secondary structure elements. The
spectra proﬁles do not differ signiﬁcantly from each other, but the
molar ellipticity of all the mutants is much lower than that of wild-
type enzyme. Therefore, these spectra provide evidence for local
unfolding of the mutants.
We also recorded the thermal denaturation curves in the
20÷80 °C temperature range by monitoring the molar ellipticity at
222 nm (Fig. 6b) of the most abundant oligomeric species of cleaved
PAH proteins (Figs. 3a,b; 4, Supplementary Table S1). The far-UV CD
spectra of denatured species of all samples at 80 °C are typical of
random coil (data not shown). The spectrum of cooled samples after
denaturation is virtually identical to that of the denatured protein atFig. 5. SEC-MALS analysis of wild-type PAH. Representative proﬁle of wild-type PAH
obtained from light scattering and refractive index detectors. The molecular mass is
shown. The experimental data are represented by squares and the ﬁtting of
experimental data is shown by a red line.80 °C (data not shown), thereby conﬁrming the irreversibility of the
unfolding process, as previously reported [24,40]. In the case of the
wild-type PAH, the denaturation curve of the equilibriummixturewas
also recorded; for comparison purposes, this curve and that of the
tetramer are shown in Fig. 6c. It is clear that the denaturation process
depends on the oligomeric species.
The sigmoidal denaturation curve obtained with the fused wild-
type MBP-PAH protein shows two inﬂection points, with a plateau,
corresponding to the two melting temperatures of the two proteins.
Visual inspection of the denaturation curves (Fig. 6b) of the cleaved
PAH proteins shows a sigmoidal shape with a single inﬂection point.
Differently, a detailed analysis of the curves through the ﬁrst
derivatives, revealed two midpoints corresponding to two transitions
(data not shown), according to literature data [40]. As shown in
Table 2, the melting temperatures of the PAH proteins range from 33
to 57 °C. The thermal denaturation curve of mutant p.F382L is
signiﬁcantly shifted to lower temperatures with respect to the wild-
type PAH (Fig. 6b). Therefore, we carried out the thermal inactivation
assay of the wild-type PAH and the p.F382L mutant at temperatures
between 32 and 58 °C (Fig. 6d). Consistently, the p.F382L mutant was
much more temperature sensitive than the wild-type enzyme. In fact,
under these conditions a lower amount of Tyr was produced (Fig. 6d),
and the half-inactivation temperature was close to 44 °C, which well
agrees with the value of Tm2=43.6 °C obtained by CD. These ﬁndings
show that the stability of speciﬁc mutants, such as p.F382L, can
markedly diverge from that of the wild-type protein.
3.4. N&B analysis
Confocal microscopy observation of cells expressing GFP-wild-
type PAH and GFP-A403V fusion proteins revealed a cytoplasmic
localization of PAH and its mutant p.A403V, as expected (Fig. 7a,b). No
ﬂuorescence was detected in the cell nuclei. To estimate the number
of subunits constituting wild-type PAH and the p.A403V mutant at
steady state in live cells, the recently developed N&B technique was
performed on cells expressing the fusion proteins treated and not
with BH4 for 6 h. The “brightness” of the GFP-wild-type PAH fusion
protein was 1.091 and 1.099 upon BH4 treatment, which, at the t-test,
was not signiﬁcantly different from values obtained without BH4
treatment. On the contrary, in cells expressing the GFP-A403V fusion
protein there was a statistically signiﬁcant (pb0.001) shift of
brightness from 1.047 without BH4 to 1.094 upon its addition.
Fig. 6. CDmeasurements. a) Far-UV spectra recorded in buffer C (see text) at 20 °C. b) CD-monitored thermal unfolding curves in the 25–80 °C temperature range. The change of the
molar ellipticity at 222 nm was monitored versus the temperature. The most abundant oligomeric form was considered for each PAH protein. c) Thermal denaturation of the
tetrameric form and of the equilibrium mixture of cleaved wild-type PAH. d) Thermal inactivation assay of wild-type and F382L PAH. Proteins were incubated at increasing
temperatures and the amount of produced tyrosine was determined.
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subunits that constitute each PAH oligomer at steady state, namely
wild-type and p.A403V before and after BH4 administration (see
Material andmethods for details). Brieﬂy, a calibration curve (number
of subunits vs brightness) was constructed using reference GFP-basedTable 2
Melting temperatures inferred by ﬁrst derivative of unfolding curves.a
Forms of PAH Tm1±1.0 (°C) Tm2±1.0 (°C)
Wild-type PAH 52.2 57.6
MBP-PAH 52.0 57.5
p. I65M 53.0 59.2
p.N223Y 54.2 57.6
p.R297L 50.8 59.0
p.F382L 32.6 43.6
p.K398N 46.4 53.6
p.A403V 46.0 55.6
p.Q419R 50.1 57.3
All experiments were conducted in buffer C (see Material and methods).
a See also Fig. 6b.molecules constituted by 1, 2 or 3 GFPmonomers andmeasuring their
brightness in the same experimental conditions used above. The
reference curve obtained (which was perfectly linear) was used to
extrapolate the unknown number of subunits from the brightness of
GFP-PAHs. The wild-type PAH conserved an average number of
subunits (see Material andmethods for deﬁnition of “average number
of subunits”) equal to approximately 3.1, which reﬂects the presence
of tetramers and dimers in equilibrium. The addition of BH4 did not
affect this number. Differently, exposure of the A403V-PAH mutant
form to BH4 caused the subunit number to increase from 2.4 to 3.1,
this latter being the same as that of the wild-type enzyme (Fig. 7c).
4. Discussion
4.1. The oligomerization equilibrium is shifted toward the dimeric form
in PAH mutants
To characterize the oligomeric state of PAH in solution, we
performed SEC with on-line detection of LS and refractive index
signals. This approach allowed us to measure the molecular mass of
Fig. 7. N&B analysis. a) Confocal microscopy images of cells expressing GFP-wild-type PAH protein and b) GFP-p.A403V mutant protein. c) Histograms showing the oligomeric state
of both GFP-wild-type PAH and GFP-p.A403V mutant in untreated (blue bars) and BH4-treated (red bars) cells. Asterisks above the bars indicate statistical signiﬁcance for the
p.A403V mutant protein.
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composition and elution volume. The operative conditions used in the
SEC experiments were the same for all samples. No substrate, cofactor
or any other compound was added and only a buffer at physiological
pH (buffer A; pH 7.4) was used because a lower pH and the addition of
L-Phe can affect the oligomeric equilibrium [10].
In line with previous data [10,21,24], the SEC proﬁle of the fused
wild-type MBP-PAH protein revealed that tetramer was the dominant
species (88.4%), whereas the dimeric form was less abundant and the
monomeric form was absent. Differently, all three species were
obtained in the cleaved full-length wild-type enzyme (see Fig. 4 and
Supplementary Table S1 for the relative percentages). The observation
of three distinct peaks demonstrates that self-association of mono-
mers or dimers is slow on the time scale of separation. Previous
studies showed that both fused and truncated/cleaved forms of wild-
type and mutant enzymes consist of an equilibrium mixture of
dimeric and tetrameric species in a ratio that depends on the protein
nature and on the experimental conditions used [10,24].
Only in a few cases in which proteins were expressed in a coupled
in vitro transcription–translation eukaryotic system [41,42] was the
monomeric form also detected. Here, we report evidence that a
monomer species occurs in the equilibriummixture of PAH albeit in a
low amount. The presence of a monomer species may have been
underestimated in previous studies for several reasons: i) because of
its low abundance, ii) because the fused protein was analyzed [24] or
iii) because the cleaved wild-type PAH was analyzed in the presence
of MBP which co-elutes with the PAH monomer [10]. Western blot
analysis (Fig. 3c) and re-chromatography of the isolated tetramer of
wild-type PAH, which regenerate the dimer and the monomer peak
(data not shown), indicate that the monomer contributes to the
equilibriummixture. The equilibriummixture of the PAH enzyme can
be described as follows: 4M⇆2D⇆T.The oligomerization process of the mutants is clearly disturbed by
the mutation, except in the case of mutant p.R297L that has a SEC
proﬁle similar to that of the wild-type enzyme although it lacks a
monomer (Fig. 3a). For all the other mutants (p.I65M, p.N223Y,
p.F382L, p.K398N, p.A403V and p.Q419R), the equilibriumwas shifted
toward the dimeric enzyme (Fig. 3b). In any event, all mutants present
a reduced activity of the enzyme because of the diverse composition
of the equilibriummixture. This conﬁrms that oligomerization defects
of PAH variants are one of the most common causes of HPAs.
4.2. Thermal stability and defect at the secondary structure level of
PAH mutants
The CD spectrum of wild-type PAH is characterized by typical
ﬁngerprints of α/β proteins (Fig. 6a), in line with the known 3D
structure [43]. Despite the similarity of CD spectra proﬁles in thewild-
type and mutant forms of PAH, the latter present a partial loss of
secondary structure with respect the wild-type folded structure, their
molar ellipticity being signiﬁcantly decreased (Fig. 6a). This loss
occurs for all the mutants except for mutant p.R297L in which the loss
is less pronounced. Therefore, the CD spectra have provided evidence
for a folding defect at secondary structure level. To characterize
further all the PAHmutants, we estimated the α-helical content using
the equation of Richardson and Makhatadze [44]. The calculations
showed a progressive decrease of the α-helical content of the PAH
mutants (see Supplementary Table S2).
Thermal denaturation of all the PAH proteins proved to be an
irreversible process as previously reported [40]. Therefore, the
thermodynamic features of the enzyme cannot be further character-
ized. As expected for the wild-type MBP-PAH fused protein, the two
steps in the sigmoidal curve correspond to two independent
unfolding processes for the two proteins. Indeed, the two melting
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collapse of PAH (52.0 °C) and MBP (57.5 °C), respectively (see also
Supplementary data for details).
Earlier differential scanning calorimetry, ﬂuorescence and CD
experiments indicated that, upon heating, two partially overlapping
transitions occur with an apparent melting temperature Tm1 of about
46 °C and a Tm2 of about 54 °C, respectively [14,40]. Apart from rare
exceptions, two transitions were identiﬁed also in the mutants. Their
melting temperatures diverged from that of wild-type PAH within a
range from −6 to +2 °C [24,45]. On the other hand, unfolding
experiments conducted on the truncated PAH (aa 112–452) revealed
only one cooperative transition centered at about 54 °C [40].
Therefore, the ﬁrst transition was interpreted as a denaturation of the
N-terminal regulatory domain and the second, partially overlapping
transition as a denaturation of the catalytic-tetramerization domain
[40].
Unfolding experiments were carried out for wild-type PAH and
mutants in buffer C and the ellipticity at 222 nm was monitored as a
function of temperature. Two overlapping transitions occurred for the
wild-type PAH and all the mutants. For the wild-type PAH, the Tm1
and Tm2 were 52.2 °C and 57.6 °C, slightly different from previous
reports [24,40,45]. This discrepancy is due to the species studied. If the
denaturation process is followed using only the PAH tetramer, as in
our case, the melting temperatures are Tm1=52.2 °C and
Tm2=57.6 °C. On the other hand, if all the species present in the
oligomerization equilibrium are considered, the Tm1 well agrees with
that reported previously (Tm1=46.1 °C) (Fig. 6c) [24,40,45]. To verify
that the unfolding process depends only on the oligomerization
equilibrium, we carried out unfolding experiments in the same buffer
and scan-rate conditions used in previous studies (buffer B, scan-rate
0.7 °C/min) [40,45], and obtained a Tm1 and Tm2 of 52.0 °C and 54.8 °C,
respectively. Indeed, a small destabilization has been reported for
most of the previously described mutants, as shown by a decrease in
ΔTm of about a couple of degrees. There are only a few instances
where ΔTm decreases down to ~6 °C [45]. For example, Tm1 and Tm2
decreased by as much as 42.6 °C and 52.0 °C and 40.7 °C and 50.2 °C,
respectively in the non-natural mutants p.N223D and p.T427P with
respect to wild-type enzyme Tm1 and Tm2 [45].
Themelting temperatures of mutants p.I65M and p.N223Y indicate
a very marginal stability gain, being only a couple of degrees higher
with respect to the wild-type enzyme (Table 2). Furthermore, the
denaturation curves of p.R297L and p.Q419R are similar, and the
denaturation slopes differ only slightly from that of the wild-type
enzyme, which indicates that the thermal stability is hardly affected.
Formutants p.K398N and p.A403V, however, the Tm1 is about 6° lower
and the Tm2 about 2–3° lower with respect to the wild-type, thereby
indicating a loss of stability. Interestingly, the Tm1 (33.0 °C) and Tm2
(43.6 °C) of mutant p.F382L are about 20 °C and 14 °C lower with
respect to those of the wild-type enzyme, which indicates that this
enzyme variant has a high thermal structural instability.
The results of thermal denaturation experiments of the p.F382L
mutant suggest that the replacement of L-Phe by L-Leu at position 382
leads to temperature-dependent functional alterations. These results
were conﬁrmed by the thermal inactivation assay performed on the
p.F382L mutant and, for comparison, on the wild-type PAH. Indeed,
the half-inactivation temperature obtained for this mutant (~44 °C)
well agrees with the Tm2 of 43.6 °C obtained by CD (Fig. 6b and d,
Table 2).
4.3. Mapping the mutations to search for structural alterations
For the present study, we built a composite model of the full-
length human enzyme and used it as a template for structural analysis
of the wild-type and mutant proteins. Mutations p.I65M and p.Q419R
fall in the regulatory and tetramerization domain, respectively;
mutations p.N223Y, p.R297L, p.F382L, p.K398N and p.A403V fall inthe large catalytic domain. All mutations are far from the active and
cofactor binding sites. All, except mutations at positions 65 and 403,
are located on the surface of the molecule in hydrated regions. In
Fig. 1, the position of the seven mutations is drawn on the monomer
structure. There are four previously identiﬁed variants at codon 65
(p.I65T, p.I65V, p.I65N, and p.I65S). The PAH database contains in
vitro expression data only for p.I65T, namely, increased proteolytic
degradation in pulse-chase experiments, increased aggregation and
decreased solubility. The residual activity of the I65T/V mutants,
tested in different in vitro systems, was about 21–29% (http://www.
pahdb.mcgill.ca).
Ile65 is located in a hydrophobic environment of the regulatory
domain. In the mutant enzyme p.I65M, the Ile change to a somewhat
larger but differently shaped Met may distort the hydrophobic
packing of the region [30]. In addition, Ile 65 makes a favorable
interaction with the catalytic domain of another subunit within the
dimer (the Ile65 oxygen atom is hydrogen-bonded to the hydroxyl
group of Tyr 216). As a result, both the tertiary structure and the
quaternary structure are perturbed. These data are in line with the
dimer abundance (Fig. 4 and Supplementary Table S1).
Asn223 is located in a solvent exposed loop [46]. In mutant
p.N223Y the structural perturbation is mainly due to tyrosine solvent
exposure that may affect the function. It has been proposed that this
residue is embodied in an intra-domain hinge bending region [45]
that is involved in the conformational transition induced by substrate
binding. Overall, its properties are similar to those of the wild-type
enzyme, except that the dimeric form is favored over the tetramer.
Mutant p.R297L exhibits properties very similar to those of the wild-
type enzyme. Interestingly, two other mutants reported in the
database, i.e., p.R297C and p.R297H, which are also associated with
a mild phenotype, indicate that mutations at this site are not critical
[32].
Mutant p.F382L is the one that differs most from the wild-type
enzyme. It occurs prevalently as a dimer (88.3%). Moreover, the
mutation falls in a region rich in aromatic residues. L-Phe forms
various stacking aromatic interactions with the aromatic residues
Tyr356 and Tyr277 in the wild-type enzyme [33]. The replacement by
Leu, despite the hydrophobic nature of this residue, breaks the
aromatic network and results in marked destabilization. This is in line
with larger ΔTm1 (19.6 °C) and ΔTm2 (14.0 °C) and with a lower
inactivation temperature compared to the wild-type protein (Fig. 6d).
This is the largest difference observed so far for a PAH mutant. This
highlights that L-Phe in position 382 is crucial for the stability of this
aromatic amino acid-rich region.
Lys398 is located at the tetramer interface, although it is not
directly engaged in intersubunit interactions. The positively charged
Lys is embedded in a negatively charged environment because of the
presence of Asp394 and Glu390 [43]. The high dimer/tetramer ratio
observed for mutant pK398N (75.0/17.2, Fig. 4 and Supplementary
Table S1) is in line with tetramer destabilization. Also the structural
stability was decreased. In fact, Tm1 and Tm2 were lower than that of
the wild-type enzyme being 5.6 and 4.0 °C, respectively (Table 2).
Q419 lies in a hydrated region at the dimer/tetramer interface. The
substitution of Gln by an Arg generates unfavorable ionic interactions
with a nearby Arg241 that destabilize the tetramer. The thermal
stability of p.Q419R is not signiﬁcantly affected by the mutation.
4.4. BH4 effect and the dimer–tetramer p.A403V equilibrium
In this study, we investigated the effect of BH4 on p.A403V that, in
our geographic area, is the most frequent mutant in mild, BH4-
responsive patients [32,33]. To this aim, we used the N&B technique
that has been successfully employed to discern minor changes in
molecular composition [37,38]. We monitored the ﬂuorescent
molecular forms of GFP-wild-type PAH and the GFP-A403V mutant
after transient transfection of HeLa cells. The addition of BH4 to the
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to cells expressing the p.A403Vmutant promoted a shift from dimeric
to tetrameric molecular forms.
The BH4 responsiveness in HPA has been the subject of numerous
studies. Various mechanisms have been proposed to explain BH4-
responsiveness, namely: increased enzyme activity [1,30,47,48],
correction or compensation of the BH4 decreased afﬁnity, protection
toward catalytic inactivation and chaperone-like activity that, by
stabilizing the protein, protects it from proteolytic degradation
[1,15,30]. In addition, BH4 supplementation may restore the optimal
concentration of BH4 cofactor in hepatocytes [28,46]. In our study, the
N&B technique revealed that the addition of BH4 to HeLa living cells
inﬂuences the oligomerization equilibrium of the p.A403V mutant by
shifting it toward a tetrameric quaternary structure.
4.5. Concluding remarks
About 600 mutations associated with the PKU/HPA phenotype
have been identiﬁed in the PAH gene. The resulting phenotypes range
frommild to severe HPA. This study demonstrates that our seven gene
variants reduce the enzymatic activity to 38–69% of that of wild-type
activity and affect the oligomerization state, thermal stability and
folding of PAH protein. Perturbation of these biophysical and
biochemical features may, therefore, be considered major disease-
causing alterations, also in mild phenotypic forms of HPAs. In addition
to the well recognized effect of BH4 on the stability of PAH mutants
[30], we provide the ﬁrst evidence, obtained with the N&B technique,
that in cellulo exposure to BH4 inﬂuences the oligomerization
equilibrium of the p.A403V mutant. Therefore, we surmise that, in
this case, a shift from dimer to tetramer plays a major role in BH4
responsiveness.
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 Appendix A. Supplementary data 
 
Selection of the operative conditions for CD measurements 
Any compound that absorbs in the region of interest (250-190 nm) should be avoided. Salt 
absorption, particularly of alogen anions hampers the protein CD spectra below 200 nm. In 
addition, their presence increases the high tension voltage leading to a detector saturation. 
Consequently, we extensively dialyzed all protein samples before CD measurements to eliminate 
salts.  
 
Analysis of the α-helical content of PAH proteins 
To estimate approximately the fractional helical content from the ellipticity at 222 nm, the 
following equation was used [44]: 
                         fh = ( [θ ] − [θ ]c ) / ( [θ ]h − [θ ]c )  Eq.1 
where ƒh is the fractional helical content, [θ]h and [θ]c are the molar ellipticities of the full helical 
and full coiled states, respectively, which are given by [θ]h = (-40000 + 250T) [1 - (2.5/Nres)] and 
[θ]c = (640 - 45T), where T is the temperature (Celsius degrees). The results, reported in 
Supplementary Table S2, show a decrease of the α-helical content from 65% (wt-hPAH) to 35%, 
for the mutant p.K398N. The percentages are over-estimated in comparison with high resolution 
experimental X-ray structure [8, 22]. 
 
Thermal unfolding of MBP at pH 7.4 
Previous studies show that thermal unfolding of MBP is characterized by a single two-state 
transition, of which Tm is largely affected by experimental conditions [49]. In particular, pH and 
the presence of maltose can influence the melting of MBP. Tm values were reported only for pH 
<3.4 or pH > 8.3; Tm are 52.6°C and 62.6°C at pH 3.4 and 8.3 respectively [49]. Furthermore, 
because MBP is widely used as a carrier protein for the production of recombinant fusion proteins, 
 several studies evaluated unfolding of the fused protein [24]. Since no data are available at neutral 
pH values, and taking into account that all our measurements were performed at pH7.4, we 
recorded the thermal unfolding curve of commercial MBP by monitoring the molar ellipticity θ at 
222 nm, in buffer C, at pH 7.4. In the case of MBP, the Tm was 57.5°C. This value coincides with 
the Tm2 of the fused protein MBP-PAH (Table 2, Fig. 6b). 
 
Supplementary Table S1. Percentages of molecular species 
 
Aggregates (%) Tetramer (%) Dimer (%) Monomer(%) 
Wild-type 
PAH 
4.0 ± 1.0 30 Ref 21 70.7 ± 0.4 53 Ref 21 23.9 ± 0.6 12 Ref 21 1.4 ± 0.9 nd Ref 21 
MBP-PAH 4.8 ± 0.9 38 Ref 10,41 88.4 ± 0.3 86.2 Ref 10 6.8 ± 0.8 13.8 Ref 10 Nd nd Ref 21 
  p.I65M Nd 16.5±0.5 80.1±0.3 3.4±0.8 
p.N223Y 5.0±1.0 38.9±0.5 53.2±0.5 2.9±0.8 
p.R297L 8.9±0.8 60.0±0.3 31.1±0.4 Nd 
p.F382L Nd 11.7±0.4 88.3±0.3 Nd 
p.K398N 6.5 ± 0.9 17.2 ± 0.5 75.0±0.4 1.3±0.9 
p.A403V 7.3 ± 0.8 23.8 ± 0.4 64.8 ± 0.3 4.1±0.8 
p.Q419R 3.7 ± 1.0 31.4 ± 0.4 64.9 ± 0.3 Nd 
 
  
Supplementary Table S2. α-helical content of PAH proteins obtained through the Eq. 1  
PAH protein α-helical content 
PAH WT 65% 
I65M 45% 
N223Y 40% 
R297L 51% 
F382L 38% 
K398N 35% 
A403V 42% 
Q419R 48% 
 
